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Pregnancy Associated Breast Cancer: an Analysis of Fetal Treatment Risk 
Melissa Barnett 
Abstract 
 There are several viable treatment options for patients with PABC considered un-harmful 
to fetal development. Trastusumab, or Herceptin, targets HER2 protein and successfully combats 
aggressive breast cancer. In standard doses, it appears to be safe to the fetus even when 
administered during the first trimester.  A likely side effect of Herceptin is anhydramnios, which 
can be monitored for throughout the stages of a pregnancy (Shrim et al. 2008). Anthracyclines, 
commonly used in chemotherapy, appear to be non-toxic, and have been used to successfully 
cure PABC patients in their second and third trimester. However, first trimester spontaneous 
abortions are documented to increase dramatically in anthracycline receiving PABC patients 
(Ring A. E. et al. 2005). Taxanes, such as paclitaxel, docetaxel, and vinorelbine, are microtubule 
agents that are highly active against breast cancer. As cytotoxic drugs they can possibly disrupt 
organogenesis and their administration should therefore be delayed until after the first trimester.  
Taxanes as well as anthracycline treatments should also be halted three weeks prior to delivery to 
prevent the occurrence of neutropenia, a decrease in white blood cells (neutrophil) that raises the 
risk of infection, and allow for regeneration of platelet count in the bloodstream (Mir O.  et al 
2008). Breast surgery can be safely performed at any point of a pregnancy although it is 
recommended to be postponed until after the first trimester. External beam radiation and 
hormone therapy are both documented to have negative effects on a developing fetus and 
therefore should not be considered as possible treatment options for PABC patients. In 
diagnosing and assessing PABC, ionizing radiation should be replaced by chest x-rays 
accompanied with proper shielding to protect the fetus.  Sonograms appear to be more effective 
in diagnosing breast cancer than mammograms, because of the changes in pregnancy related 
breast density. Although PABC treatment is more complicated than standard breast cancer 
treatment, treatment during pregnancy has been proven to be a feasible and recommended option 
(Loibl S. et al. 2005).  
Introduction 
Pregnancy Associated Breast Cancer (PABC) presents a treatment plan quandary. The 
diagnosis appears to present a conflict between the mother and fetus’ health.  The challenge 
facing the health care provider is how to balance the mother’s cancer care, with the fetus’ pre-
natal care.  The aim of the physicians is to provide optimal treatment to the mother so as to 
maximize her chances of survival whilst minimizing risk to the fetus.  This will often require an 
extensive healthcare group consisting of an OBGYN, a medical oncologist, radiation oncologist, 
pediatricians, and sometimes a breast surgeon. This complex scenario arises in approximately 
three percent of breast cancer cases. However, this statistic is likely to increase as women are 
increasingly delaying pregnancy until a later age (Ring A. E. et al 2005).  It is therefore crucial to 
gain a clear understanding of this commonly misconceived situation.   
 It has generally been the public supposition that a woman with cancer who was found to 
Melissa	Barnett,	BS	’09	graduated	Touro	with	a	degree	in	Biology.	She	is	currently	in	a	B.S.N	program	at	Seton	
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be pregnant would have to choose: her life or her baby’s. However, with the publication of many 
more case studies it has become evident that, at least in regard to breast cancer, this is not the 
case.  It has been shown through controlled case studies that the prognosis for women who 
undergo voluntary abortion is not more favorable than for those women who continue their 
pregnancy (Gottlieb S. 1999).  Analysis of the treatment options will support the recommended 
course of treatment to the highest possible standard despite the difficulties in the diagnosis and 
treatment of breast cancer.  
  The major difficulties in diagnosing breast cancer in a pregnant woman arise from the 
physiological changes that occur in the breast, and from the inability to use certain staging 
investigative procedures that are normally used in non-pregnant women. Mammograms have 
been shown to be relatively ineffectual in pregnant women because they are too hard to interpret 
due to the increased breast density in pre-menopausal and pregnant women. Therefore, 
sonography is more often the method of choice to diagnose PABC. There are also many routine 
staging investigations for breast cancer that use ionizing radiation, which should certainly not be 
used on a pregnant woman within the first trimester. In addition, not enough proof is available to 
support the safety of this technique for the fetus even during the later stages of pregnancy. 
Instead, chest X-rays are considered relatively safe in pregnancy when proper shielding is used 
(Ring A. E. et al 2005a).  
 Treatment for breast cancer is manifold. There are various options and each case must be 
individually assessed to design a treatment plan that will work. The basic care recommendations 
are breast surgery, radiation, systemic chemotherapy and other cytotoxic drugs, hormone 
therapy, and supportive care. Breast surgery may be performed throughout pregnancy, however, 
because there is a greater chance of spontaneous abortion within the first trimester. It is 
recommended that surgery be postponed until the second or third trimesters and that fetal activity 
be monitored throughout surgery. External beam radiation is contraindicated during pregnancy 
because of the serious risks associated with fetal exposure, such as mental retardation and other 
malformations. Hormone therapy should be postponed until after delivery, because defects have 
been seen in mice studies; there have been reports of Goldenhar’s syndrome and of ambiguous 
genitalia in children born to women exposed to hormone therapies.  Supportive care for 
anthracycline-based chemotherapy is safe after the first trimester (Loibl S. et al 2005). The use of 
systemic chemotherapy is dependent on the drug type and the trimester in which it is used. 
Research on cytotoxic drugs is ongoing and is mostly confined to case studies and individual 
case reports. There are several specific drugs that deserve further analysis. They are: 
Trastuzumab or Herceptin, anthracycline-based drugs such as the doxorubicin, 
cyclophosphamide, and fluorouracil combination, and taxanes or anti microtubule agents such as, 
docetaxel, paclitaxel, and vinorelbine.  
Trastuzumab 
 Trastuzumab, generically also known as Herceptin, is an IgG1 monoclonal antibody that 
is directed against the 2(HER2)protein. The HER2 protein is a member of the epidermal growth 
factor receptor family. In recent years, researchers have found that in certain breast cancer cases 
this protein can be over expressed. When this occurs it causes increased cell growth and 
proliferation leading to a much more aggressive breast cancer. This type of cancer was 
considered one of the more fatal breast cancers until the advent of drugs like trastuzumab that 
target this protein. The drug has been shown to significantly improve outcomes in patients with 
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HER2-positive breast cancer (Shrim A. et al 2008). Because HER2 over-expression has been 
found in up to 35% of breast cancer cases in young patients (<35 years), it is probable that it will 
be concurrent with PABC. Therefore, trastuzumab may be necessary during pregnancy, and the 
risk factors must be analyzed.  
 Epidermal growth factor receptors seem to be important in fetal development. HER2 is 
expressed in embryofetal tissue. Therefore, it might be critical to fetal development. It has also 
already been demonstrated that transplacental transfer of maternal monoclonal IgG1 antibodies is 
possible. It is therefore reasonable to expect that trastuzumab might cross the placental barrier 
(Witzel I. D. et al 2007). In this regard, however, animal research has not exhibited any fetal 
harm. Reproduction studies were conducted in monkeys at 25 times the weekly human dose, and 
no decrease in fertility or fetal harm were noted. This study indicates that more research is 
required on the exact mechanism of action of the HER2 protein in fetal development (Shrim A et 
al 2008).  
 There are several reports of case studies where trastuzumab was part of the treatment in a 
pregnant breast cancer patient. With this particular drug, there does not seem to be increased 
harm to the fetus if it is administered during the first trimester. This conclusion is drawn from the 
case of a patient presenting with metastatic breast cancer who was treated with trastuzumab at 
normally recommended doses throughout the first 24 weeks of her pregnancy. She underwent a 
caesarean section at 37 weeks and was delivered of a healthy baby. However, in another case a 
woman received 25 cycles of trastuzumab before becoming pregnant, then nine more cycles 
during pregnancy, and in this case, the fetus was affected. Because the mother presented at 27 
weeks pregnant with severe vaginal bleeding, the baby was delivered preterm at 28 weeks via 
caesarean section. The baby suffered several disorders and died 21 weeks later due to multiple 
organ failure. This second case does not specifically indicate that trastuzumab caused the 
irregularities in the fetus because they could be related purely to prematurity. However, in this 
case the drug dose to the mother was much higher, which could indicate that despite reassuring 
findings in other research, higher doses of the drug could affect fetal development and result in 
an impaired prognosis of the newborn.  
 Treatment after the first trimester does not appear to result in long term fetal harm. There 
are two case studies of women with metastatic breast cancer who underwent trastuzumab 
treatment during the second trimester and had no reports of any disorders. One woman was 
treated until 24 weeks gestation, and the other started treatment at 27 weeks gestation and 
delivered a healthy male at 34 weeks.  The other case reports of women treated with the drug 
during the second or third trimesters all document a condition called anhydramnios, a lack of 
amniotic fluid. One patient was treated with trastuzumab until 23 weeks when anhydramnios was 
diagnosed, and treatment was discontinued. The anhydramnios resolved itself after 
discontinuation of the drug and a healthy baby was delivered at 37 weeks. Two other patients 
underwent trastuzumab treatment in their second and third trimesters and suffered anhydramnios. 
In one case the mother received treatment from her 26th week to her 32nd week when a caesarean 
section was performed. The baby showed signs of several dysfunctions, however these were 
probably related to its prematurity, and were resolved. The child’s further development was 
normal. In the second case, a mother treated at weekly intervals until 35 weeks gestation when 
labor was induced, showed persistent anhydramnios throughout treatment. However, she was 
delivered of a healthy baby.  It appears that trastuzumab treatment is possible during pregnancy 
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with close monitoring of the fetus, especially monitoring of fetal renal function and amniotic 
fluid volume (Witzel I. D. 2007).  
Anthracycline Based Chemotherapeutic Drugs 
 Anthracyclines are a drug species that damage DNA through different mechanisms. One 
of these mechanisms is topoisomerase IIalpha poisoning. Since topoisomerase is over-expressed 
in rapidly growing tissues, it can lead to poisoning which can cause severe damage to the embryo 
or fetus. However, only low concentrations of anthracyclines have been found in fetal tissues and 
their cytotoxic potential is unknown. Also, existing case research appears to prove that 
anthracycline use during pregnancy is not toxic to the fetus, especially when not used during the 
first trimester. Anthracyclines are one of the most used and effective types of chemotherapy for 
breast cancer patients, and it is therefore useful to understand their effect on the fetus. 
Anthracyclines such as commonly used doxorubicin do not easily cross the placenta because of 
their high molecular weight. They are also substrates of the P-gp, a placental drug-transporting 
glycoprotein. This glycoprotein is of great importance in limiting the fetal penetration of 
potentially harmful compounds. Indeed, it has been noted that after intravenous injection of 
anthracyclines only barely detectable concentrations can be found in the fetus (German N. et al 
2003). It would appear that anthracyclines are not likely to be toxic, however specifically with 
anthracycline-based chemotherapy, like the combination previously mentioned, the date of 
administration has an effect on the risks to the fetus.  
 The first trimester of pregnancy is the time of organogenesis, and the fetus is therefore at 
its most susceptible. When chemotherapy is administered in the first few weeks of pregnancy 
there is a very high rate of spontaneous abortion. Throughout the rest of the first trimester there 
is still a chance of spontaneous abortion and there is the additional risk of fetal malformations. 
The risk of fetal malformations when chemotherapy is administered within the first trimester is 
up to 17% as opposed to 1.3% in the two subsequent trimesters. In two different studies three 
women treated during the first trimester all suffered spontaneous abortions. However, one 
woman in a study from the University of Texas M.D Anderson Cancer Center was treated at 11 
weeks and experienced no apparent adverse effects. As a result of these significant risk factors to 
the fetus, chemotherapy is usually avoided during the first trimester (Ring A. E. et al 2005b).  
 Treatment with anthracycline-based chemotherapy in the second or third trimesters does 
not appear to increase the risk of malformations. There are three large case study series published 
about this treatment. In a U.K study 16 children of mothers exposed to anthracyclines showed no 
congenital malformations. In a French survey 18 children were identified as having been exposed 
and none of them presented malformations. The M.D Anderson series reported 23 children 
exposed none of whom had malformations. However, when the doxorubicin dose exceeds 70 
mg/mg2 per cycle it has been shown that risk of severe fetal toxicity increases 30 fold. There is 
also a specific risk of cardiotoxicity associated with anthracycline toxicity later in pregnancy, 
although this has not been observed in any case studies. While chemotherapy appears to be safe 
during the second and third trimesters, it is advisable to stop treatments at least three weeks prior 
to delivery, in order to prevent neonatal infection, neutropenia and to ensure that the mother’s 
blood counts are optimal at delivery (German N. et al 2003).   
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Taxanes 
 Among emerging therapeutic options for breast cancer are antimicrotubule agents or 
taxanes such as paclitaxel, docetaxel, and vinorelbine. These drugs display a high activity against 
breast cancer, and it is therefore necessary to understand how they may be used in conjunction 
with pregnancy. Because these drugs are relatively new the available research is confined to case 
studies, some animal data and knowledge of the nature of the drug.  
 Paclitaxel, docetaxel, and vinorelbine are mainly metabolized by cytochrome P450 
isoforms. Because the maturation of these cytochromes mostly occurs in the first weeks of 
neonatal life, fetus’ cannot metabolize these drugs and would therefore be highly susceptible to 
their toxic effects if a transplacental transfer were to occur. These drugs would actually be 
expected to cross the placenta because they have a relatively low molecular weight and are 
highly lipophilic. However, they are highly bound to plasma proteins and plasma protein binding 
is increased during pregnancy, which would potentially lead to a decreased active fraction of 
these drugs. These drugs are also substrates for the Pgp which has been found in high expression 
in the placenta. The placental Pgp serves to protect the fetus from a broad range of xenobiotics. 
The placental Pgp therefore appears to reduce transplacental transfer of antimicrotubule agents, 
making their clinical use possible in the second and third trimesters (Mir O. et al 2008).  
 Animal studies have shown paclitaxel and docetaxel to be toxic to the fetus. This has not 
been evident in human case studies, although it is recommended to postpone the use of these 
cytotoxic drugs until after the first trimester. This is firstly, to prevent spontaneous abortion, and 
secondly, to prevent disruption of organogenesis which could lead to malformations (Ring A. E. 
et al 2005a).  
 There are four reports of PABC treated with Paclitaxel. The median maternal age in the 
reports is 36 years. Treatment was started during the second trimester in 3 cases and during the 
third in one case. There were no documented complications, and three out of the four patients 
underwent caesarean section with no reported malformations. In all cases there was a follow up 
with a median of 16 months, where all the children appeared healthy and normally functioning. 
However, in three cases, women treated with paclitaxel combination therapies in the last three 
weeks before delivery, exhibited mild anemia in two fetus’ and one case of grade four 
neutropenia.  
 In a literature review study there were six reports of patients with breast carcinomas who 
were pregnant and treated with docetaxel.  The median maternal age was 34.5 years and 
docetaxel was only administered by itself in one case. Treatment was initiated during the second 
trimester in three cases, and in the third trimester in three cases as well. One fetus developed 
hydrocephalia only before treatment with docetaxel, but remained stable thereafter. The child 
developed normally and was considered healthy at 28 months. In the other five cases no 
malformations were reported. All the offspring appeared healthy with a median follow-up of 
17.5 months.   
 There were five identifiable cases of PABC treated with vinorelbine. Vinorelbine is 
generally associated with other cytotoxic drugs such as fluorouracil, csiplatin,or trastuzumab. 
The advantage of using vinorelbine is primarily its lower rate of side effects, which is especially 
a factor in pregnant women. The median maternal age of these five reported women was 32 
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years. The drug treatment was started in the second trimester in two cases and during the third 
trimester in three cases. There was no grade three or four maternal toxicity reported, and there 
were no fetal malformations. All the children were reported healthy at a 23 month median follow 
up (Mir O. et al 2008).    
 Researchers and medical practitioners have voiced the safety of using taxanes during the 
second and third trimesters of pregnancy based on the data available. It is agreed that the use of 
these cytotoxic drugs should be stopped for three weeks prior to delivery in order to prevent 
neutropenia, and to allow the mother’s blood to regenerate its platelet counts. Further research 
and analysis is required to investigate the possibility of low birth weight being associated with 
the use of taxanes during pregnancy.  
Conclusion 
 This area of study is an ongoing development and does indeed require much more 
investigative research. One of the principal problems standing in the way of a clearer 
understanding of placental transfer of drugs is the inability to ethically analyze live placental 
tissue.  In order to observe and document the way in which these drugs react within the placental 
barrier one would need to inject the drug into the placental tissue: not a feasible option. When the 
placenta exits the uterus after delivery the tissue dies immediately, and the activity of the drug 
within its tissues would be totally different then when it is in its living state. This means that 
essentially all the understanding and chemical analysis of the way drugs pass through the 
placenta is conjecture. Furthermore, there is no way to test human subjects with increased doses 
of these drugs to observe their potential toxicity, and animal testing has  given results that do not 
match human experience. Many women abort a pregnancy in the face of a serious diagnosis 
causes less real life cases to be analyzed. 
 This last reason is the principal impetus behind this paper. The ability to treat cancer 
during pregnancy is generally believed to be a modern, groundbreaking concept. In reality, the 
cases of women successfully cared for while they were pregnant date back to the 1970’s. Yet still 
today, the public is just beginning to understand that one need not make that most painful of 
choices (Paul P. 2008).  The situation presented by a breast cancer patient who is also pregnant 
and wishes to continue their pregnancy, is still unusually sensitive. The idea of harming a fetus to 
benefit the mother is difficult. The majority of women who do choose to continue their 
pregnancy, even today, generally do so because of religious beliefs, not because they think they 
and their babies will survive and be healthy. It is this public misconception that must be righted. 
Women should not be allowed to feel self-doubt or nervousness, because they are opting to be 
treated while continuing their pregnancy. Although research on breast cancer specifically is most 
extensive, based on its higher rate of correlation with pregnancy, the examples made in this field 
of cancer also apply to various other less documented cancers. It is crucial that further research 
and analysis, such as the ongoing study at the MD Anderson Cancer Center, continue and are 
publicized, so that unborn children need not be lost, and so that mothers should not be forced to 
make an impossible choice.    
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Clostridium difficile Associated Disease (CDAD) 
Rivka H. Borger 
	
Abstract	
Clostridium	 difficile	 bacteria	 (C.	 difficile)	 are	 a	 spore-forming	 species	 of	 bacteria	 that	 lies	
dormant	in	the	colon,	in	the	presence	of	normal	intestinal	flora.		Due	to	overuse	of	certain	antibiotics,	
normal	 intestinal	 bacteria	 may	 be	 depleted,	 and	 combined	 with	 other	
possible	 risk	 factors,	 	 allow	 C.	 difficile	 bacterial	 spores	 to	 develop	 into	
active,	 infectious,	and	extremely	 resistant	 toxin-producing	bacteria.	 	The	
toxins	cause	severe	damage	and	 inflammation	to	the	 intestinal	wall	 that	
can	 result	 in	gastrointestinal	discomfort	and	severe	pseudomembranous	
enterocolitis	 that	 must	 be	 treated	 with	 a	 low-risk	 C.	 difficile	 targeting	
defense.				
	
Introduction	
Clostridium	 difficile	 bacteria	 (C.	 difficile)	 are	 a	 spore-forming	
species	of	bacteria	that	 lie	dormant	in	the	human	colon,	 in	the	presence	
of	normal	intestinal	flora.		It	is	a	commensal	bacterium	in	a	minority	of	the	population.		Smaller	numbers	
do	 not	 develop	 into	 significant	 disease.	 	 (Nation	Master	 Encyclopedia,	 2005)	Most	 commonly	 due	 to	
overuse	 of	 certain	 antibiotics,	 normal	 intestinal	 bacteria	 may	 be	 depleted,	 and	 through	 nutrient	
competition,	allow	C.	difficile	bacterial	spores	to	develop	into	active,	infectious,	and	extremely	resistant	
toxin-producing	 bacterial	 overgrowth.	 	 The	 toxins	 cause	 severe	 damage	 and	 inflammation	 to	 the	
intestinal	wall	resulting	in	a	wide	range	of	disease,	but	most	commonly	-	severe	enterocolitis.	 	 	(Merck	
Manual	of	Diseases,	2006)		
The	following	discourse	will	detail	the	morphology,	mechanism	of	 infection,	causes,	diagnoses,	
treatment,	and	prevention	of	Clostridium	difficile	Associated	Disease.			
	
Clostridium	difficile	Bacteria	
	 Clostridium	 difficile	 is	 a	 Gram-positive	 anaerobic	 rod-shaped	 bacterium	 (Kunkel,	 2006).	 	 The	
species	was	named	 ‘difficile’	because	 it	was	 initially	hard	 to	 culture	 (Schroeder,	MD,	American	Family	
Physician,	 2005).	 	 It	 belongs	 to	 the	 Clostridiaceae	 Family	 and	 genus	 Clostridium,	 which	 form	 spores.		
They	are	motile	bacteria	that	are	numerous	through	nature,	particularly	soil.		Clostridium	show	optimal	
growth	 at	 human	 body	 temperatures,	 but	 can	 exist	 under	 stress	 in	 the	 more	 tolerant	 spore	 form.	
(Nation	Master	Encyclopedia,	2005).		The	spores	are	resilient	and	resistant	to	high	temperatures.			Early	
studies	 demonstrated	 that	 C.	 difficile	 could	 be	 isolated	 from	 the	 gastrointestinal	 tracts	 of	 most	
neonates,	identifying	it	as	a	commensal	organism	(Schroeder,		2005).		It	is	found	as	part	of	the	normal	
Figure 1 –Endoscopic 
view of classic C difficile–
associated 
pseudomembranous 
colitis (Hull and Beck, 
FMC, 2006) 
Rivka	H.	Borger,	BS	’09	graduated	Touro	College	with	her	degree	in	Biology.		She	is	currently	a	student	at	SUNY	
Downstate	Medical	Center	Physician	Assistant	Program.	
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intestinal	flora,	and	passed	out	with	the	feces	of	those	with	C.	difficile	spores	in	their	intestines.		(EMIS	
and	PIP,	2007)		
Clostridium	 difficile	 produce	 at	 least	 two	 exotoxins:	 an	 enterotoxin	 (Toxin	 A)	 and	 a	 cytotoxin	
(Toxin	B).	 	They	can	kill	cells	by	altering	the	apical	membrane	permeability	of	 the	mucosal	cells	of	 the	
intestinal	 wall,	 and	 are	 subsequently	 responsible	 for	 severe	 inflammation	 possibly	 leading	 to	
enterocolitis	 (Gerding	 et	 al,	 1995).	 Another	 toxin,	 binary	 toxin,	 has	 been	 identified	 without	 a	 role	 in	
CDAD	infection.		(Nation	Master	Encyclopedia,	2005)	
C.	 difficile	 can	 be	 passed	 through	 fecal	 matter	 and	 spores	 can	 lie	 almost	 anywhere	 in	 the	
environment.			
Clostridium	 difficile	 is	 considered	 a	member	 of	 infant	 intestinal	 flora	 as	 up	 to	 50%	 of	 infants	
carry	asymptomatic	C.	difficile	in	their	intestinal	tracts.		It	can	grow	to	high	numbers	with	elevated	toxin	
production	 with	 no	 harmful	 effects	 to	
infants.		(Bongaerts	and	Lyerly,		1996)	
The	 normal	 intestinal	 flora	
under	 typical	 conditions	 keep	 the	
spores	 of	 C.	 difficile	 inactive	 by	
outnumbering	 them	 in	strength.	 	Upon	
depletion	of	normal	 flora,	 the	dormant	
inactive	 spores	 develop	 into	 active,	
infectious,	 and	 resistant	 bacteria	 –	
replacing	 the	 lost	 bacteria	 due	 to	
imbalance	(Merck	Manual,	2006)		
More	 recently,	 C.	 difficile	
infections	 are	more	 rampant	 –	 severe,	
extremely	 resistant,	 and	 easily	
recurrable.	 	 (Kelly	 and	 LaMont,	 2008).		
It	 is	 the	 most	 frequent	 etiologic	 basis	
for	 healthcare-associated	 diarrhea	 and	
a	 common	 cause	 of	 antibiotic-
associated	diarrhea	 (AAD),	accounting	 for	15-25%	of	all	AAD	episodes	 (Center	 for	Disease	Control	and	
Prevention	(CDC),	2004).	 	There	have	been	increasing	rates	of	CDAD-associated	mortality,	and	this	can	
be	due	either	to	elevated	risk	population	or	identification	of	new	highly	virulent	strains	of	the	disease.		
(Center	for	Disease	Control	and	Prevention	(CDC),	2005).			
Additionally,	 two	studies	have	proven	C.	difficile	 to	be	the	most	 frequent	cause	of	nosocomial	
diarrhea.	 	Multiple	 studies	 demonstrate	 the	 link	 between	C.	 difficile	 and	 noscomial	 infection	 –	many	
cases	arise	from	contamination	of	hospital	environment	(Gerding,	et	al,		1995).	
Figure 2 –Scanning electron microscopy of Clostridium 
difficile bacteria specimen,  obtained from human intestine 
(Wiggs, University of Waikato, 2007) 
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Clostridium	 difficile	 was	 first	 linked	 to	 disease	 in	 1978	 when	 it	 was	 identified	 as	 primary	
causative	agent	of	pseudomembranous	colitis.		It	can	cause	disease	ranging	from	minor	gastrointestinal	
discomfort	 to	 severe	
enterocolitis,	toxic	megacolon,	or	
death.	 	 (Sunenshine	 and	
McDonald,	2006)	
	
Pathogenesis	
	 Inflammation	 develops	
when	 environmental	 spores	
ingested	 infect	 the	 patient.		
Spores	can	survive	 the	 low	pH	of	
the	 gastrointestinal	 tract	 and	
survive	 well	 in	 the	 anaerobic	
environment	 of	 the	 large	
intestine,	 allowing	 for	
germination.	 	 Upon	 depletion	 of	
normal	 intestinal	 flora,	C.	difficile	
spores	 no	 longer	 have	 to	
compete	 with	 other	 microbes,	
allowing	them	to	thrive	to	full	capacity,	growing	to	large	numbers	–	approximately	108	bacteria	per	gram	
of	feces.		In	the	absence	of	colonic	flora	depletion,	colonization	of	C.	difficile	will	be	asymptomatic	and	
harmless	(Bongaerts	and	Lyerly,		1997).		
	Antibiotic	overuse	 is	 the	most	 common	 form	of	 intestinal	 flora	depletion.	 	 The	 inactive	 spore	
from	of	C.	difficile,	once	held	in	check	by	nutrient	competition,	becomes	the	dominant	intestinal	species.		
It	is	transformed	to	its	infectious	form,	producing	toxins	that	inflame	and	damage	the	intestinal	mucosa.			
Inflammation	 results	 in	 hyperleukocytosis,	 influxing	 towards	 the	 colon.	 	 Colitis	 is	 variable	 in	
degree,	 from	 mild	 to	 extremely	 severe.	 	 In	 pseudomembranous	 colitis,	 a	 more	 severe	 form,	 toxins	
destroy	 the	 tissue	 of	 the	 intestinal	 epithelia	 until	 the	 tissue	 falls	 off,	 mixes	 with	 leukocytes	 in	 pus	
discharge;	 giving	 the	 appearance	 of	 a	white	membranous	 patch	 on	 the	 inner	 intestinal	 lining.	 	 Some	
patients	infected	with	C.	difficile	do	not	develop	colitis,	but	are	carriers	of	the	disease,	able	to	transmit	it	
to	other	high-risk	individuals.			
Clostridium	difficile	bacteria’s	capacity	to	form	spores	allows	the	organism	to	persist	 in	various	
areas	of	the	environment.		Additionally,	the	spores	can	be	spread	through	fecal	contamination,	infecting	
at-risk	individuals.	(EMIS	and	PIP,	2007)		Transfer	can	occur	via	the	hands	of	healthcare	workers	as	well.		
(Center	 for	Disease	Control,	2008).	 	 Infection	used	to	be	 limited	to	elderly	hospitalized	 individuals	but	
has	grown	rampant	more	recently.		(DeNoon,	2006).			
Figure 3 – 
Scanning electron microscopy of Clostridium difficile bacteria spreading on 
a surface 
(Dave McCarthy and Annie Cavanagh, School of Pharmacy, University of 
London, 2008) 
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	 After	 colonic	 colonization,	 C.	 difficile	 bacteria	 carry	 out	 metabolic	 activities	 similar	 to	 other	
anaerobic	 organisms.	 	 The	 bacteria	 use	 some	 monosaccharides	 (i.e.	 glucose,	 fructose,	 mannitol,	
mannose,	 and	 xylitol),	 but	 not	 disaccharides	 (i.e.	 lactose	 or	 sucrose),	 oligosaccharides,	 or	
polysaccharides	 (i.e.	 starch).	 	 C.	 difficile	 uses	 substances	 not	 found	 free	 in	 nature,	 such	 as	 N-acetyl-
glucosamine	 and	 N-acetyl-neuraminic	 acid,	 by	 using	 extracellular	 hydrolytic	 enzymes	 to	 degrade	
substrates	for	nutrition.	 	 It	can	then	obtain	carbohydrates,	amino	acids,	and	related	nutrients	allowing	
the	 bacteria	 to	 thrive	 in	 the	 intestine.	 	With	 the	 depletion	 of	 normal	 flora,	 there	 are	more	 nutrients	
available	for	the	bacteria	to	thrive	on.		Additionally,	when	a	large	amount	of	resident	intestinal	bacteria	
are	destroyed,	 it	allows	Clostridium	difficile	exposure	to	previously	hidden	sites	of	 the	 intestine.	 	They	
can	 be	 then	 used	 for	microcolony	 formation	 or	 receptor	 sites	 for	 toxins	 in	 toxigenic	 strains.	 	 	 As	 the	
organism	grows,	it	becomes	harder	for	normal	flora	to	replace	it	since	the	bacteria	produces	inhibitory	
metabolic	 products,	 such	 as	 p-cresol,	 ammonia,	 and	 isocaproic	 acid	 –	 all	 inhibiting	 growth	 of	 normal	
flora,	and	disturbing	intestinal	epithelial	cell	membrane	function.	(Bongaerts	and	Lyerly,		1997)	
Pathogenic	strains	of	Clostridium	difficile	cause	enterocolitis	primarily	through	the	production	of	
toxin	A	 (enterotoxin)	 and	 toxin	 B	 (cytotoxin).	 Both	 toxins	 are	 capable	 of	 stimulating	 proinflammatory	
cytokine	production	implicated	in	pseudomembranous	colitis	infection.		Toxins	act	by	altering	regulation	
of	 cytoskeletal	 protein,	 leading	 to	 cell	 rounding	 and	 cell	 death.	 	 (Hull	 and	 Beck,	 College	 of	 Family	
Physicians	 of	 Canada,	 2004)	 	 The	 toxins	 cause	 leukocyte	 chemotaxis	 and	 the	 upregulations	 of	
inflammatory	mediators	such	as	cytokines,	producing	colonic	inflammation.		Clinical	evidence	would	be	
a	 significantly	 elevated	white	blood	 cell	 count,	 correlating	 to	presence	of	 infection.	 	 Focal	 ulcerations	
occur	with	increasing	severity	of	colitis,	and	necrotic	tissue	form	a	membrane-like	material.	 	Thus,	 it	 is	
Figure 4 – The Potent Effects on Toxin B vs. Toxin A on Intestinal Epithelium 
(A) Control, treated with buffer alone – no toxins.  (B) treated with 32 nM of toxin A for 5 hours.  (C) and (D) 
treated with 3 nM of toxin B for 5 hours. 
(B) Exposure to toxin A shows disruptions of superficial epithelium with crypt epithelium intact.  (C) treatment 
with toxin B shows disruption of superficial epithelium as well.  (D) shows higher magnification of colonic 
damage wrought by toxin B. 
(Riegler, et al, Journal of Clinical Investigation, 1995) 
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called	pseudomembranous	colitis	(Schroeder,		2005).		
Animal	 models	 show	 toxin	 A	 induction	 of	 epithelial	 desquamation,	 increased	 mucosal	
permeability	leading	to	increased	fluid	secretion	in	the	intestine.		Toxin	B	has	less	enterotoxic	effects	in	
animals	with	less	correlation	as	a	cause	of	disease	in	humans,	but	recent	in	vitro	data	based	on	human	
intestinal	epithelial	cell	testing	suggests	that	toxin	B	is	ten	times	more	likely	to	 induce	colonic	damage	
than	 does	 toxin	A.	 	 In	 this	 experiment,	 human	 intestinal	mucosa	was	 exposed	 to	 varying	 amounts	 of	
both	Clostridium	difficile	toxins	A	and	B	for	five	hours	and	subsequent	damage	was	observed.		Significant	
damage	was	observed	afterward,	both	electrophysiologically	and	morphologically.	 	Both	toxins	caused	
disruption	 to	 cellular	 F-actin	 and	 patchy	 damage	 and	 exfoliation	 was	 noted	 on	 superficial	 intestinal	
epithelium.		The	difference	lay	in	the	potency	of	individual	toxins.		While	both	toxin	A	and	toxin	B	caused	
severe	intestinal	damage,	toxin	B	disrupted	the	colon	in	a	minute	concentrated	amount,	while	toxin	A’s	
measurement	was	significantly	greater.		This	suggests	the	high	potency	of	toxin	B	in	Clostridium	difficile	
Associated	Diseases.		(Riegler	et	al,	1995)	
In	a	1999	study	hypothesizing	how	C.	difficile	–	induced	alterations	in	intestinal	barrier	facilitate	
microbial	entry	to	the	intestinal	mucosa	(thus	facilitating	microbial	pathogenic	shift	within	the	intestine),	
mature	enterocytes	were	deliberately	treated	with	varying	concentrations	of	toxins	A	and	B	followed	by	
an	hour	 incubation	with	 an	 enteric	microorganism	 such	 as	Escherichia	 coli.	 	 Effects	 of	 toxins	A	 and	B	
were	assessed	on	all	aspects	of	enterocyte	 function	ability.	 	Testing	of	 the	effects	of	 toxin	A	and	B	on	
mature	enterocytes	 in	vitro	resulted	in	damage	and	alterations	in	enterocyte	actin,	 increased	bacterial	
adherence	and	paracellular	transmigration,	thus	correlating	that	Toxins	A	and	B	may	facilitate	bacterial	
adherence	and	penetration	of	the	intestinal	epithelium.			(Feltis,	et	al,		1999)		
If	the	infecting	strain	is	toxigenic,	the	patient	is	at	risk	for	disease.		There	are	other	factors	that	
possibly	 affect	 its	 potency	 such	 as	 fimbriae	 (enabling	 bacterial	 adherence)	 and	 glycocalyx	
(antiphagocytic	 capsule),	 both	 of	 which	 are	 produced	 in	 greater	 numbers	 in	 toxigenic	 strains	 of	 C.	
difficile.	 	 Some	highly	virulent	 strains	produce	elevated	protease	 levels,	 linked	among	other	 clostridial	
pathogens	 to	 increased	 virulence.	 	 Other	 extracellular	 hydrolytic	 enzymes	 may	 play	 a	 similar	 role	
(Bongaerts	and	Lyerly,	1997).			
C.	 difficile	 bacteria	 can	 also	 have	 specific	 antibiotic-resistant	 genes,	 targeting	 specific	
antimicrobial	agents	through	unique	bacterial	physiology	and	biochemistry.	 	An	example	of	this	would	
be	the	ermB	gene,	encoding	a	23S	ribosomal	methylase	that	causes	resistance	to	macrolide-lincosamide-
streptogrammin	 (MLS)	 antibiotics.	 	 This	marker	was	 noted	 in	 several	 cases	 of	C.	 difficile	 after	 use	 of	
Clindamycin,	a	lincosamide	derivative.		(Hull	and	Beck,		2004).			
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Another	 strain	 of	 Clostridium	 difficile	 bacteria	 has	 been	 identified	 relatively	 recently,	 named	
North	 American	 pulsed-field	 gel	 electrophoresis	 type	 1	 (NAP	 1),	 causing	 several	 outbreaks	 in	 North	
America	 and	 Europe.	 	 It	 is	 resistant	 to	 both	 gatifloxacin	 and	 moxifloxacin	 antibiotics	 (both	 of	 the	
fluoroquinolone	antibiotic	group),	unlike	other	strains	previously	designated.			NAP	1	produces	16	times	
greater	 toxin	A	and	23	 times	greater	 toxin	B	 than	other	 strains	do,	possibly	 related	 to	a	deletion	 in	a	
negative	 regulatory	 gene.	 	 It	 also	 produces	 a	 third	 toxin,	 binary	 toxin,	 whose	 purpose	 has	 not	 been	
deemed	 significant	 yet.	 	 (Sunenshine	 and	 McDonald,	 	 2006).	 This	 new	 strain	 has	 become	 the	 more	
dominant	strain,	due	to	the	high	rate	of	mutation.		It	is	highly	virulent	and	has	raised	C.	difficile-related	
death	 rates	 by	 35%	 yearly	 (DeNoon	 and	 Chang,	 2008).	 	 Additionally,	 resistance	 to	 fluoroquinolone	
antibiotics	 gives	 the	 NAP-1	 strain	 with	 the	 ability	 to	 spread	 more	 rapidly	 among	 healthcare	
environments	where	those	antimicrobial	agents	are	most	frequently	used.		(Center	for	Disease	Control	
and	Prevention	(CDC)	2005)	
	
Causes	and	Risk	Factors	
	 The	primary	cause	of	infection	is	due	to	
antimicrobial	 therapy,	 more	 prevalent	 in	
certain	antibiotic	groups.					
Antimicrobial	 agents	 that	 target	
anaerobic	 bacteria	 are	 potentially	more	 lethal,	
possibly	because	 they	alter	 intestinal	 flora	and	
microbial	ecology.		(Gerding	et	al,	1995)	
	 Almost	 all	 antimicrobial	 agents	 except	
for	 aminoglycosides	 are	 associated	 with	
Clostridium	 difficile	 infection	 (Sunenshine	 and	
McDonald,	Cleveland	Clinic	Journal	of	Medicine,	
2006).	 Clindamycin	 has	 been	 identified	 as	 a	
targeting	 agent,	 confirmed	 by	 ermB	 gene	 isolation,	 encoding	 methylase	 enzyme	 causing	 antibiotic	
resistance	 to	 lancosamides	 (Clindamycin	 belonging	 to	 that	 family).	 (Hull	 and	 Beck,	 College	 of	 Family	
Physicians	of	Canada,	2005).	Other	common	high-risk	antibiotics	are	broad	spectrum	penicillins,	second	
and	 third	 generation	 cephalosporins,	 erythromycin,	 sulfonamides,	 chloramphenicol,	 tetracycline,	 and	
fluoroquinolones.	 	 Fluoroquinolones	 in	 particular	were	 isolated	 in	 a	 cohort	 study	 as	 the	 predominant	
risk	factor	for	CDAD	in	a	specific	epidemic	in	Quebec	2003-4	(Pepin	et	al,	2005).				It	is	most	commonly	
due	 to	 oral	 antibiotics	 but	 can	 also	 occur	 due	 to	 intravenous	 or	 intramuscular	 antibiotics.	 (Merck	
Manual,	2006).		Other	antimicrobial	agents,	including	antiviral	and	antifungal	drugs	increase	the	risk	as	
well	(Mayo	Clinic	2006).	Risk	more	than	doubles	with	greater	than	three	days	of	antimicrobial	therapy.			
Reduced-risk	 antibiotics	 include	 vancomycin,	 metronidazole,	 and	 antipseudomonals.		
(Schroeder,		2005).			 		
Figure 5– marked exudates protruding through 
mucosal ulcerations 
(Cleveland Clinic, 2006) 
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The	critical	point	of	infection	is	right	after	normal	intestinal	flora	depletion	before	replenishing	
(Bongaerts	and	Lyerly,		1997).			
Other	 drugs	 may	 increase	 susceptibility	 as	 well,	 such	 as	 drugs	 and	 conditions	 that	 decrease	
gastric	 acidity.	 	Over	 the	 counter	 antacids	 and	proton	pump	 inhibitors	 such	as	 aciphex,	 prevacid,	 and	
related	 drugs	would	 put	 a	 patient	 at	 higher	 risk	 (Merck	Manual,	 2006).	 	 Proton	 pump	 inhibitor	 (PPI)	
utilization	 is	 associated	 with	 upper	 gastrointestinal	 tract	 colonization	 and	 altering	 of	 intestinal	 flora.		
Decreased	 gastric	 acidity	 is	 a	 known	 risk	 factor	 for	 infectious	 diarrheal	 illnesses.	 	 Since	 Clostridium	
difficile	bacteria	thrive	on	higher	gastric	pH	levels,	decreased	gastric	acidity	may	also	pose	a	risk	factor	
for	 CDAD.	 This	 is	 supported	 by	 CDAD	 cases	 reported	 from	 patients	 receiving	 Helicobactor	 pylori	
treatment	–	 combining	proton	pump	 inhibitors	with	antibiotics.	 	A	 study	comparing	 rate	of	C.	difficile	
infection	in	patients	undergoing	gastric	acid	suppressive	therapy	with	those	who	did	not,	with	PPI	usage	
increasing	the	risk	significantly.	(Dial	et	al,	CMAJ,	2004).		Two	case-controlled	studies	conducted	over	ten	
years	 showed	 the	 increase	 in	 rate	 of	Clostridium	 difficile	 infection	 due	 to	 PPI	 usage	 and	H2	 blockers.		
(Dial,	et	al,	JAMA,	2005).	
Additional	 risk	 factors	 included	use	of	non-steroidal	anti-inflammatory	drugs	 (NSAIDs),	such	as	
ibuprofen.		Being	methicillin-resistant	Staphylococcus	aureus	positive	increases	susceptibility	in	hospital	
patients.		(Dial,	et	al,	JAMA,	2005).	
Exposure	to	Clostridium	difficile	can	occur	through	a	variety	of	methods.		Transfer	of	pathogenic	
organisms	 is	 highly	 prevalent	 via	 the	 hands	 of	 health-care	workers	 and	 is	 considered	 the	most	 likely	
mechanism.		(Centers	for	Disease	Control	and	Prevention	(CDC)	2007).			
Other	risk	factors	 include	underlying	 illness,	weakened	 immune	system,	recent	hospitalization,	
residency	 in	 long-term	 care	 facilities,	 recent	 surgery	 –	 primarily	 abdominal/gastrointestinal,	 chronic	
colon	disease	such	as	inflammatory	bowel	disease	or	colon	cancer.		Additionally,	previous	infection	with	
Clostridium	 difficile	 increases	 patient	 susceptibility	 to	 reinfection.	 	 (Mayo	 Clinic,	 2006).	 	 	 Highest	 risk	
patients	are	those	with	recent	immunosuppressive	therapy	or	recent	surgical	procedures,	partly	due	to	
patients’	 inability	to	generate	IgG	antibody	immune	response	against	Clostridium	difficile	toxin	A.	 	 	 IgG	
immune	 response	 ability	 does	 not	 protect	 against	 colonization	 but	 can	 decrease	 risk	 of	 morbidity,	
mortality,	or	recurrence	with	C.	difficile	infection	(Schroeder,		2005).			
Cancer	chemotherapy	and	increased	age	and	severity	of	underlying	illness	are	other	possible	risk	
factors	(Hull	and	Beck,		2005)	
	
Clinical	Manifestations	of	Enterocolitis	
											More	commonly,	patients	experience	colonization	rather	than	disease.	 	Such	patients	exhibit	no	
clinical	 symptoms	even	 though	 they	would	 test	positive	 for	C.	difficile	organism	and/or	 toxins.	 	Other	
times,	 patients	 contract	Clostridium	difficile-Associated	 Disease	 (CDAD)	 and	 exhibit	 clinical	 symptoms	
(Centers	for	Disease	Control	and	Prevention,	2005).			
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														Common	 symptoms	 for	Clostridium	difficile	 infection	 are	watery	 diarrhea	 (characterized	 by	 at	
least	 three	 bowel	 movements	 daily	 for	 more	 than	 two	 days	 but	 usually	 ten	 or	 more),	 abdominal	
cramping	and	tenderness,	nausea,	loss	of	appetite,	and	fever	of	up	to	104	–	105	degrees	F.			(Centers	for	
Disease	Control	and	Prevention,	2004).	 	 It	 is	also	possible	to	have	an	abnormal	heartbeat	(Healthwise,	
2006).	 	Other	 symptoms	 include	blood	or	pus	 in	 the	 stool,	dehydration,	and	weight	 loss	 (Mayo	Clinic,	
2006).	 	Watery	 diarrhea	 is	 the	most	 common	 symptom	 of	 CDAD	 in	 children	 (Infectious	 Diseases	 and	
Immunization	Committee,	2000).	Rarely	are	symptoms	manifested	outside	the	gastrointestinal	tract,	but	
can	include	cellulitis,	bacteremia,	visceral	abscess	formation,	and	reactive	arthritis.		A	common	indicator	
would	be	leukocytosis	with	a	white	blood	cell	count	greater	than	30.0	x109/L	(Hull	and	Beck,		2004).			
													Symptoms	can	appear	 immediately	after	or	during	antimicrobial	 therapy,	but	can	often	appear	
several	 weeks	 after	 completing	 all	 antibiotics.	 	 This	 was	 evidenced	 in	 a	 study	 of	 cancer	 outpatients	
diagnosed	with	CDAD	where	the	median	interval	(range	2-60	days)	from	discharge	to	infection	was	20.3	
days	–	a	3	week	delay	(Sunenshine	and	McDonald,		2006).		
												Range	 of	 disease	 can	 vary	 in	 different	 individuals	 from	 asymptomatic	 colonization	 to	 severe	
fulminant	pseudomembranous	colitis.			
	Many	cases	are	mild.		Such	patients	develop	mild	to	moderate	watery	diarrhea	with	abdominal	
cramping	and	nausea,	similar	to	ordinary	viral	gastroenteritis.		They	may	last	a	short	duration	to	several	
weeks	 but	 usually	 improve	without	 treatment	 (EMIS	 and	 PIP,	 2007).	 	 Systemic	 symptoms	 are	 usually	
 
Figure 6 – 
Pathogenesis of 
Clostridium difficile  
Infection (Adapted 
from “Clostridium 
difficile –Associated 
Diarrhea”, Schroeder, 
2005) 
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absent	and	disease	would	only	be	considered	due	to	abdominal	tenderness	upon	physical	examination	
(Sunenshine	 and	McDonald,	 2006).	 	 They	may	 also	 include	 low	 grade	 leukocytosis	 and	 tenesmus	 –	 a	
sudden	urge	to	evacuate	the	rectum	(Hull	and	Beck,	2004).			
Moderate	 infectious	symptoms	include	leukemoid	reaction	–	a	stress	response	to	disease	with	
an	 increased	 leukocyte	count	of	approximately	50.0	x109/L,	 fever,	dehydration,	nausea,	 vomiting,	and	
abdominal	tenderness.	Hull	and	Beck,	2004).			
The	 severest	 cases	 present	 with	 dehydration	 and	 electrolyte	 disturbance,	 severe	 bloody	
diarrhea,	fever,	and	abdominal	pain	and	cramping	(EMIS	and	PIP,	2007).	It	may	lead	to	sepsis	and	shock,	
acidosis	 (increased	 acidity	 of	 blood	 plasma),	 tachycardia,	 multisystem	 organ	 failure	 including	 kidney	
failure	 (due	 to	 rapid	dehydration),	hypoalbuminemia,	paralytic	 ileus,	ascites	 (fluid	accumulation	 in	 the	
peritoneal	cavity),	acute	abdomen	–	colonic	perforation,	toxic	megacolon	(toxic	colitis	with	dilatation),	
and	death.		Endoscopic	evaluation	of	the	colon	will	show	pseudomembraneous	white	patches	or	lesions	
with	erythema	and	edema.		The	lesions	are	yellow	plaques	2-10	mm	in	diameter	with	interposed	normal	
intestinal	mucosa	(Hull	and	Beck,	2004).		Should	a	patient	develop	paralytic	ileus	or	toxic	megacolon,	it	
may	 actually	 lead	 to	 a	 decrease	 in	 diarrheal	 episodes.	 	 (Sunenshine	 and	 McDonald,	 2006).	 	 Toxic	
megacolon	 is	 rare	 but	 has	 been	 documented	 in	 several	 cases,	 leading	 to	 a	mortality	 rate	 of	 33%	 for	
those	 who	 develop	 it.	 	 A	 critical	 factor	 in	 survival	 would	 be	 early	 diagnosis	 of	 Clostridium	 difficile-
associated	pseudomembranous	colitis	(Cone	and	Wetzel,	1982).		
Diagnosis		
Detailed	history	is	the	first	step	to	proper	diagnosis.		Patients	are	screened	for	recent	antibiotic	
usage,	 abdominal	 pain,	 diarrhea,	 and	 related	 symptoms.	 	 Doctors	 may	 still	 test	 without	 presence	 of	
diarrhea	 since	 in	 rare	 instances	C.	difficile	 bacteria	 can	 cause	abdominal	pain	and	 tenderness	without	
diarrhea	(MedicineNet,	2008).		C.	difficile	is	also	suspected	when	diarrhea	develops	during	or	soon	after	
hospitalization	(EMIS	and	PIP,	2007).				
Figure 7 – (L) Image of normal cecum  
(R) Image of pseudomembranes formed from Clostridium difficile overgrowth of 
cecum.   
(Adapted from  Johnson, Medical Microbiology,  2009) 
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Treating	 without	 diagnostic	 laboratory	 basis	 is	 not	 indicated,	 especially	 since	 only	 30%	 of	
hospitalized	patients	with	diarrhea	have	CDAD,	even	during	epidemics.			There	are	some	exceptions	for	
which	 empiric	 therapy	 would	 be	 necessary	 –	 including	 severely	 ill	 or	 rapidly	 deteriorating	 high-risk	
patients	(Sunenshine	and	McDonald,	2006).		
												Patients	 with	 CDAD	 often	 have	 leukocytosis	 with	 strong	 elevation	 in	 severe	 enterocolitis.		
Physicians	 may	 screen	 leukocyte	 count	 as	 well	 as	 for	 white	 blood	 cell	 presence	 in	 the	 stool.		
Confirmation	 of	 those	 two	 tests	 proves	 positive	 for	 colitis	 and	would	 need	more	 testing	 to	 diagnose	
CDAD	 (MedicineNet,	 2008).	 	 	 Stool	 leukocyte	 measurement	 may	 have	 limited	 diagnostic	 accuracy	
(Nation	Master	Encyclopedia,	2005).			A	sudden	rise	in	the	leukocyte	count	to	between	30-50x109/L	cells	
combined	 with	 severe	 bandemia	 (immature	 white	 blood	 cells)	 is	 an	 indicator	 of	 fulminant	 colitis.		
Patients	 should	 be	monitored	 for	 leukemoid	 reaction	 as	 shock	 can	 progress	 very	 quickly	 (Schroeder,	
2005).	
Stool	assay	for	Clostridium	difficile	is	a	routine	method.			It	is	not	always	reliable	as	it	sometimes	
produces	false-negatives	(Mayo	Clinic,	2006).			Additionally,	although	the	most	sensitive	test	possible,	it	
can	 also	 cause	 false-positives	 due	 to	 the	 available	 non-
toxigenic	strains.	 It	must	grow	48-96	hours	anaerobically	
for	 proper	 results.	 	 (Centers	 for	 Disease	 Control	 and	
Prevention	 (CDC),	 2005).	 	 It	 has	 an	 overall	 sensitivity	 of	
95%	 but	 has	 a	 low	 specificity,	 necessitating	 toxicity	
testing	 (Canadian	 Paediatric	 Society,	 Paediatrics	 &	 Child	
Health,	 2000).	 	 	 It	 is	 not	 specific	 for	 pathogenic	 toxin-
producing	 strains	 of	 Clostridium	 difficile	 and	 is	 not	 as	
clinically	 helpful	 (Schroeder,	 American	 Family	 Physician,	
2005).	 	 It	 is	 the	 least	 chosen	 method	 of	 testing	 in	
hospitals	 due	 to	 cost	 and	 length	 of	 procedure.	 	 It	 does	
however	have	an	advantage	of	lending	itself	to	molecular	
typing	 of	 strains,	 useful	 in	 a	 C.	 difficile	 outbreak	
(Sunenshine	and	McDonald,	2006).	
Antigen	 detection	 for	 C.	 difficile	 are	 rapid	 tests	
completed	in	less	than	an	hour,	used	to	detect	presence	of	C.	difficile	antigen	by	latex	agglutination	or	
immunochromatographicassays.	 	 It	 must	 be	 combined	 with	 toxin	 testing	 for	 diagnostic	 confirmation	
(Centers	for	Disease	Control	and	Prevention	(CDC),	2005).		
Toxin	testing	includes	both	enzyme	immunoassay	and	tissue	culture	cytotoxicity.			
Enzyme	 immunoassay	detects	 toxins	A,	B,	or	both	 together.	 	 It	uses	monoclonal	antibodies	 to	
detect	toxin	(Hull	and	Beck,	2004).		Assay	is	completed	same-day	but	is	less	sensitive	than	tissue	culture	
cytotoxicity	 assay	 (Centers	 for	 Disease	 Control	 and	 Prevention	 (CDC),	 2005).	 	 Enzyme-linked	
Immunoabsorbant	Assay	(ELISA)	has	a	sensitivity	rate	of	63-99%	and	a	specificity	of	93-100%.	 	Experts	
recommend	 sending	 as	many	as	 3	 samples	 to	 rule	out	disease	 if	 patients	 receive	negative	 result,	 but	
Figure 8 – anaerobic culture of 
Clostridium difficile bacteria on 
Cycloserin-Cefoxitin Fructose Agar 
(Anaerobe Systems, CA)  
(Adapted from  Johnson, Medical 
Microbiology,  2009) 
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may	 not	 be	 necessary	 as	 much	 with	 ELISA	 (Nation	 Master	 Encyclopedia,	 2005).	 	 	 	 The	 majority	 of	
combination	enzyme	immunoassays	have	a	sensitivity	of	85-95%.		It	should	not	be	used	as	an	indicator	
of	response	to	therapy	since	results	remain	positive	for	extended	duration	in	25%	of	successfully	treated	
patients	(Schroeder,	2005).		
Tissue	culture	cytotoxicity	tests	only	for	presence	of	toxin	B.		It	is	called	the	‘gold	standard’	toxin	
bioassay	 (Canadian	Paediatric	 Society,	Paediatrics	&	Child	Health,	 2000).	 It	 requires	24-48	hours	 for	 a	
final	result	and	is	very	sensitive	for	C.	difficile	(Centers	for	Disease	Control	and	Prevention	(CDC),	2005).			
Organisms	are	cultured	on	selective	medium	and	tested	for	toxin	production	and	cytopathic	effect	in	cell	
culture.		It	is	the	most	sensitive	and	specific	test	although	it	is	slow	and	labor-intensive	(Nation	Master	
Encyclopedia,	2005).			Due	to	its	high	specificity	and	sensitivity,	one	should	be	cautious	for	false	results	
(Canadian	Paediatric	Society,	2000).	
C.	 difficile	 toxin	 is	 very	 unstable.	 	 Toxin	 degrades	 at	 room	 temperature	 and	 may	 not	 be	
detectable	2	hours	after	collection	of	stool.			False-negative	results	are	prevalent	due	to	delayed	testing	
or	lack	of	refrigeration.			
Stool	 lactoferrin	levels	can	also	be	a	diagnostic	test	but	has	limited	diagnostic	accuracy	as	well	
(Nation	Master	Encyclopedia,	2005).			Other	rapid	testing	such	as	Immunocard	(Meridian	Diagnostics)	is	
highly	specific	but	has	poor	sensitivity	with	up	to	20%	false	negative	results	(Canadian	Paediatric	Society,	
2000).	 	 Latex	agglutination-based	assays	 recognize	enzyme	glutamate	dehydrogenase	but	do	not	have	
sensitivity	 (Hull	 and	 Beck,	 2004).	 	 Polymerase	 chain	 reaction	 (PCR)	 detects	 toxigenic	 C.	 difficile.		
Amplification	 of	 a	 gene	 portion	 of	 either	 toxin	 A,	 toxin	 B,	 or	 a	 combination	 of	 the	 two	 genes	 is	
performed.	 	PCR	can	be	conducted	on	the	specimen	organisms	for	presence	of	toxins	that	match	with	
the	 reading	 of	 the	 known	 toxins.	 	 One	 testing	 conducted	 (Kato	 et	 al)	 amplified	 only	 toxin	 A	 from	C.	
difficile.		Others	had	similar	or	less	success.		It	is	not	as	sensitive	as	other	testing	methods	(Gerding	et	al,	
1995).		
Colon	 examination	 is	 used	 to	 confirm	 diagnosis	 of	 Clostridium	 difficile.	 	 Patients	 undergo	
sigmoidoscopy	or	colonoscopy	to	screen	for	presence	
of	 inflammation	 and	 pseudomembrane	 appearance,	
both	suggesting	CDAD	(Mayo	Clinic,	2006).			It	should,	
however,	be	 reserved	 for	when	a	patient’s	condition	
needs	rapid	diagnosis,	to	rule	out	other	diagnoses,	or	
when	 clinical	 suspicion	 is	 high	 despite	 negative	
results.	 	 Colonoscopy	 can	 detect	 more	 than	 a	
sigmoidoscopy	 since	 it	 examines	 the	 whole	 colon	
where	C.	difficile	can	encompass,	rather	than	just	the	
sigmoid	colon	(Hull	and	Beck,	2004).			
Imaging	 tests	 such	 as	 CT	 scans	 provide	
detailed	 images	 of	 the	 colon.	 	 Scans	 can	 show	
thickening	 of	 the	 colon	 wall,	 common	 in	
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pseudomembranous	 colitis	 (Mayo	 Clinic,	 2006).	 	 In	 conjunction	 with	 the	 clinical	 history,	 presence	 of	
ascites,	colon	wall	thickening,	or	dilation	can	predict	severity	of	enterocolitis	(Schroeder,	2005).														
Treatment	
	 No	 treatment	 is	 necessary	 for	 colonization	 without	 symptomology.	 	 Should	 symptoms	 be	
present	with	diagnosis	confirmed,	there	are	different	treatment	options.			
	 If	at	all	possible,	the	disease-causing	antibiotics	should	be	stopped.		This	alone	can	allow	normal	
intestinal	flora	to	regenerate.		Overgrowth	of	C.	difficile	would	be	reduced	with	less	symptoms	ensuing.		
For	mild	to	moderate	diarrhea	and	other	symptoms,	cessation	of	antimicrobial	therapy	may	be	the	only	
necessary	 cause	 of	 treatment	 (EMIS	 and	 PIP,	 2007).	 	 CDAD	 typically	 resolves	 in	 23%	 of	 cases	 upon	
removal	from	the	antimicrobial	treatment	(Centers	for	Disease	Control	and	Prevention	(CDC),	2005).			
	 Fluids	 may	 be	 given	 to	 prevent	 dehydration	 and	 restore	 electrolyte	 balance	 in	 the	 blood	
(Healthwise,	2006).		
	 For	severe	cases	of	diarrhea	or	diagnosed	colitis,	patients	will	be	treated	with	an	antibiotic	that	
eradicates	C.	difficile	organisms,	usually	Vancomycin	(Vancocin)	or	Metranidazole	(Flagyl),	for	ten	days.		
In	 a	 study	 of	 189	 patients	 with	 CDAD,	 97%	 responded	 to	 initial	 antibiotic	 therapy	 (Sunenshine	 and	
McDonald,	Cleveland	Clinic	Journal	of	Medicine,	2006).		Symptoms	should	subside	within	2-3	days.		The	
antibiotics	can	also	prevent	perforation	of	the	colon	if	treated	in	time	(EMIS	and	PIP,	2007).		Drugs	are	
usually	 effective	 with	 few	 side	 effects	 (Centers	 for	 Disease	 Control	 and	 Prevention	 (CDC),	 2007).	 	 In	
severe	 cases,	 intravenous	 medications	 may	 need	 to	 be	 administered	 (Robert	 Michael	 Educational	
Institute,	2007).			Both	Vancomycin	and	Metranidazole	are	equally	effective.		Physicians	may	choose	to	
prescribe	Metranidazole	first	since	it	is	far	less	expensive	than	Vancomycin.		Vancomycin	is	reserved	for	
patients	who	are	allergic	to	Metronidazole,	do	not	respond	to	it,	or	have	side	effects.		Other	physicians	
choose	Vancomycin	primarily	for	severe	colitis	since	 it	can	achieve	higher	antibiotic	 levels	 in	the	colon	
and	 can	 theoretically	 be	 more	 effective	 at	 eradicating	 bacteria	 there	 with	 more	 area	 specificity	
(MedicineNet,	 2008).	 	 	 It	 can,	 however,	 contribute	 to	 the	 growth	 of	 antibiotic-resistant	 bacteria.		
Metranidazole	can	not	be	used	for	women	who	are	pregnant	or	breastfeeding.		Both	antibiotics	kill	only	
the	active	infectious	form	of	C.	difficile,	not	the	tougher	spores.		Since	spores	are	resistant	and	remain	in	
the	body,	 infection	 can	 return,	 requiring	 further	 treatment	 (Mayo	Clinic,	 2006).	 	 	 For	 those	unable	 to	
tolerate	 oral	 medication,	 IV	 Metronidazole	 is	 used	 since	 it	 is	 excreted	 in	 the	 intestine	 (Canadian	
Paediatric	Society,	2000).	
	 Other	drug	regimens	compared	in	randomized	therapeutic	trials	for	CDAD	with	good	results	are	
Bacitracin,	Teicoplanin,	and	Colestipol.	 	Cure	rates	in	Bacitracin	are	somewhat	lower	than	Vancomycin,	
and	 it	 should	be	 treated	 as	 a	 secondary	 agent	 in	 treatment.	 	 Colestipol	 is	 even	 lower	 than	Bacitracin	
(Gerding	et	al,	1995).		
	 Some	 physicians	 prescribe	 supplementary	 probiotics	 to	 restore	 normal	 intestinal	 flora.	 	 A	
natural	 yeast,	 Saccharomyces	 boulardii,	 and	 Lactobacillus	 species	 has	 proven	 effective	 in	 treating	 C.	
difficile	infections	together	with	antibiotic	(Sunenshine	and	McDonald,	2006).			
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Antidiarrheal	 medications	 such	 as	 loperamide,	 diphenoxylate,	 and	 bismuth	 compounds	 are	
contraindicated	and	can	worsen	 the	course	of	pseudomembranous	colitis.	 	 Slowing	of	 fecal	 transit	 tie	
can	 possibly	 extend	 toxin-associated	 damage.	 	 Cholestyramine,	 usually	 used	 to	 lower	 cholesterol,	 is	
more	 effective	 in	 slowing	bowel	motility	without	 causing	more	damage	 (Nation	Master	 Encyclopedia,	
2005).		
	If	the	disease	causes	fulminant	colitis,	surgical	resection	of	the	colon	may	be	needed,	especially	
with	 colon	 perforation	 (EMIS	 and	 PIP,	 2007).	 	 	 In	 e	 cases	 causing	 severe	 pain,	 organ	 failure,	 or	
inflammation	 of	 abdominal	 wall	 lining,	 surgical	 removal	may	 be	 the	 only	 option	 (Mayo	 Clinic,	 2006).			
Surgery	should	be	considered	especially	if	initial	treatment	does	not	resolve	the	disease	and	symptoms	
progress	 rapidly.	 	 Still,	 treatment	 should	 not	 be	 considered	 failure	 before	 6-7	 days	 of	 therapy	
(Sunenshine	and	McDonald,	2006).	 	At	 times,	a	patient	may	 relapse	with	 recurring	episodes	of	CDAD.		
Multiple	courses	of	antibiotics	may	be	needed.	 	Probiotic	 treatment	may	be	helpful	 for	this	 (Canadian	
Paediatric	Society,		2000).		Approximately	15-35%	of	patients	have	recurrent	disease.		This	could	be	from	
reinfection	or	germination	from	residual	spores.		The	most	likely	reason	for	relapse	is	that	C.	difficile	had	
not	 been	 completely	 eradicated	 during	 treatment	 (MedicineNet,	 2008).	 	 	 	 There	 is	 no	 evidence	 that	
recurring	 infections	cause	more	severe	disease	(Hull	and	Beck,	College	of	Family	Physicians	of	Canada,	
2004).	 	 	Another	possible	 reason	 leading	 to	 relapse	 is	 the	body’s	 inadequate	production	of	antibodies	
against	 the	bacterial	 toxins	 (MedicineNet,	2008).	 Fecal	enemas,	however,	 are	difficult	 to	perform	and	
there	is	an	increased	risk	of	transmitting	retroviruses	or	other	infectious	diseases	(Schroeder,	2005).				
	Fecal	 bacteriotherapy,	 sometimes	 commonly	 called	 a	 “stool	 transplant”,	 has	 its	 basis	 in	
probiotic	 therapy	 research.	 	 Normal	 intestinal	 bacterial	 flora	 obtained	 from	 the	 feces	 of	 a	 healthy	
individual	 is	 infused	 through	 the	 intestine	of	 the	patient	 in	 an	 effort	 to	 restore	 normal	 flora	 balance,	
decreasing	the	strength	of	the	C.	difficile	organisms	and	lessen	likelihood	of	recurrence.		This	treatment	
is	usually	used	for	people	with	recurring	episodes	of	disease.		It	has	a	success	rate	of	nearly	95%	(Nation	
Figure 10 – Laboratory preparation of stool for fecal bacteriotherapy  
(The Medical Post, 2009) 
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Master	 Encyclopedia,	 2005).	 	 	 Anaerobic	 bacteria	 and	 fecal	 rectal	 enemas	 are	 usually	 obtained	 from	
healthy	relatives	to	promote	better	acceptance	by	the	patient’s	body.		They	are	instilled	rectally	and	can	
restore	colonic	flora	(Hull	and	Beck,	2004).	
For	patients	with	multiple	relapses	possibly	due	to	antibody	deficiency,	passive	 immunizations	
with	human	gammaglobulin	can	be	administered	intravenously.	 	This	will	grant	them	large	amounts	of	
antibodies	to	eradicate	the	disease.		Additional	work	is	in	progress	to	promote	active	vaccination	against	
C.	difficile	toxins,	to	increase	patient	levels	of	antibodies.		(MedicineNet,	2008)	
	
Prevention	
	 Most	 importantly,	 avoid	 using	 antibiotics	 unless	 absolutely	 necessary.	 	 Antibiotics	 will	 not	
eradicate	 viral	 illnesses,	 yet	 they	 are	 still	 used	 for	 that	 purpose	 several	 times	 annually.	 	 Even	 some	
common	bacterial	ailments	 like	bronchitis	and	ear	 infections	can	be	treated	without	antibiotics	 (Mayo	
Clinic,	 2006).	 	 In	 particular,	 restriction	 of	 Clindamycin	 has	 been	 shown	 to	 decrease	 incident	 of	 CDAD	
(Schroeder,	2005).		
	 If	antibiotics	are	necessary,	have	 the	physician	prescribe	 from	a	narrow-spectrum	range	 to	be	
taken	 in	 the	 shortest	 amount	 of	 time	possible	 for	 least	 likelihood	of	 disrupting	 intestinal	 flora	 (Mayo	
Clinic,	2006).		
	 Use	 probiotic	 supplements	 –	 yogurt	 with	 live	 cultures,	 acidophilus,	 and	 similar	 during	 the	
antibiotic	 course.	 	 However,	 only	 Saccharomyces	 boulardii	 is	 proven	 effective	 against	 C.	 difficile	
specifically	 (Mayo	 Clinic,	 2006).	 	 Lactobacilli	 have	 been	 proven	 effective	 against	 antibiotic-associated	
diarrhea,	but	not	necessarily	that	caused	by	Clostridium	difficile.			
	 Any	patient	with	CDAD,	 even	 asymptomatically	 colonized,	 can	 transmit	 the	disease	 to	others.		
Only	those	on	antibiotics,	hospitalized,	or	with	other	prevailing	risk	factors	are	most	likely	to	get	ill.		To	
reduce	 transmission,	wash	hands	 carefully	especially	after	 restroom	use	and	before	eating.	 	Regularly	
clean	 surfaces	 used	 routinely,	 such	 as	 kitchens	 and	 bathrooms	 (Centers	 for	 Disease	 Control	 and	
Prevention	(CDC),	2007).	 	 Ideally,	a	mixture	of	bleach	and	water	should	be	used	–	with	a	ratio	of	1:10	
bleach	to	water.		Patients	with	diarrhea	should	try	to	avoid	using	the	same	toilet	other	family	members	
use	unless	it	can	be	washed	out	each	time	with	the	bleach	and	water	mixture	(Robert	Michael	2007).		
	 Hospitalized	patients	known	or	suspected	to	have	the	disease	should	be	treated	using	the	1994	
Hospital	Infection	Control	Practices	Advisory	Committee	(HICPAC)	Guideline	for	Isolation	Precautions	in	
Hospitals	 recommended	 contact	 precautions	 (Sunenshine	 and	 McDonald,	 Cleveland	 Clinic	 Journal	 of	
Medicine,	2006).		Place	those	patients	in	private	rooms	if	possible,	or	with	other	patients	with	C.	difficile-
associated	disease.		Use	gloves	and	gowns	to	prevent	transmission	and	wash	hands	with	alcohol-based	
hand	rubs	or	soap	and	water.	Soap	and	water	alone	is	best	for	direct	care	of	CDAD	patients	as	it	is	more	
effective	against	spore-forming	bacteria.	 	Dedicate	equipment	to	them	wherever	possible.	 	(Division	of	
Healthcare	Quality	 Promotion	 (DHQP),	 2005)	 	 Visitors	 should	wash	 hands	with	 soap	 and	warm	water	
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before	entering	and	leaving	a	CDAD	patient’s	room.	(Mayo	Clinic,	2006).	 	One	hospital	reported	a	60%	
decrease	in	CDAD	after	instituting	more	stringent	precautions	(Sunenshine	and	McDonald,	2006).			 		
	
Summary	
	 Clostridium	 difficile-Associated	 Disease	 (CDAD)	 may	 be	 a	 slightly	 rare	 disease	 but	 with	
devastating	 effects.	 	Due	 to	depletion	of	 normal	 intestinal	 flora	 in	 conjunction	with	other	 risk	 factors	
including	 immunocompromised	 state	or	 recent	hospitalization,	 dormant	 resistant	 spores	 transform	 to	
virulent	 possibly	 toxigenic	 infectious	 form	 of	 bacteria	 that	 can	 multiply	 rapidly.	 	 Although	 broad	 in	
arrange	 of	 symptomology,	 the	 possibility	 of	 leading	 to	 severe	 pseudomembranous	 colitis	with	 risk	 of	
colonic	perforation,	toxic	megacolon,	or	death	exists.		Treatment	is	possible	–	with	expensive	drugs	and	
other	measures,	but	not	without	the	possibility	of	relapse,	even	numerous	reoccurrences.	 	Prevention	
must	be	taken	to	avoid	susceptibility	to	this	virulent	and	damaging	organism	altogether,	by	maintaining	
proper	precautions.	 	 	Should	someone	already	have	the	disease,	proper	care	must	be	 implemented	to	
ensure	 no	 further	 transmission	 as	 spores	 can	 be	 spread	 through	 contact	 and	 fecal-oral	 methods.		
Research	is	still	preliminary	for	other	treatments,	including	vaccination	against	C.	difficile	toxins.			With	
proper	prevention	and	treatment,	and	increase	in	patient	antibodies	to	target	the	organism,	even	in	the	
absence	of	normal	intestinal	flora,	Clostridium	difficile-Associated	Disease	can	be	eradicated.		
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																																																																		Aspartame:	A	sweet	toxin?	
Atara	Rena	Degani	
Abstract	
L-aspartyl-L-phenylalanyl-methyl	 ester,	 commonly	 known	 as	 aspartame,	 is	 one	 of	 the	 most	
widely	used	and	controversial	sweeteners.	Many	have	questioned	the	safety	of	this	chemical,	concerned	
that	it	may	be	neurotoxic	and	carcinogenic.	Numerous	studies	have	been	conducted	on	the	three	basic	
constituents	of	aspartame:	aspartic	acid,	phenylalanine	and	methanol;	scientists	have	tried	to	determine	
whether	 the	 ingestion	 of	 aspartame	will	 cause	 a	 significant	 increase	 in	 blood	 plasma	 levels	 of	 these	
chemicals,	and	whether	such	an	increase	is	dangerous.	This	review	analyzes	various	studies	conducted	
on	the	health	effects	of	these	metabolitic	byproducts	of	aspartame.	
	
Introduction	
	 Consumers	were	 thrilled	when	 aspartame	was	 introduced	 to	 the	market.	 	 Since	 this	 artificial	
sweetener’s	 safety	was	approved,	 it	has	 found	 its	way	 into	over	6,000	products,	 including	soft	drinks,	
chewing	gum,	hot	chocolate,	candy,	desserts,	sweeteners,	and	yogurt.	Sold	commercially	under	names	
such	 as	 Nutra-Sweet,	 Equal	 and	 Canderel,	 aspartame	 is	 two	 hundred	 times	 sweeter	 than	 sucrose.		
Although	 it	 has	 the	 same	 number	 of	 calories	 per	 gram	 as	 sucrose,	 people	 generally	 use	 less	 of	 it,	
consuming	fewer	calories	(Soffritti	et	al.	2006).	
The	discovery	of	aspartame	was	accidental.	In	1965,	James	M.	Schlatter	discovered	this	chemical	
as	he	was	trying	to	produce	an	anti-ulcer	drug	candidate	for	G.D.	Searle	&	Company.	Some	aspartame	
spilled	on	his	hand,	yet	he	did	not	wash	it	off,	believing	that	it	was	not	toxic.	He	came	to	recognize	its	
sweetness	when	he	 licked	his	 fingers	 in	 order	 to	pick	 up	 a	weighing	paper.	 	Despite	 its	 unintentional	
discovery,	aspartame	has	had	a	profound	impact	on	the	dieting	habits,	and	it	is	one	of	the	most	widely	
used	artificial	sweeteners	in	the	world	(Sofffritti	et	al.,	2007).	
Aspartame’s	 unique	 formula	 helps	 obese	 maintain	 their	 weight	 loss	 programs	 and	 allows	
diabetics	to	enjoy	exceptional	dishes	within	their	dietary	restrictions	(Butchko	et	al.	2002).		In	the	United	
States,	 the	 acceptable	 daily	 intake	 (ADI)	 of	 aspartame	 is	 50	mg/kg	 body	weight.	 Consumption	 by	 the	
general	population	 ranges	 from	2	 to	3	mg/kg	body	wt,	and	 the	average	consumption	by	children	and	
women	of	child	bearing	age	has	been	estimated	at	2.5-5.0	mg/kg	bw/day	(Soffriti	et	al.,	2007).	
Extensive	research	was	done	on	the	safety	of	aspartame	before	it	entered	the	market.	Various	
studies	were	conducted	with	a	number	of	human	populations	in	order	to	determine	its	safety;	research		
was	done	on	a	range	of	ages	and	on	various	segments	of	society,	such	as	obese	 individuals,	diabetics,	
and	individuals	heterozygous	for	the	genetic	disease	phenylketonuria	(Butchko	et	al.	2002).		While	many	
studies	affirm	the	safety	of	aspartame,	numerous	scientists	have	raised	serious	concerns	regarding	the	
harmfulness	 of	 this	 chemical,	 pointing	 to	 the	 toxic	 nature	 of	 its	 constituents.	 Today	 controversy	 still	
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exists	about	 its	safety.	Numerous	anecdotal	 reports	were	released	subsequent	to	aspartam’s	approval	
describing	 the	 adverse	 health	 affects	 associated	with	 it.	Written	 complaints	 include	 that	 of	 dizziness,	
visual	 impairment,	disorientation,	ear	buzzing,	 tunnel	 vision,	 loss	of	equilibrium,	 severe	muscle	aches,	
numbing	of	extremities,	increased	blood	pressure,	retinal	hemorrhaging	and	depression	(Monte	1984).	
Even	more	serious	 is	 the	startling	rise	 in	brain	tumor	rates	since	the	 introduction	of	aspartame	to	the	
market	(Olney	et	al.	1996).	
	
FDA	Approval	
Aspartame	was	approved	by	the	FDA	for	use	in	solid	foods	in	1981,	in	soft	drinks	in	1983,	and	as	
a	general	sweetener	in	1996.	The	FDA	denied	approval	of	this	sweetener	for	eight	years	before	allowing	
it	on	the	market	since	researchers	had	discovered	that	the	ingestion	of	aspartame	yielded	toxic	effects.	
A	Public	Board	of	Inquiry	(PBOI)	convened	in	1980	to	review	the	research	of	G.D.	Searle	and	Company	
and	they	denied	approval	of	the	chemical	due	to	lack	of	sufficient	evidence	proving	that	aspartame	did	
not	 cause	 cancer.	 The	 FDA	 commissioner,	 Arthur	 Hull	 Hayes,	 established	 another	 PBOI	 in	 1981.	 This	
board	did	not	reach	a	consensus	regarding	the	chemical,	yet	the	commissioner	overruled	his	own	board	
of	inquiry	and	approved	the	food	additive.	Conspiracy	theories	brew	because	Hayes	left	the	FDA	in	1983	
to	join	the	public	relations	department	of	Searle	(Whitmore	1996).	The	validity	of	the	FDA’s	approval	is	
further	 questioned	 when	 the	 research	 conducted	 on	 aspartame	 is	 analyzed.	 	 One	 is	 compelled	 to	
question	 the	 design	 efficiency	 of	many	 studies	when	 one	 notes	 that	 100%	of	 the	 74	 industry-funded	
studies	found	no	problem,	while	83	out	of	90	non-industry	funded	studies	found	one	or	more	problem	
with	aspartame	(Warner	2006).	
Structure	and	Components	of	Aspartame		
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Aspartame	is	a	dipeptide	which	has	the	formula	L-aspartyl-L-phenylalanyl-methyl	ester	(Maher	
and	 Wurtman	 1987).	 	 Upon	 ingestion,	 aspartame	 is	 metabolized	 in	 the	 gastric	 tracts	 to	 its	 three	
constituents:	 aspartate,	 phenylalanine,	 and	methanol.	 These	 components	 proceed	 to	 be	 transformed	
into	 other	 products.	 Aspartate	 is	 transformed	 into	 alanine	 and	 oxaloacetate;	 phenylalanine	 is	
transformed	 into	 tyrosine,	 phenylethylamine	 and	 phenylpyruvate,	 and	 methanol	 is	 transformed	 into	
formaldehyde	 which	 later	 forms	 formic	 acid	 (Soffritti	 et	 al.	 2006).	 While	 these	 components	 are	
commonly	 digested,	 concerns	 have	 been	 raised	 about	 their	 safety	 when	 they	 are	 metabolized	 after	
aspartame	ingestion.	
	
Aspartate	
	 Aspartate	is	an	extremely	common,	non-essential	amino	acid.	It	is	usually	rapidly	metabolized	by	
the	body	and	subsequently	incorporated	into	proteins	and	utilized	for	energy.	This	amino	acid	is	found	
in	large	concentrations	in	natural	products;	100g	of	chicken	yields	2600	mg	of	aspartate	whereas	a	355	
ml	beverage	sweetened	100%	with	aspartame	only	provides	70	mg	of	aspartate.	Furthermore,	a	glass	of	
no-fat	milk	 provides	 13	 times	 as	much	 aspartic	 acid	 as	 a	 beverage	 sweetened	 100%	with	 aspartame	
(Monte	1984).	
While	aspartate	is	not	toxic	when	absorbed,	even	in	large	quantities,	from	natural	foods,	it	may	
be	 harmful	 to	 the	 body	when	 it	 is	 absorbed	 after	 the	 consumption	 of	 aspartame.	 Blood	 component	
levels	of	amino	acids	such	as	aspartate	and	phenylalanine	will	not	rise	significantly	after	the	digestion	of	
natural	proteins.	Due	to	their	quaternary	structures,	natural	proteins	are	digested	slowly	and	enzymes	
must	catalyze	the	protein	and	release	numerous	amino	acids	before	phenylalanine	or	aspartate	can	be	
released.	On	the	other	hand,	the	digestion	of	aspartame	can	raise	component	blood	levels	rapidly	since	
the	chemical	only	requires	the	breakage	of	two	bonds	for	absorption	(Monte	1984).	
	 When	aspartate	 it	 is	absorbed	 in	excess,	 it	can	wreak	significant	damage	on	the	body.	Daabes	
and	co-workers	(1985)	determined	that	plasma	levels	of	aspartate	and	glutamate	which	exceeded	110	
numol/dl,	 induce	hypothalamic	neuronal	necrosis	 in	neonatal	 rodents.	Later,	Olney	and	Sharpe	 (1969)	
conducted	a	similar	experiment	on	non-human	primates.	They	delivered	 large	boluses	of	glutamate,	a	
similar	dicarboxylic	amino	acid,	and	found	that	 it	 led	to	hypothalamic	neuronal	necrosis.	Furthermore,	
scientists	have	found	that	high	plasma	levels	of	this	amino	acid	cause	endocrine	disorders	in	mammals,	
leading	 to	 the	 release	 of	 pituitary	 gonadotropins	 and	 prolactin	 in	 the	 rhesus	monkey	 and	 noticeably	
elevated	plasma	levels	of	luteinizing	hormones	and	testosterone	in	rats	(Monte	1984).	
	 Experiments	have	determined	that	aspartame	alone	will	not	elevate	plasma	aspartate	levels	for	
an	extended	time	period.	However,	concerns	have	been	raised	about	the	ability	of	aspartame	to	spike	
plasma	 aspartate	 levels	 when	 it	 is	 ingested	 in	 conjunction	 with	mono	 sodium	 glutamate	 (MSG).	 The	
ingestion	 of	MSG	 has	 been	 known	 to	 cause	 adverse	 symptoms	 in	 individuals	 due	 to	 the	 substance’s	
neuroexcitatory	activity	(Reif-Lehrer	1976).	Since	both	aspartate	and	glutamate	are	structurally	similar,	
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and	 pose	 a	 threat	 of	 neurotoxicity	 at	 high	 dosages,	 Olney	 (1982)	 has	 suggested	 that	 consuming	
aspartame	 along	with	 foods	which	 contain	MSG	 leads	 to	 a	 risk	 of	 toxicity	 and	 of	 focal	 brain	 lesions.	
However,	 Stegink	 and	 coworkers	 (1983)	 conducted	numerous	 studies	 and	discovered	 that	while	MSG	
consumption	will	 lead	to	a	significant	 increase	 in	glutamate	aspartate	concentrations	when	consumed	
alone,	the	addition	of	aspartame	to	MSG	will	not	cause	any	further	increase	in	dicarboxylic	amino	acid	
levels.	Thus,	they	concluded	that	is	impossible	for	humans	to	ever	consume	enough	MSG	and	aspartame	
to	raise	plasma	concentrations	to	those	associated	with	rat	neurotoxicity.	
	
Phenylalanine	
	 Phenylalanine	is	an	amino	acid	which	is	beneficial	for	one’s	health,	and	can	be	found	in	protein-
containing	foods	such	as	non-fat	milk	and	fruit	juice.	This	amino	acid	can	be	lethal	to	those	who	suffer	
from	 phenylketonuria	 (PKU),	 a	 rare	 genetic	 disease.	 The	 diets	 of	 phenylketonurics	 are	 extremely	
restricted	from	shortly	after	birth	in	order	to	avoid	the	risks	of	mental	retardation	or	various	degrees	of	
cognitive	 impairment	 (Butchko	 et	 al.	 2002).	 	 However,	 phenylalanine	 is	 not	 only	 dangerous	 for	
phenylketonurics;	spikes	in	plasma	phenylalanine	levels	can	be	toxic	due	to	the	body’s	method	of	uptake	
of	this	amino	acid.	
Upon	 ingestion,	 phenylalanine	 is	 absorbed	 across	 the	 gastrointestinal	 mucosa	 into	 portal	
circulation.	Most	dietary	phenylalanine	goes	unchanged	into	systemic	circulation	and	is	taken	up	across	
the	blood-brain	barrier	and	 into	 the	central	nervous	 system	via	a	 transport	 system	 that	 is	 specific	 for	
large	 neutral	 amino	 acids	 (LNAA).	 The	 amount	 of	 amino	 acids	 which	 enter	 and	 leave	 the	 brain	 is	
determined	by	the	concentration	of	the	LNAA	and	their	specific	affinity	constants	to	the	carrier	system	
(Fernstrom	and	Wurtman	1997).	The	danger	of	spiked	plasma	levels	of	phenylalanine	lies	in	the	fact	that	
it	will	interfere	with	the	availability	of	tyrosine	and	tryptophan.	Consequently,	phenylalanine	will	act	as	a	
competitive	inhibitor	of	the	enzyme	tyrosine	hydroxylase.	This,	subsequently,	lowers	the	concentration	
of	 brain	 catecholamine	 and	 serotonin,	 which,	 in	 turn,	 mediates	 neurological	 changes	 and	 induces	
seizures	(Maher	and	Wurtman	1987).	
Some	 researchers	 suggest	 that	 aspartame	 ingestion	 poses	 a	 risk	 because	 it	 provides	
phenylalanine	without	other	 LNAA.	Consequently,	 upon	being	metabolized	 there	will	 be	 an	 increased	
phenylalanine	uptake	by	the	brain	causing	the	aforementioned	problems	(Maher	and	Wurtman	1987).		
However,	other	scientists,	such	as	Stegink	and	coworkers	(1987),	found	that	this	is	not	the	case.	In	their	
studies,	 they	 found	 that	 the	 changes	 in	 phenylalanine	 LNAA	 in	 normal	 subjects	 was	 no	 greater	 than	
those	 occurring	 under	 normal	 dietary	 conditions.	 This	 idea	 was	 reinforced	 in	 a	 study	 conducted	 by	
Koeppe	and	coworkers	(1991).	In	this	study,	positron	emission	tomography	was	used	in	order	to	observe	
the	 effects	 of	 elevated	 plasma	 phenylalanine	 levels	 after	 the	 consumption	 of	 large	 boluses	 of	
aspartame.	 An	 11.5%	 decrease	 in	 amino	 acid	 transport	 rate	 constant	 was	 observed	 along	with	 a	 6%	
decrease	in	tissue	distribution	volume	of	aminocyclohexanecarboxylate.	Thus,	under	normal	dietary	use,	
aspartame	is	unlikely	to	cause	changes	in	brain	amino	acid	uptake	which	would	be	measurable	by	PET.	
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Despite	the	fact	that	many	scientists	do	not	believe	aspartame	will	negatively	affect	the	brain’s	
uptake	of	amino	acids,	several	adverse	side	effects	are	observed	after	phenylalanine’s	digestion.	Many	
individuals	 have	 reported	 that	 they	 have	 suffered	 from	 neurological	 or	 behavioral	 reactions	 in	
association	with	 aspartame	 consumption,	 a	 symptom	which	 can	be	 linked	 to	 increased	phenylalanine	
levels	 (Maher	and	Wurtman	1987).	Furthermore,	Walton	and	coworkers	 (1993)	 found	 that	 individuals	
with	 a	 history	 of	mood	disorders,	 such	 as	 depression	 and	 bipolar,	 exhibited	 stronger	 symptoms	 after	
consuming	 aspartame.	 They	 hypothesize	 that	 the	 disorders	 are	 exacerbated	 by	 aspartame’s	
phenylalanine	component	which	upsets	the	balance	of	neurotransmitters.	
Another	 concern	 raised	 regarding	 phenylalanine	 is	 its	 ability	 to	 induce	 seizures.	 In	 one	 study,	
mice	were	given	dosages	in	which	phenylalanine	levels	rose	above	tyrosine	levels,	a	phenomenon	which	
will	 occur	 after	 any	 aspartame	 dose	 in	 humans.	 	 Subsequently,	 the	 mice	 were	 introduced	 to	
epileptogenic	 drugs,	 inhaled	 fluorotyl	 or	 electro	 convulsive	 drugs;	 the	 frequency	of	 seizures	 following	
these	 treatments	 was	 greatly	 increased	 due	 to	 increased	 plasma	 phenylalanine	 levels	 (Maher	 and	
Wurtman	 1987).	 Some	 researchers	 disagree	 with	 these	 findings.	 In	 research	 done	 by	 Dailey	 and	
coworkers	 (1989),	acute	oral	doses	of	aspartame,	 ranging	 from	0	–	2500	mg/kg	were	administered	 to	
CD-1	 mice.	 Increases	 in	 phenylalanine	 and	 tyrosine	 and	 modest	 reduction	 in	 brain	 serotonin	 and	 5-
hydroxinol	 acetic	 acid	 were	 observed.	 However,	 these	 changes	 were	 insufficient	 to	 cause	 functional	
deficits	 which	might	 have	 the	 capacity	 to	 facilitate	 pentyl	 enterazol-induced	 seizures.	 Thus	 scientists	
have	not	been	able	to	conclusively	determine	whether	or	not	aspartame	will	induce	seizures.	
	
Methanol	
	 Methanol,	or	wood	alcohol,	is	the	simplest	alcohol	with	the	formula	CH3OH.	Occurring	naturally	
in	fruit	juices	and	alcohol,	it	can	be	found	in	considerable	quantities	in	a	daily	diet;	for	instance,	tomato	
juice	provides	six	times	more	methanol	than	an	equivalent	amount	of	beverage	sweetened	100%	with	
aspartame	 (Butchko	 et	 al.	 2002).	 	 Ten	 percent	 of	 aspartame’s	 weight	 is	 absorbed	 as	 methanol.	 This	
chemical	 is	 released	 in	 the	 small	 intestine	 after	 chymotrypsin	 hydrolyzes	 the	 methyl	 group	 of	 the	
dipeptide.	 	 	 It	 is	 transformed	 later	 into	 formaldehyde	 and	 formic	 acid.,	 both	 toxic	 metabolites.	
Absorption	of	methanol	 increases	 if	 it	 is	 ingested	 as	 free	methanol,	 such	 as	 in	 heated	 foods	 and	 soft	
drinks	(Monte	1984).	
	 The	 dangers	 of	 methanol	 consumption	 via	 aspartame	 have	 been	 raised	 over	 the	 years.	
Methanol	does	not	cause	toxicity	when	consumed	in	wines	and	juices	because	of	the	beverages’	natural	
protective	 features.	 For	 instance,	 juices	 and	 wines	 contain	 high	 ethanol	 to	 methanol	 ratios;	 some	
neutral	spirits	contain	200	molecule	of	ethanol	per	molecule	of	methanol	and	orange	juice	contains	0.8	
mg/L	of	methanol	and	380	mg/L	of	ethanol.	This	has	a	protective	effect	since	ethanol	slows	the	rate	of	
methanol	 being	 transformed	 into	 formaldehyde,	 thereby	 allowing	 the	 body	 to	 excrete	 methanol	 in	
breath	and	 in	urine.	 Juices	have	an	added	protection	 since	 they	have	high	osmolality	 and	an	average	
caloric	 density	 of	 500	 kcal/L,	which	 also	 puts	 definite	 limits	 on	 consumption	 level	 rates	 of	methanol.	
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Since	 aspartame	 is	 not	 limited	 by	 calories	 or	 osmolarity,	 daily	 methanol	 levels	 may	 rise	 to	
unprecedented	levels,	and	may	prove	to	be	a	cumulative	toxin	(Monte	1984).	
	 One	of	the	key	concerns	about	methanol	is	its	production	of	the	methyl	alcohol	syndrome.	This	
toxicity	 is	found	only	 in	humans	because	man	has	 limited	biochemical	pathways	for	detoxification.	For	
twelve	to	eighteen	hours	after	the	methanol	consumption	there	 is	a	 latent	period,	 followed	by	severe	
acidosis	which	is	caused,	in	part,	by	formic	acid	formation.	Patients	complain	of	confusion,	lethargy,	and	
impairment	 of	 articulation,	 and	 may	 also	 suffer	 from	 back	 pain,	 vertigo,	 abdominal	 pain,	 labored	
breathing,	leg	cramps,	and	visual	loss.	There	are	also	fatal	cases	in	which	the	liver	kidney	and	heart	show	
parenchymal	 degeneration	 and	 the	 lungs	 display	 desquamation	 of	 epithelium,	 edema,	 emphysema,	
congestion,	and	bronchial	pneumonia	(Monte	1984).	
	 The	 danger	 of	 methanol	 is	 rooted	 in	 its	 production	 of	 formaldehyde,	 a	 known	 carcinogen.	
Formaldehyde	 has	 been	 proven	 to	 form	 squamous-cell	 carcinomas	 when	 inhaled	 by	 experimental	
animals.	 It	 reacts	with	DNA	 causing	 irreversible	 denaturation	 and	 can	 interfere	with	DNA	 replication,	
thus	 causing	mutations	 (Monte	1984).	 Studies	have	 verified	 that	 formaldehyde	accumulates	 after	 the	
consumption	 of	 aspartame.	 Trocho	 and	 coworkers	 (1998)	 synthesized	 aspartame	 using	 a	 methanol	
group	 which	 had	 radioactive	 C-14	 and	 fed	 it	 to	 mice.	 They	 later	 found	 that	 the	 methanol	 had	
accumulated	 in	 plasma	 and	 in	 the	 liver,	 and	was	 bound	 to	 protein,	 thus	 determining	 that	 aspartame	
contributes	 to	 the	 formation	 of	 formaldehyde	 adducts	 and	 its	 affects	 are	 cumulative	 Not	 only	 does	
aspartame	metabolize	to	form	formaldehyde,	but	it	even	intensifies	the	toxicity	of	this	chemical.	Forty	
percent	of	aspartame	breaks	down	into	excitotoxic	amino	acids,	and	formaldehyde’s	toxicity	 increases	
when	it	is	in	the	presence	of	high	levels	of	free	radicals	(Saito	et	al.	2005).	
	 One	of	the	dangerous	consequences	of	methanol	absorption	is	the	increased	risk	of	developing	
lymphomas	and	leukemias.	A	case-control	study	in	Argentina	discovered	that	urinary	tract	tumors	(UTT)	
were	 directly	 correlated	 with	 aspartame	 consumption.	 The	 risk	 of	 UTT	 was	 significantly	 increased	 in	
long-term	aspartame	users	compared	with	non-aspartame	users	(Andreatta	et	al.	2008).	Another	long-
term	study	which	studied	the	affect	of	aspartame	consumption	on	the	incidence	of	tumors	took	place	in	
Italy.	Soffritti	and	coworkers	(2007)	observed	Sprague	Dawley	rats	from	eight	weeks	of	age	until	natural	
death.	They	observed	a	statistically	significant	increase	in	the	incidence	of	malignant	tumors	among	rats	
that	had	ingested	aspartame.	These	tumors	 included	lymphomas,	 leukemia,	preplastic,	neoplastic,	and	
lesions	 of	 the	 renal	 pelvis	 and	 ureter.	 	 Since	 rodents	 have	 been	 found	 to	 be	 consistent	 predictors	 of	
human	 cancer	 risks,	 they	 conclude	 that	 aspartame	 is	 a	multipotential	 carcinogenic	 compound	whose	
carcinogenic	effects	are	evident	even	at	daily	dose	of	20	mg/kg	bw.	
	 Despite	 the	 compelling	 evidence,	 some	 researchers	 do	 not	 believe	 that	 methanol	 will	 cause	
toxicity	in	humans	when	ingested	in	the	form	of	aspartame.	They	assert	that	the	alcohol	is	absorbed	in	
such	minimal	 levels	 that	 it	will	 be	unlikely,	 and	even	 impossible,	 to	 reach	 levels	of	 toxicity	 associated	
with	cancers	and	lymphomas	(Butchko	et	al.	2002).	Nonetheless,	there	are	still	significant	concerns	with	
aspartame’s	production	of	formaldehyde.	
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Conclusion	
The	 results	and	conclusions	of	 the	different	 studies	about	 the	 safety	of	aspartame	are	 spread	
over	a	large	spectrum;	views	range	from	those	who	claim	that	aspartame	is	absolutely	safe	to	those	who	
claim	that	it	is	toxic.	Research	is	centered	on	the	possible	risks	associated	with	the	ingestion	of	each	of	
aspartame’s	constituents.	Regarding	aspartate,	many	claim	that	high	levels	of	this	amino	acid	can	induce	
neuronal	 necrosis	 and	 endocrine	 disorders.	 A	 large	 group	 of	 scientists	 believe	 that	 the	 ingestion	 of	
aspartame	can	lead	to	dangerous	spikes	in	aspartate	plasma	levels	when	eaten	in	conjunction	with	MSG,	
while	many	others	believe	that	such	a	spike	is	impossible.	
The	 debate	 about	 phenylalanine’s	 toxicity	 revolves	 around	 the	 ability	 of	 this	 amino	 acid	 to	
interfere	with	 LNAA	at	 the	blood-brain	 barrier.	 Some	 researchers	 are	 concerned	 that	 this	 constituent	
can	 exacerbate	 mood	 disorders	 and	 induce	 seizures.	 However,	 the	 issue	 is	 still	 debated,	 and	 many	
scientists	have	determined	that	aspartame’s	phenylalanine	will	not	cause	adverse	effects.	
Methanol	 consumption	 has	 raised	 significant	 concerns	 since	 this	 alcohol	 is	 metabolized	 as	
formaldehyde,	 a	 known	 toxin.	 Long-term	 studies	 have	 proven	 that	 the	 methanol	 component	 of	
aspartame	 has	 caused	 lymphomas	 and	 leukemias	 in	 rats.	 Nonetheless,	 other	 scientists	 debate	 these	
results	and	claim	that	typical	ingestions	of	aspartame	will	not	cause	toxic	effects.	
Summary	
	 Aspartame	is	one	of	the	most	controversial	sweeteners.	The	pro-aspartame	camp	presents	data	
that	shows	that	the	ingestion	of	this	sweetener	does	not	lead	to	significant	negative	health	effect.	They	
claim	 that	 the	 negative	 studies	 on	 lab	 animals	 are	 run	with	 high	 concentration	 of	 materials	 that	will	
never	be	present	during	normal	 consumption.	 	On	 the	other	hand,	 the	anti-aspartame	camp	believes	
that	the	fast	digestion	of	aspartame	leads	to	the	concentration	of	 its	constituents	in	the	body,	causing	
toxic	 effects.	 Clearly,	 more	 research	 must	 be	 conducted	 on	 the	 subject	 in	 order	 to	 conclusively	
determine	whether	aspartame	is	harmful	or	not.	In	the	interim,	it	would	be	advisable	that	people	who	
are	 susceptible	 to	metabolic	 conditions	which	 are	 possibly	 affected	by	 aspartame	 should	 try	 to	 avoid	
significant	consumption	of	the	sweetener.	
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Folic	Acid	and	Neural	Tube	Defects	
Rachel	Leah	Feinstein	
	 Neural	tube	defects	(NTD)	are	the	most	common	types	of	birth	defects.	Research	shows	that	
folic	acid	taken	periconceptionally	greatly	reduces	the	risk	of	having	a	NTD	affected	child.	This	paper	will	
explain	the	role	that	folate	plays	in	the	metabolism,	specifically	in	synthesizing	methionine.	It	will	bring	
evidence	to	show	that	methionine	is	crucial	for	normal	neural	tube	development.	In	addition,	it	will	
explore	the	genetic	factor	involved	in	folate	metabolism	and	possible	folate	deficiency.		
	 The	central	nervous	system	in	an	embryo	begins	as	a	flat	region,	which	then	rolls	into	a	tube	
known	as	the	neural	tube.	The	development	of	the	neural	tube	is	completed	28	days	after	the	baby	is	
conceived.	When	the	neural	tube	fails	to	close	completely,	it	is	known	as	a	neural	tube	defect.	The	
nerves	that	are	exposed	to	the	environment	due	to	the	failure	of	the	tube	to	close	may	become	
damaged	causing	the	affected	baby	to	have	a	disability,	specifically	some	measure	of	paralysis.	Neural	
tube	defects	are	one	of	the	most	common	birth	defects,	and	affects	1.3-	2.0	babies	in	every	1,000	live	
births	in	the	United	States.	There	are	two	main	types	of	NTDs,	depending	on	whether	the	cranial	or	
caudal	end	of	the	neural	tube	fails	to	fuse	properly.	The	foremost	cranial	defect	is	known	as	
anaencephaly	which	is	usually	fatal.	The	main	caudal	defect	is	spina	bifida	(Pitkin,	2007).		
	 The	exact	causes	of	NTDs	are	not	clear.	It	is	believed	that	a	combination	of	environmental	
factors,	genetics,	and	nutrition	contribute	to	the	development	of	a	NTD.	However,	as	early	as	the	1970	
scientists	have	suspected	that	folic	acid	taken	by	the	pregnant	mother	helps	prevent	NTDs.	In	the	United	
Kingdom,	R.	W.	Smithells	noticed	that	a	disproportionate	amount	of	babies	affected	with	NTD	were	born	
to	mothers	of	a	lower	socioeconomic	class.	He	hypothesized	that	the	birth	defects	may	have	been	
caused	by	the	mothers’	poor	nutrition.	He	conducted	tests	and	in	1976	reported	that	women	who	had	a	
child	with	an	NTD	had	much	lower	red	cell	folate	and	vitamin	C	levels	than	mothers	who	had	an	
unaffected	child	(Smithells,	Sheppard,	&	Schorah,	1976).	He	then	conducted	a	placebo-controlled	study	
in	which	he	gathered	women	who	had	already	given	birth	to	a	NTD	affected	child.	He	gave	one	group	of	
women	a	multivitamin	and	an	iron	tablet	containing	360	ug	of	folic	acid.	The	group	of	women	who	were	
given	the	vitamin	pill	only	had	a	.5%	occurrence	of	NTD	births,	while	the	control	group	had	a	4%	NTD	
birth	rate	incidence	(Smithells	et	al,	1981).	Smithells	results	were	published,	however	his	experiment	
was	criticized	because	his	subjects	had	not	been	randomized.		
K.	M.	Laurence	in	Whales	also	performed	experiments	with	folic	acid	based	on	Smithells’	works.	
He	performed	a	double	blind	randomized	controlled	trial	of	folate	treatment	prior	to	conception.	Among	
the	group	that	received	the	folate,	there	were	no	NTDs	in	the	group’s	44	births.	However,	in	the	control	
group	there	was	6	NTDs	in	67	births.	Laurence’s	work	was	not	considered	statistically	significant	since	it	
was	performed	on	such	a	small	population	(Mills	et	al.	1996).			
Smithells’	findings	were	eventually	proved	definitively	by	the	Medical	Research	Council	in	1991.	
The	MRC	conducted	a	double-blind	randomized	study	on	women	who	had	a	previous	NTD	pregnancy.	
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Women	received	4	mg	of	folic	acid,	a	multivitamin,	both,	or	iron	and	calcium.	There	was	a	74%	
reduction	of	NTD	births	in	the	group	taking	folic	acid,	but	no	effect	in	the	groups	that	did	not	receive	
folic	acid.	Another	study,	conducted	just	one	year	later	also	helped	to	validate	Smithell’s	works.	Czeizel	
and	Dudas	in	Hungary	enrolled	women	who	had	never	had	an	affected	pregnancy.	They	were	
randomized	and	given	a	multivitamin,	some	with	.8	mg	folic	acid,	and	some	without.	The	group	of	2394	
women	who	were	given	folic	acid	had	no	affected	offspring,	and	the	group	of	2310	women	who	did	not	
receive	folic	acid	had	6	babies	with	NTD	(Mills	et	al.	1996).		
	 Due	to	the	solid	evidence	of	the	protective	role	of	folic	acid,	public	health	officials	recommend	
women	of	childbearing	age	to	take	400	ug	of	folic	acid	at	least	4	weeks	before	conception,	and	through	
the	first	trimester	of	pregnancy.	Folic	acid	is	the	oxidized	and	most	active	form	of	folate.	They	may	do	
this	by	taking	a	folic	acid	supplement.	They	are	also	encouraged	to	eat	folic	acid	enriched	grain	products	
and	large	amounts	of	folate	rich	foods	such	as	green	leafy	vegetables,	or	liver.	The	United	States,	as	well	
as	other	countries,	have	implemented	a	mandatory	folic	acid	food	fortification	and	have	seen	about	a	
50%	reduction	in	the	occurrence	of	NTDs	(Lamers,	Prinz-Langenohl,	Bramswig,	Pietrzik,	2006).			
	 Despite	the	awareness	of	the	role	that	folic	acid	plays	in	preventing	NTDs,	the	exact	mechanism	
used	to	achieve	this	is	not	so	clear	and	is	still	being	studied.	However,	based	on	various	experiments	
scientists	have	come	to	a	basic	understanding	as	to	how	a	folate	deficiency	would	contribute	to	an	NTD	
development.		
	 Folate	is	a	term	to	describe	a	water-	soluble	B-complex	vitamin	and	it	serves	many	important	
roles	in	the	body.	It	is	vital	for	cell	division	and	homeostasis	due	to	the	essential	role	of	folate	
coenzymes	in	nucleic	acid	synthesis,	methionine	regeneration,	and	in	the	shuttling,	oxidation	and	
reduction	of	one	carbon	units	required	for	normal	metabolism	and	regulation.	There	is	an	increase	in	
folate	requirement	in	pregnant	women	to	support	the	rapid	growth	of	the	embryo	and	uteroplacental	
organs.	There	has	been	much	focus	on	the	role	folate	plays	in	methionine	regeneration	in	regard	to	
studies	of	NTDs.	In	this	process	folate	is	reduced	in	the	body	to	dihydrofolate	and	then	to	
tetrahydrofolate.	Tetrahydrofolate	acts	as	an	acceptor	molecule	that	accepts	and	donates	one	carbon	
units	in	metabolic	pathways.		A	one	carbon	unit	is	transferred	from	serine	to	THF	by	serine	
hydroxymethyltransferase	to	form	5,10	methylene	tetrahydrofolate.	This	compound	is	then	reduced	by	
methylene	tetrahydrofolate	reductase	(MTHFR)	to	form	5	methyl	tetrahydrofolate.	The	5	methyl	
tetrahydrofolate	is	acted	upon	by	methionine	synthase	together	with	a	B-12	cofactor	which	facilitates	
the	removal	of	the	N-5	methyl	group	from	the	5	methyl	tetrahydrofolate	and	deposits	it	onto	
homocysteine.	The	homocysteine	with	the	extra	methyl	group	is	known	as	methionine.	A	mother	who	is	
lacking	in	folate	would	not	be	able	to	carry	out	this	metabolic	pathway,	since	5	methyl	tetrahydrofolate	
is	the	only	compound	capable	of	this	one	carbon	transfer	(Bailey,	&	Gregory,	1999).	It	would	therefore	
seem	plausible	to	say	that	mothers	lacking	in	folate,	and	therefore	at	risk	for	an	NTD	baby,	would	have	
elevated	homocysteine	levels	and	low	methionine	levels.	Subsequent	studies	have	indeed	supported	
this	theory.	 		
	 Steegers-	Theunissen	et	al.	(1995)	was	one	of	the	first	to	report	elevated	amniotic	fluid	
homocysteine	in	women	who	were	carrying	an	NTD	fetus.	Since	then	there	have	been	many	reports	that	
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plasma	or	amniotic	fluid	homocysteine	is	higher	in	NTD	infants	and	their	mothers	than	non-NTD	infants	
and	their	mothers.	One	such	study	was	conducted	by	Mills	in	which	blood	samples	were	collected	during	
pregnancy	from	women	carrying	affected	fetuses,	and	random	women	carrying	healthy	fetuses.	The	
homocysteine	levels	in	the	blood	were	measured,	and	the	mothers	if	NTD	fetuses	had	significantly	
higher	levels.	These	studies	pointed	to	the	relative	inability	of	mothers	with	NTD	babies	to	metabolize	
homocysteine	(Mills	et	al.	1996).		
	 Since	it	has	been	established	that	NTD	mothers	have	higher	levels	of	homocysteine,	research	
turned	to	try	to	establish	if	too	much	homocysteine	is	what	actually	inhibits	the	neural	tube	closure.	In	
order	to	test	this	hypothesis	Greene,	Dunlevy	and	Copps	(2003)	cultured	mouse	embryos	in	the	
presence	of	homocysteine	thiolactone	during	the	periods	of	cranial	neural	tube	closure.	While	the	
homocysteine	thiolactone	did	cause	growth	retardation	and	other	negative	effects,	it	did	not	increase	
the	incidence	of	neural	tube	defects.	Another	study	conducted	by	Afman,	Blom,	Van	Der	Put,	and	Van	
Straaten	(2003)	and	his	colleagues	administered	homocysteine	to	chick	embryos	in	ova.	This	resulted	in	
several	malformations,	but	did	not	increase	the	number	of	NTDs.	These	results	suggest	that	too	much	
homocysteine	is	unlikely	to	be	the	direct	cause	of	NTD.	
	 Since	the	overabundance	of	homocysteine	in	a	mother	of	an	NTD	child	does	not	seem	to	cause	
the	NTD,	perhaps	the	lack	of	methionine	that	should	have	been	made	from	the	homocysteine	plays	a	
role	in	the	development	of	an	NTD.	Methionine	is	an	essential	amino	acid	that	cannot	be	obtained	
sufficiently	through	dietary	intake	and	therefore	must	be	synthesized	by	the	body.	Methionine	formed	
from	homocysteine	is	converted	to	S-	adenosylmethionine,	which	is	a	methyl	donor	for	many	reactions	
including	DNA	methylation	(Friso	et	al.	2002).	This	theory	was	tested	in	a	few	different	ways.	Coelho,	
Weber,	Klein,	Daniels,	and	Thomas	(1989)	conducted	a	study	in	which	he	grew	rat	embryos	in	cow	
serum.	Cow	serum	has	a	much	lower	level	of	methionine	than	rat	serum.	They	supplemented	some	cow	
serum	with	methionine,	and	did	not	supplement	others.	There	was	a	significant	decrease	in	the	
occurrence	of	NTD	in	the	embryos	that	were	grown	in	the	serum	that	was	supplemented	with	
methionine.	Essein	and	Wannberg	(1993)	conducted	a	study	involving	pregnant	mice	with	an	Axd	(axial	
defect)	mutation	which	is	known	to	cause	NTDs.	They	injected	these	pregnant	mice	with	methionine	on	
days	8	and	9	of	the	pregnancy.	At	a	dose	of	180	mg/	kg	body	weight	the	methionine	produced	a	47%	
reduction	of	NTDs.	They	also	conducted	studies	with	mice	with	the	Axd	mutation	in	which	they	
supplemented	the	mice	with	folinic	acid,	but	it	had	no	effect	on	the	incidence	of	NTDs.	This	seems	to	
suggest	that	folate,	or	lack	of	it,	is	an	indirect	cause	of	NTD,	and	methionine	is	the	needed	product	of	
the	folate	for	normal	neural	tube	development.	Perhaps	the	Axd	mutation	codes	for	a	mutation	in	an	
enzyme	that	is	crucial	to	make	methionine,	or	a	vital	product	of	methionine,	but	is	not	involved	with	
folate	at	all.				
	 Shaw,	Velie,	Schaffer	(1997)	conducted	a	study	concerning	the	effect	of	methionine	on	humans.	
His	study	involved	424	mothers	of	NTD	children,	and	440	mothers	of	unaffected	children.	Each	mother	
was	interviewed	in	which	they	answered	a	100	item	food	frequency	questionnaire.	The	data	was	then	
established	into	quartiles	of	average	daily	maternal	dietary	intake	of	methionine	in	the	3	months	before	
conception.	There	was	a	30-	40	%	reduction	in	NTD	affected	pregnancies	among	women	whose	average	
daily	intake	of	methionine	was	above	the	lowest	quartile.	These	observations	were	unrelated	to	the	
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maternal	level	of	folate	intake,	which	supports	the	theory	that	methionine,	or	what	methioine	is	
converted	to,	is	what	is	actually	crucial	for	normal	neural	tube	development.			
	 Assuming	that	methionine	is	vital	for	normal	embryonic	development,	and	the	synthesis	of	
methionine	is	formed	by	homocysteine	and	5	methyl	tetrahydrofolate	interaction,	then	it	is	clear	how	a	
folate	deficiency	would	result	in	a	NTD.	However,	many	studies	since	Smithells	have	reported	that	NTD	
mothers	are	not	necessarily	folate	deficient.	One	such	study	was	conducted	in	Molloy	and	Kirke,	Hillary,	
Weir,	and	Scott	(1985).	They	studied	the	serum	samples	taken	during	pregnancy	from	32	mothers	with	
pregnancies	affected	by	NTD	and	395	randomly	selected	unaffected	pregnant	women.	The	serum	folate	
levels	and	vitamin	B-12	levels	(vitamin	B-12	is	the	coenzyme	that	facilitates	the	removal	of	a	methyl	
group	from	the	5	methyl	tetrahydrofolate	onto	the	homocysteine)	were	measured	and	analyzed.	To	
analyze	the	data	the	information	was	sub-	classified	into	folate	deficient,	possible	deficient,	and	
sufficient	ranges.	The	ranges	were	0-2	ng/ml,	2.01-	2.7	ng/ml,	and	2.71-20	ng/ml	respectively.	
Surprisingly,	only	21.9%	of	the	NTD	group	was	deficient	in	either	folate	or	vitamin	B-12	while	22.8%	of	
the	control	group	samples	were.	43.8%	of	the	NTD	group,	and	35.7%	of	the	control	group	showed	
sufficient	serum	concentrations	of	both	folate	and	vitamin	B-12.	These	results	show	that	a	significant	
percent	of	women	who	had	folate	sufficient	levels	had	a	pregnancy	affected	by	NTD.	This	seems	to	
indicate	that	folate	deficiency	may	not	be	the	sole	or	main	cause	of	neural	tube	defects.	There	may	be	a	
more	subtle	problem	among	women	who	gave	birth	to	NTD	babies	than	simply	not	consuming	enough	
folate	as	part	of	their	diet.	These	results	do	not	contradict	Smithells’	findings,	since	he	reported	that	
NTD	mothers	have	lower	red	cell	folate	levels.	This	study	was	only	able	to	measure	the	serum	folate	
levels,	and	this	difference	seems	to	be	significant.	
	 Red	cell	folate	levels	and	serum	folate	levels	were	further	investigated	in	other	studies.	Once	
such	study	was	conducted	by	Yates	et	al.	(1986)	measured	vitamin	levels	in	twenty	women	less	than	35	
years	of	age	who	had	two	or	more	NTD	pregnancies.	Each	case	was	compared	to	a	control	female	who	
was	matched	for	age,	obstetric	history,	and	social	class.	The	red	cell	folate	levels	were	measured	and	
showed	a	linear	relationship	with	the	number	of	NTD	pregnancies.	However,	there	was	no	significant	
difference	between	the	subjects	and	controls	in	relation	to	serum	folate	levels.	The	diets	of	the	study	
and	control	women	were	ascertained	through	a	questionnaire.	There	was	no	statistically	significant	
difference	between	the	folate	dietary	intakes	of	the	two	groups	of	women.	However,	regression	analysis	
showed	a	difference	between	the	two	groups	in	regard	to	the	relationship	of	red	cell	folate	to	dietary	
folate.	This	study	provides	additional	evidence	that	low	red	cell	folate	is	linked	to	NTD,	but	also	
demonstrates	that	low	red	cell	folate	is	not	necessarily	due	to	a	folate	deficient	diet.	The	difference	
between	the	red	cell	folate	levels	among	women	with	similar	folate	intake	supported	the	increasingly	
popular	idea	that	NTD	may	be	linked	to	a	disorder	in	folate	metabolism,	and	not	exclusively	to	a	folate	
deficient	diet.	
	 More	recently,	in	1992	Mills	et	al.	conducted	a	study	which	measured	the	maternal	serum	folate	
of	89	NTD	pregnancies	and	178	control	pregnancies.	This	study	also	demonstrated	no	relationship	
between	maternal	serum	folate	during	pregnancy	and	the	risk	of	NTDs	(Mills	et	al.	1996).	
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	 There	is	also	a	strong	hereditary	link	for	neural	tube	defects.	The	chance	of	having	a	NTD	child	is	
about	0.15	percent.	However,	once	a	woman	has	a	child	with	a	NTD	the	chance	of	having	a	second	child	
with	NTD	is	increased	to	about	2-5%.	Furthermore,	if	the	women	herself	has	a	NTD	the	chances	of	
having	an	affected	baby	increases.	This	supports	the	idea	that	there	may	be	a	genetic	mutation	that	
predisposes	someone	for	NTD	among	those	who	are	affected	by	it	(Genetics	and	Neural	Tube	Defects,	
2005).	
	 Due	to	the	evidence	provided	by	studies	such	as	the	ones	mentioned	above,	there	has	been	
much	speculation	that	there	is	possibly	a	genetic	defect	that	affects	the	metabolism	of	folate.	To	prove	
this	hypothesis	researchers	have	identified	several	common	polymorphisms	of	genes	that	code	for	
folate	metabolizing	enzymes,	including	the	677C	/	677T	and	the	1298A/	1298C	alleles	of	5,	10	
methylenetetrahydrofolate	reductase	(MTHFR).	These	polymorphisms	are	common,	and	their	frequency	
varies	by	race	and	ethnicity.	A	recent	study	by	Yang	et	al.	(2008)	tried	to	determine	the	role	that	these	
different	alleles	play	in	the	metabolism	of	folate	and	homocysteine	levels.		
	 Data	for	this	study	was	taken	from	the	third	National	Health	and	Nutrition	Examination	Survey	
(NHANES	III).	The	NHANES	III	endeavored	to	obtain	a	nationally	representative	sample	of	the	civilian	
United	States	population.	Each	survey	participant	was	given	an	interview,	a	physical	examination,	and	
gave	a	sample	of	their	blood.	The	researchers	genotyped	selected	polymorphisms	of	folate	metabolizing	
enzymes	in	DNA	samples	(obtained	from	the	blood	specimen)	for	7159	individuals.	They	also	measured	
the	serum	folate	levels	and	homocysteine	levels	in	each	blood	sample.	Based	on	the	interviews	of	the	
participants	their	average	daily	intake	of	folate	was	determined.	The	effects	of	MTHFR	677C/677T	
genotype	and	the	MTHFR	1298A/1298C	genotype	on	the	inverse	relationship	between	folate	intake	and	
serum	homocysteine	concentrations	were	then	examined.		
	 The	researchers	observed	significant	differences	in	the	serum	folate	and	homocysteine	
concentrations	for	individuals	with	the	MTHFR	677	TT	genotype.	The	adjusted	geometric	mean	of	serum	
folate	concentration	was	24.83	%	lower	if	they	had	the	TT	genotype	that	if	they	had	the	CC	genotype.	
The	adjusted	geometric	mean	of	serum	total	homocysteine	concentration	was	29.06%	higher	if	they	had	
the	TT	genotype	than	if	they	had	the	CC	genotype.	The	other	polymorphism,	1298A/1298C,	was	not	
significantly	associated	with	serum	folate	or	homocysteine	concentrations.		
	 Folic	acid	consumption	also	played	an	important	part	in	determining	serum	folate	levels.	Those	
with	the	677	TT	genotype	that	took	400	ug	of	folic	acid	per	day	had	higher	serum	folate	concentrations	
than	those	with	the	MTHFR	677	CC	who	did	not	take	folic	acid	supplements.	As	the	folic	acid	
consumption	increased,	the	difference	between	the	levels	of	serum	folate	of	the	TT	and	CC	genotypes	
decreased	significantly.	The	difference	actually	became	non	significant	among	the	group	who	took	
400ug	or	more	of	folic	acid	per	day.	However,	homocysteine	levels	among	the	MTHFR	677TT	only	
decreased	by	11-14%	with	the	supplemental	folic	acid.			
		 These	results	seem	to	indicate	that	having	677	TT	alleles	on	the	gene	that	codes	for	MTHFR	
results	in	some	sort	of	defect	on	the	enzyme	which	causes	lower	folate	levels	than	in	someone	who	has	
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the	same	folate	dietary	intake	but	has	the	677	CC	alleles.	However,	consuming	a	lot	of	folic	acid,	
specifically	400	ug	per	day,	can	overcome	the	problem	and	bring	the	serum	folate	to	sufficient	levels.		
	 The	exact	explanation	for	what	the	polymorphism	codes	for,	and	how	the	folate	is	able	to	
overcome	the	defect	can	be	explained.	The	677T	polymorphism	occurs	in	exon	4	of	the	genetic	code	and	
results	in	a	valine	substitution	of	alanine	at	codon	222.	This	valine	lies	on	the	binding	site	for	the	MTHFR	
enzyme’s	cofactor	flavin	adenine	dinucleotide	(FAD).	This	affects	the	binding	of	the	FAD	to	the	enzyme,	
making	the	binding	site	exposed	instead	of	imbedded	in	a	barrel-like	structure.	The	exposure	results	in	a	
weakened,	thermolabile	MTHFR/FAD	complex	and	the	MTHFR	677TT	enzyme	has	been	shown	to	
dissociate	with	the	FAD	cofactor	more	readily	than	the	MTHFR	677CC	enzyme.	This	results	in	decreased	
enzymatic	activity.	The	MTHFR	enzymes	with	the	677TT	genotype	have	a	30%	in	vitro	MTHFR	enzyme	
activity	as	compared	to	the	MTHFR	677CC	enzymes.		However,	an	abundance	of	5-	
methyltetrahydrofolate	substrates	have	been	shown	to	strengthen	the	complex	and	protect	the	MTHFR	
from	losing	the	FAD	cofactor.	This	explains	how	consuming	an	abundance	of	folic	acid	overcomes	a	
natural	genetic	deficiency	(Robien,	&	Ulrich,	2003).		
	 The	results	of	the	study	by	Yang		et	al.	explains	the	findings	in	the	studies	which	show	that	
people	of	similar	folate	intake	may	have	different	red	cell	folate	levels.		However,	in	the	those	studies,	
the	women	who	had	given	birth	to	NTD	children	did	have	sufficient	serum	folate	levels,	while	in	the	
study	by	Yang	the	MTHFR	reduced	activity	was	specifically	reflected	in	low	serum	levels.	It	is	possible	
that	this	can	be	explained	simply	by	the	different	states	of	the	subjects	of	the	studies.	The	studies	that	
showed	similar	serum	levels	were	conducted	on	pregnant	women.	It	has	already	been	established	that	
pregnant	women	are	in	high	need	of	folate.	The	plasma	is	the	provider	of	folate	during	pregnancy	and	
therefore	the	body	does	al	it	can	to	ensure	sufficient	serum	folate.	When	the	maternal	serum	folate	
reaches	deficient	levels,	folate	is	taken	from	the	red	cells	that	serve	as	folate	storage	tissue	(Lamers,	
Prinz-Langenhol,	Bramswig,	&	Pietrzik,	2006).	That	would	explain	the	consistent	findings	of	low	red	cell	
folate	levels,	but	sufficient	serum	folate	levels	of	the	NTD	mothers.	However,	the	study	of	
polymorphisms	was	conducted	on	a	representational	population	of	United	States	residents,	and	
therefore	presumably	only	has	a	small	percent	of	pregnant	women.	Since	folate	is	not	as	desperately	
needed	among	non-pregnant	people,	the	body	has	no	urgent	need	to	bring	up	the	serum	folate	levels,	
and	therefore	they	remain	deficient.		
	 If	the	677TT	MTHFR	polymorphism	is	actually	what	leads	to	low	serum	folate	and	high	total	
homocysteine	levels,	perhaps	it	would	be	more	efficient	to	simply	supplement	the	body	with	what	the	
MTHFR	should	be	synthesizing	rather	than	with	folic	acid	which	stabilizes	the	enzyme.	This	speculation	
was	proven	true	in	a	study	by	Lamers	et	al.	(2006).	The	study	involved	144	women	aged	19-33	who	were	
not	pregnant	or	lactating.	The	study	was	a	24	week	double-blind	placebo-controlled	trial.		The	women	
received	either	400ug	of	folic	acid,	416	ug	[6S]	5	methyltetrahydrofolate,	208	ug	[6S]	5	
methyltetrahydrofolate,	or	a	placebo	daily.	Blood	samples	were	collected	every	4	weeks	of	the	study.	At	
baseline,	the	4	groups	did	not	differ	significantly	with	respect	to	red	cell	and	serum	folate	concentration.	
No	change	in	dietary	intake	was	observed	throughout	the	study	period.	Although	all	3	groups	receiving	
supplements	showed	significant	red	cell	and	serum	folate	increases,	the	increase	in	red	cell	folate	and	
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serum	folate	was	significantly	greater	in	the	group	receiving	416	ug	[6S]	5	methyltetrahydrofolate	than	
the	other	2	groups.	The	group	that	received	400	ug	of	folic	acid	had	the	second	highest	increse.			
	 This	study	proves	that	supplemental	[6S]	5	methyltetrahydrofolate	at	approximately	the	same	
dosage	as	supplemental	folic	acid	is	more	efficient	than	folic	acid	at	raising	folate	levels.		This	supports	
the	idea	that	the	lag	in	the	folate	metabolism	present	in	some	people	occurs	at	the	MTHFR	enzyme	
which	is	supposed	to	synthesize	5		methyltetrahydrofolate.	Therefore	providing	the	body	with	the	
product	of	the	enzyme	overcomes	the	defect	more	efficiently	than	trying	to	stabilize	the	enzyme	with	
additional	folic	acid.		
	 The	role	that	folic	acid	plays	in	the	prevention	of	the	occurrence	of	a	NTD	is	well	documented	
and	proven.	Folic	acid	aids	in	the	deposition	of	a	methyl	group	on	homocysteine,	thereby	creating	
methionine.	Methionine	is	then	converted	to	other	substances,	such	as	S-	adenosylmethionine,	which	is	
essential	for	normal	embryonic	development.	Pregnant	women	who	are	folate	deficient	may	therefore	
not	have	sufficient	methionine	levels	to	support	a	growing	embryo.	This	could	lead	to	birth	defects,	such	
as	the	failure	of	the	neural	tube	to	close	properly.	Pregnant	women	may	be	folate	deficient	due	to	a	
poor	diet.	However,	even	women	who	do	have	a	folate	sufficient	diet	may	have	low	red	cell	folate	
serum	levels	if	they	have	the	677TT	MTHFR	polymorphism.	This	genetic	defect	can	be	overcome	by	
consuming	an	abundance	of	folic	acid,	beyond	what	is	normally	considered	sufficient.	Today	there	is	
much	effort	expended	on	educating	the	public	about	the	beneficial	role	of	folic	acid,	and	encouraging	
women	of	child	bearing	age	to	take	folic	acid	supplements.		
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Cholera: An Overview of a Disease 
 Ezriel Leifer 
Abstract 
Although the disease, cholera, has been recognized since antiquity, the bacteria responsible for causing it 
was only discovered in the mid-19th century. Since 1817, cholera has spread on a global basis to cause 
seven pandemics. According to information reported to the World Health Organization in 1999, almost 
8,500 people died and another 223,000 became sick with cholera worldwide. During the period between 
full outbreaks, the cholera organism, Vibrio cholerae, thrives in brackish waters, in harmless as well as 
disease-causing forms. Vibrio cholerae is just one of a variety of ocean-borne microbes that can sicken 
humans via seafood, drinking water, and swimming. Location, time, and intensity of cholera epidemics 
can now be accurately predicted from satellite observations of sea surface temperature, sea surface height, 
and chlorophyll in the water. Bacteria such as Vibrio cholerae have been found to be able to communicate 
with members of their own species and others to coordinate their behavior in response to cell density in a 
process known as quorum sensing, which relies on the production of and sensitivity to one or more 
secreted signal molecules. A growing body of scientific studies has identified a complex quorum sensing 
network in the human pathogen Vibrio cholerae. To gain a better understanding of this pathogen, this 
study provides an overview of the bacterium Vibrio cholerae, the mechanism of its virulence, a discussion 
concerning the symptomatology of the bacterium and its epidemiology. An analysis of how quorum 
sensing influences the virulence of the bacterium is followed by a discussion of diagnostic and treatment 
considerations. A discussion of ongoing preventative measures is followed by a summary of the research 
and salient findings in the conclusion. 
Introduction 
 As the current swine flu epidemic reaches pandemic proportions, attention has been drawn away 
from yet another continuing threat to global health in the form of Vibrio cholerae and the cholera disease 
it can cause. Despite this inattention, the threat of cholera remains, and researchers are actively involved 
in investigating its etiology to identify the best practices in its prevention and treatment. To gain a 
snapshot of the historic and current efforts to combat this disease, this study provides an overview of the 
bacterium, Vibrio cholerae, the mechanism of its virulence, a discussion concerning the symptomatology 
of the bacterium and its epidemiology. An analysis of how quorum sensing influences the virulence of the 
bacterium is followed by a discussion of diagnostic and treatment considerations. A discussion of ongoing 
preventative measures is followed by a summary of the research and salient findings in the conclusion. 
Review and Analysis 
Overview of the Bacterium, Vibrio Cholerae 
 The cholera disease that is caused by Vibrio cholerae has been a source of dread for mankind 
since the first recorded pandemic in 1817 because of the high death rate associated with it and the rapidity 
with which it spreads. To date, about 200 O antigens have been distinguished serologically; however, just 
O1 and O139 have been found in epidemic and pandemic cholera isolates (Salim, Lan & Reeves, 2005). 
One of the preeminent researchers into the spread of cholera, Colwell, reports that, “Cholera, a diarrheal 
disease, has been with us for a very long time, even being mentioned in ancient Sanskrit writings. A 
medical textbook published in 1875 reported cholera to be a global pandemic, consistently appearing in 
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India, Bangladesh, Latin America, and Africa. Today, cholera remains a serious problem” (2006, p. 753). 
The bacterium that causes cholera was first identified in 1854 and has continued to be investigated since 
that time (Faruque & Nair, 2008).  
 This scientific interest has been fueled in large part by the fact that the disease has become 
prevalent worldwide rather than being restricted to the Indian subcontinent as in years past. In this regard, 
Colwell (2006) reports that, “Until the nineteenth century, cholera was generally confined to the Indian 
subcontinent, but it then began to appear in Europe and the Americas as well. Since 1817, Western 
medical history describes seven global pandemics of cholera that have spread illness and death around the 
world. “The second of these seven pandemics reached the United States in 1832, traveling from New 
York to Philadelphia in a couple of weeks, and then cases appeared along the Atlantic coast all the way to 
the Gulf of Mexico” (Colwell, 2006). Likewise, according to Osborne (2008), “The pandemic that swept 
North American cities in 1832 was caused by a comma-shaped bacterium, Vibro cholerae, known by 
various names including Asiatic cholera and Cholera morbus. It is now generally accepted that Vibro 
cholerae originated in India, where cholera was endemic, and first reached the West in the early 
nineteenth century”. 
 In their account of historic efforts to combat the spread of cholera, Albertine, Persily and 
Riegilman (2007) repeat a well-known story thusly:  “In 1855, pioneering epidemiologist John Snow 
traced the emergence of cholera in London to the public water supply. He persuaded authorities to remove 
the pump handle on the Broad Street well and thereby slowed and then stopped an outbreak of cholera”. It 
should be noted that Colwell (2006), though, suggests that the outbreak was stopped as a result of the 
operation of natural forces more than this 
straightforward public health tactic, but the fact remains that the bacterium has been with mankind for 
millennia and efforts to stop its spread remain an ongoing source of investigation throughout the world.  
 The seventh pandemic (1961-present) is still widespread and has a severe impact on three 
different continents. The sixth pandemic ended in 1923, but the clone persisted at least until the 1990’s 
(Safa, Bhuiyan, Alam, Sack & Nair, 2005). In addition, a number of cholera outbreaks were reported after 
the sixth pandemic retreated, but before the start of the seventh pandemic. Isolates from these outbreaks 
were recognized as different from those of the sixth pandemic and were allocated to the El Tor biotype, 
while the sixth and fifth pandemics, both of which had been studied microbiologically, were referred to as 
the classical biotype (Safa et al.).  
 The outbreaks of the El Tor biotype took place in Indonesia and the Middle East (1926-1960) and 
are frequently described as being prepandemic isolates because they were later viewed as predecessors of 
the subsequent seventh pandemic, an episode that is also of the E1 Tor biotype (Safa et al.). Today, the 
environmental aspects of V. cholerae have been the focus of a considerable amount of research, and the 
major components of the El Tor phenotype have been shown to be present in most environmental isolates; 
the classical biotype is thought to have emerged through the loss of characters that are otherwise 
widespread in the species (Safa et al.). In addition, instances of sporadic indigenous cholera have been 
detected in Australia as well as the United States, both of which have been of the O1 El Tor biotype (Safa 
et al.). These are generally referred to as the US Gulf and Australian clones. All of the pathogenic forms 
discussed above had the O1 serotype, but in 1992 a variant of the seventh pandemic appeared with a new 
O antigen, O139; this variant is known as V. cholerae O139 Bengal (Safa et al.).  
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Mechanism of Virulence for Vibrio Cholerae.  
 Adherence to intestinal cells. The infectivity of V. cholerae is related to its ability to defeat the 
protective qualities that are typically present in the intestinal cells (Sparling, 1985). Microbial adherence 
to epithelial cell surfaces has been implicated as the first step in the initiation of several infectious 
diseases. Subinhibitory concentrations of antibiotics affect the adherence properties of microorganisms in 
various ways. They can inhibit the expression of fimbriae and the synthesis of other surface components, 
and they may also cause the release of constituents from the cell. The ability of antibiotics to affect the 
properties of microbial adherence to cell surfaces may be an important criterion in selecting an antibiotic 
for therapy. The relationships of V. cholerae have been studied in several ways, but the most useful 
insights have come from multilocus enzyme electrophoresis and more recently by multilocus sequence 
analyses (Salim et al.). According to Paz and Broza, “Vibrio cholerae bacteria are common hitchhikers 
attached to the surface of adult nonbiting midges (observed mainly with Chironomus sp., family 
Chironomidae). Both males and females have been reported to carry Vibrio cholerae strains that remain 
viable and culturable even after 14 days”. In fact, researchers have been investigating the ability of Vibrio 
cholerae to adhere to animal cells and different ligands involved in intestinal colonization for some time, 
including virulence-associated toxin co-regulated pilus (TCP), outer membrane proteins, and 
lipopolysaccharides (Zampini et al. 2006). According to these researchers, “Its interactions with 
substrates present in the aquatic environment have been described more recently. V. cholerae O1 El Tor 
does not use TCP to form a biofilm on abiotic surfaces (borosilicate and cellulose), but rather the 
mannose-sensitive hemagglutinin (MSHA) pilus, which has no role in pathogenicity” (p. 267). The ability 
of V. cholerae to attach to chitin 
has been demonstrated to be independent of the MSHA pilus, a finding that indicates divergent pathways 
for biofilm formation on nutritive and nonnutritive abiotic surfaces (Zampini et al.). Researchers have 
also determined that MSHA is involved in V. cholerae O1 El Tor and O139 adhesion to the exoskeleton 
of the planktonic crustacean Daphnia pulex and other ligands are believed to be used by V. cholerae O1 
classical strains for zooplankton adhesion (Zampini et al.). In addition, V. cholerae O1 classical strain 
membrane proteins have been found to mediate N-acetyl glucosamine (GlcNAc)-sensitive attachment to 
chitin particles in vitro (Zampini et al.). 
 Release of toxins and their operation. The fatal effects of the disease are mainly due to the 
cholera toxin produced by specific strains of Vibrio cholerae (Paz & Broza). According to DNA 
researcher Lang, “Instead of having one circular chromosome, like most bacteria, the organism has two. 
The larger chromosome, comprising nearly three million base pairs, contains most of the organism's 
critical genes, including those coding for the disease-causing toxins and proteins that carry out essential 
cell functions” (2000, p. 39). The ability of V. cholerae to adhere to epithelial cell surfaces and release 
these disease-causing toxins has been cited as the first step in its infectivity (Shibl, 1985). In this regard, 
Todar (2009) reports that, “Cholera toxin activates the adenylate cyclase enzyme in cells of the intestinal 
mucosa leading to increased levels of intracellular cAMP, and the secretion of H2O, Na+, K+, Cl-, and 
HCO3 into the lumen of the small intestine. The effect is dependent on a specific receptor, monosialosyl 
ganglioside (GM1 ganglioside), present on the surface of intestinal mucosal cells” (p. 3). The specific 
manner in which V. cholerae operates is described by this clinician thusly:  “The bacterium produces an 
invasin, neuraminidase, during the colonization stage which has the interesting property of degrading 
gangliosides to the monosialosyl form, which is the specific receptor for the toxin” (Todar, p. 3). The 
toxin released by V. cholerae contains (a) 5 binding (B) subunits of 11,500 
daltons, (b) an active (A1) subunit of 23,500 daltons, and (c) a bridging piece (A2) of 5,500 daltons; the 
latter links A1 to the 5 binding subunits (Todar). After V. cholerae has penetrated the cell, the active 
subunit transfers ADP ribose from NAD+ to a protein (called Gs or Ns) enzymatically; this process 
controls the adenylate cyclase system situated on the interior of the plasma membrane of mammalian cells 
(Todar). According to Todar, “Enzymatically, fragment A1 catalyzes the transfer of the ADP-ribosyl 
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moiety of NAD+ to a component of the adenylate cyclase system. The process is complex. Adenylate 
cyclase (AC) is activated normally by a regulatory protein (GS) and GTP; however activation is normally 
brief because another regulatory protein (Gi), hydrolyzes GTP”.   
 Typically, the active subunit fragment changes the attachment of ADP-Ribose (ADPR) to the 
regulatory protein thereby creating Gs-ADPR, a protein from which GTP is unable to be hydrolyzed. 
Because GTP hydrolysis serves to shut down the adenylate cyclase process, the enzyme continues to be 
active in the cell (Todar). As a result, the bottom-line impact of the toxins released by V. cholerae are to 
cause cAMP to be produced at an inordinately high rate, a process than in turn stimulates mucosal cells to 
discharge large amounts of Cl- into the contents of the intestine (Todar). Thereafter, H2O, Na+ and other 
electrolytes are produced as a result of the osmotic and electrical gradients that are the result of the loss of 
Cl- (Todar). In sum, then, “The lost H2O and electrolytes in mucosal cells are replaced from the blood. 
Thus, the toxin-damaged cells become pumps for water and electrolytes causing the diarrhea, loss of 
electrolytes, and dehydration that are characteristic of cholera” (Todar, p. 3). Neither Vibrio cholerae, 
though, nor the toxins it releases are capable of passing through the gut wall (Gibbs, 2005).  
 
 
Symptomology of Vibrio Cholerae. 
 Accounts of the symptoms associated with the 1832 North American pandemic were grisly in 
their descriptions. For instance, Osborne reports that “Victims of the disease were stricken with severe 
diarrhea and vomiting, accompanied by excruciatingly painful cramps through the trunk and legs. As 
dehydration continued, the bodily fluids were excreted as ‘rice water’ and the victim quickly collapsed 
and turned blue. “Often, fifty per cent or more of those who caught cholera died, with death coming to the 
more fortunate victims in as little as four to six hours “(p. 30). Empirical accounts from the 1832 North 
American pandemic described one victim as being:  “. . . a young woman of apparently twenty-five ... 
absolutely convulsed with agony. Her eyes were started from their sockets, her mouth foamed, and her 
face was a frightful livid purple. She had been taken in perfect health only three hours before, but her 
features looked to me marked with a year of pain. The first attempt to lift her produced violent vomiting, 
and I thought she must die instantly” (A walk through a cholera hospital, 1832, p. 37). 
Epidemiology of Vibrio Cholerae. 
 One of the first aspects that researchers learned about cholera was about how the disease was 
transmitted:  “The disease was transmitted through human feces, generally ingested in drinking water. It 
first escaped the Indian subcontinent in 1817, reaching Moscow in September 1830 and thence westward 
across Europe. “The mysterious origins and terrifying nature of the disease added to the sense of dread it 
created in Europe and North America” (Osborne, p. 30). In 2000, scientists identified the entire order of 
paired chemical building blocks that constitute the DNA of the deadly cholera bacterium, Vibrio cholerae, 
and found that it is “a comma-shaped microbe [that] causes a severe diarrheal disease that has been 
endemic in southern Asia for at least 1,000 years” (Lang, 2000). Cholera continues to represent an 
important cause of morbidity and 
mortality in many regions of the world, and there is currently a high incidence of fresh outbreaks in 
Africa (Paz & Broza, 2007).  
 The transmission of cholera epidemics may also be related to the dominant wind direction over 
land (Paz & Broca, 2007). These researchers examined the geographic diffusion of three cholera 
outbreaks through their linkage with the wind direction: a) the progress of Vibrio cholerae O1 biotype El 
Tor in Africa during 1970-1971 and b) again in 2005-2006; and c) the rapid spread of Vibrio cholerae 
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O139 over India during 1992-1993. In addition, it is possible that the influence of the wind direction on 
windborne dissemination by flying insects, which may serve as vectors, plays a role. The analysis of air 
pressure data at sea level and at several altitudes over Africa, India, and Bangladesh by Paz and Broca 
found a correspondence between the dominant wind direction and the intracontinental spread of cholera. 
According to Holzman (2007), Vibrio cholerae is just one of a variety of ocean-borne microbes which can 
sicken humans via seafood, drinking water, and swimming. Location, time, and intensity of cholera 
epidemics can now be accurately predicted from satellite observations of sea surface temperature, sea 
surface height, and chlorophyll in the water (Foster, 2000). Likewise, Colwell (2006) notes that, “In 1977, 
my coworkers and I reported that Vibrio cholerae, the causative agent of cholera, could be cultured from 
Chesapeake Bay water samples. It was the first report of the isolation of the V. cholerae from noncholera-
endemic geographical areas; cholera had not been reported in Maryland since the 1900s. “It was difficult 
for us to make our case, namely that the cholera vibrio was a native inhabitant of the Chesapeake Bay, 
since cholera had not occurred in the region.  
 Despite this lack of evidence, though, these researchers did in fact identify Vibrio cholerae in the 
Chesapeake Bay and thereafter applied molecular techniques to demonstrate that 
the bacterium is naturally occurring in the aquatic environment, with annual peaks in the spring and fall. 
In addition, Colwell and her colleagues found that the V. cholerae is associated with plankton. We now 
know that river, estuary, and coastal waters are reservoirs of these bacteria globally, but their data 
showing an environmental source of the cholera bacteria implied a paradigm shift for the medical 
community. “It has taken about 20 years for the paradigm change of cholera being transmitted only by 
person-to-person contact to the recognition that the cholera vibrio exists in the environment as a natural 
inhabitant (p. 753). In addition, Colwell and her associates determined that the bacterium experiences a 
dormant phase between outbreaks and epidemics and through the use of gene probe molecular techniques 
were able to prove its year-round presence in the environment.  
 As noted above, V. cholerae O1 classical strains adhere to zooplankton, and Colwell and her 
colleagues determined that this relationship with zooplankton was particularly important. According to 
these researchers, “In the spring, when the water warms, phytoplankton become abundant; using sunlight 
for energy, the population of phytoplankton increases significantly. That population increase is followed 
by blooms of zooplankton, the miniature ‘cattle’ of the sea, which graze on the phytoplankton. We were 
able to show a relationship of sea surface temperature increase with onset of cholera epidemics because of 
the fact that vibrios comprise the natural microbial flora of zooplankton, the populations of which 
increase spring and fall in annual cycles. The seasonal pattern of cholera follows the seasonal rise and fall 
in sea surface temperature and height (Colwell,).  
 In 1991-1992, a massive cholera epidemic took place in Peru and about 200,000 cases and 5,000 
deaths were reported as a result of this epidemic; this was an unprecedented occurrence because cholera 
had not been reported in South America for almost a century 
(Colwell). Moreover, the epidemic took place during a period of a strong El Nino climatic event. Based 
on climatologists’ prediction concerning another comparable El Nino event in 1997-1998, Colwell and 
her associates hypothesized that there was a linkage of the 1991-1992 cholera epidemic with El Nino and 
predicted additional cholera outbreaks would occur in 1997-1998. As Colwell notes, “With colleagues 
from Peru, Chile, Ecuador, Brazil, and Mexico, we conducted a training session on molecular techniques 
for direct detection of the V. cholerae in water and plankton. As the sea surface temperatures in these 
Latin American countries increased in 1997 because of E1 Nino, the team was able to detect the presence 
of the cholera bacteria associated with plankton, with numbers of the bacteria increasing from spring to 
summer (September 1977 to March 1998) and cases of cholera occurring in late November through the 
summer of 1998” (p. 753).  
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 Colwell and her colleagues were able to conclude that E1 Nino is another important climate 
factor related to cholera, notably in cholera-endemic countries. The cases of cholera in Peru in 1997-1998 
were directly correlated with sea surface temperature. The relationship of the disease with this climate 
factor was statistically significant. In Bangladesh and other countries where severe cholera epidemics 
occur, such as Peru, Indonesia, and India, the influence of monsoons or severe weather is important. 
Matlab, near Dhaka, Bangladesh, comprises a "hotspot" of cholera. The villages are constructed around 
bodies of water, and specific locations of epidemics have been determined. Research on cholera has been 
conducted in Matlab by Colwell et al. since 1975. The influence of the Himalayas on the weather in 
Bangladesh is significant, because the monsoon rains wash nutrients into the rivers and ponds. Typically, 
houses in Bangladesh are located at the edge of a pond, from which villagers draw their water for 
household use. A definable relationship between sea surface temperatures, sea surface height, and cholera 
epidemics was established and published in the proceedings of the National Academy of Science (Lobitz 
et al., 2000). Taken together, the complex factors of sea surface temperature, sea surface height, and 
zooplankton populations provide a predictive capacity for cholera epidemics in developing countries that 
derives from climate monitoring through satellite sensors (Colwell, 2006).  
 Finally, with the assistance of sociology researchers working in Bangladesh, they were able to 
test the hypothesis they constructed: that if they could remove zooplankton from the water the villagers 
used to meet household needs, the incidence of cholera could be reduced. With a very simple filtration 
technique that Colwell et al. devised using sari cloth folded in 4 layers, the researchers were able to 
reduce cholera by approximately 50 percent in villages where families had been instructed in the filtration 
method. The complex of plankton, people, and climate, together with a simple solution based on science 
(under the electron microscope, the folded sari cloth could be seen to provide a 20 micron filter--and the 
zooplankton range in size roughly 50 to 200 microns), provides the interrelationship that allows an 
understanding of a global infectious disease--an understanding that would not otherwise be possible.  
 Moreover, studies conducted by the Smithsonian Environmental Research Center in recent years 
have also determined that cholera is far more prevalent in ballast water than previously thought; a 
sampling of ballast water from fifteen vessels entering Chesapeake Bay identified one strain of cholera, 
Vibrio cholerae O1, on every ship surveyed. In additional, a different strain of cholera, Vibrio cholerae 
O139, which had been previously unidentified in the United States, was identified in the ballast water of 
fourteen of the fifteen vessels surveyed (Foster, 2000). 
 
How Quorum Sensing Influences the Virulence of the Bacteria Vibrio Cholerae.  
 According to Cámara, Hardman, Williams and Milton (2002), “Bacteria can communicate with 
members of their own species and others to coordinate their behavior in response to cell density. This 
phenomenon, known as quorum sensing, relies on the production and sensing of one or more secreted 
signal molecules. A recent study identifies a complex quorum sensing network in the human pathogen 
Vibrio cholerae (p. 217). In this regard, Tsou, Cai, Liu, Zhu and Kulkarni (2009) report that, “The 
quorum-sensing pathway in Vibrio cholerae controls the expression of the master regulator HapR, which 
in turn regulates several important processes such as virulence factor production and biofilm formation. 
While HapR is known to control several important phenotypes, there are only a few target genes known to 
be transcriptionally regulated by HapR (p. 2747). In this study, Tsou and her colleagues combined 
bioinformatic analysis with experimental validation to discover a set of novel direct targets of HapR. The 
findings of the Tsou et al. study provide evidence for two distinct binding motifs for HapR-regulated 
genes in V. cholerae as follows. The first binding motif is similar to the motifs recently discovered for 
orthologs of HapR in V. harveyi and V. vulnificus; these results also demonstrate that this binding motif 
can vary in length in V. cholerae; the second binding motif shares common elements with the first motif, 
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but in contrast to the first binding motif, the second is fixed in length and does not have dyad symmetry at 
the terminal points (Tsou et al.). 
 
 
 
 
 
Figure 1. Quorom sensing in Vibrio harveyi. 
Source:  Camara et al. 
 In V. harveyi, a harmless marine bacterium closely related to V. cholerae, quorum sensing serves 
to activate bioluminescence (luxCDABE) at high cell density levels; to accomplish this, two parallel 
signaling systems are used to control light production. Likewise, as shown in Figure 2 below, quorum 
sensing in V. cholerae functions by restricting virulence gene expression at high cell density through the 
use of three parallel signaling systems as follows: 
1. System 1 includes CqsA, a putative synthase for the unidentified CAI-1 signal molecule, and 
CqsS, a hybrid sensor/kinase that responds to the CAI-1 signal.  
2. System 2, LuxSPQ, is identical to that of V. harveyi (see above). 
3. System 3 has not been characterized; however, this system is believed to respond to an 
intracellular signal and is therefore thought to be unrepresentative of a true quorum sensing 
system. System 3 does not seem to transmit its signal through LuxU but rather 
directly through LuxO, the pivotal regulator for all three systems. Like the V. harveyi system, LuxO 
is activated via phosphorylation at low cell density and, together with σ54, activates the expression of 
53	
	
an unidentified repressor that blocks the production of HapR, which acts as a repressor of virulence 
gene expression. As a result, at low cell density, virulence genes are expressed; at high cell density, 
though, LuxO remains inactive and cannot repress HapR. As HapR is now expressed, virulence gene 
expression is repressed (Camara et al.). 
 
Figure 2. Quorum sensing in Vibrio cholerae. 
Source:  Camara et al. 
 The quorum sensing responses in V. harveyi and V. cholerae represent instances of complex cell–
to-cell communication techniques that focus multiple cell-density–dependent, and perhaps independent, 
signals via an alternate regulatory pathway to regulate bacterial behavior (Camara et al.). According to 
these researchers, “Variations on the complexity or organization of these multiple-channel signaling 
systems may be forthcoming, as components of the V. harveyi-like signaling systems have been found in 
V. fischeri as well as the fish pathogen Vibrio anguillarum11–13; however, adding yet more complexity 
to the process, both of these organisms also possess LuxI/LuxR-type quorum sensing signaling systems” 
(Camara et al., p. 218). The coordination of a multi-cellular response to rapidly adapt to changes that take 
place in the surrounding environment is a useful survival strategy for pathogenic and non-pathogenic 
bacteria alike (Camara et al.). Just as other forms of life respond to the density levels of their populations 
in different ways, so too does the V. cholerae. In this regard, Camara and his associates report that, “Cell 
density is just one of a multitude of signaling parameters that a bacterium faces in any given environment, 
and coordination of all signals into a physiological response will require intersystem cross-talk. 
Incorporation of quorum sensing into a global network of regulatory responses may be required to 
increase selectivity and efficiency of a bacterium’s response to the stresses it encounters in its growth 
environment” (Camara et al., p. 218). 
 One unexpected outcome of a study by Miller et al. (2002) was that, in contrast to many other 
bacterial pathogens, quorum sensing in V. cholerae serves to repress, rather than activate, virulence gene 
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expression at high cell density levels in vitro (Camara et al.). A speculative model was advanced that 
indicated that following initial colonization (low cell density), LuxO represses HapR, which is also a 
repressor of virulence gene expression, thereby permitting colonization of the intestines and cholera toxin 
production. In this regard, Camara et al. add that, “As the bacterium multiplies, the quorum sensing signal 
molecules accumulate and activate the two quorum sensing systems, which inactivate LuxO. HapR is then 
produced, repressing virulence gene expression while activating the production of the protease, HapA”. 
(Camara et al., p. 218). 
HapA is believed by scientists to promote the detachment of the bacteria from intestinal tissue, thus 
facilitating the spread of the pathogen. As there is still a third unidentified signaling system influencing 
gene regulation through the LuxO regulatory cascade, and additional regulators of virulence gene 
expression to be considered, the actual role of signaling systems 1 and 2 in the virulence of V. cholerae in 
vivo remains unclear. According to these researchers, “Nonetheless, the model proposed for V. cholerae 
should provide an exciting twist on the role of quorum sensing in virulence” (Camara et al., p. 218). 
 Finally, a study by Zhu, Miller, Vance, Dziejman, Bassler and Mekalanos (2002) notes that the 
production of virulence factors including cholera toxin and the toxin-coregulated pilus in the human 
pathogen Vibrio cholerae is strongly influenced by environmental conditions. These researchers report 
that, “The well-characterized ToxR signal transduction cascade is responsible for sensing and integrating 
the environmental information and controlling the virulence regulon” (p. 3129). In their timely study, 
“Quorum-sensing regulators control virulence gene expression in Vibrio cholerae,” Zhu et al. demonstrate 
that besides the known components of the ToxR signaling circuit, quorum-sensing regulators are involved 
in regulation of V. cholerae virulence. These researchers concentrated on the regulators LuxO and HapR 
because homologues of these two proteins control quorum sensing in the closely related luminous marine 
bacterium Vibrio harveyi in this study. According to Zhu and his associates, “Using an infant mouse 
model, we found that a LuxO mutant is severely defective in colonization of the small intestine. Gene 
arrays were used to profile transcription in the V. cholerae wild type and the LuxO mutant. These studies 
revealed that the ToxR regulon is repressed in the LuxO mutant, and that this effect is mediated by 
another negative regulator, HapR. We show that LuxO represses HapR expression early in log-phase 
growth, and constitutive expression of HapR blocks ToxR-regulon expression. 
Additionally, LuxO and HapR regulate a variety of other cellular processes including motility, protease 
production, and biofilm formation. Together these data suggest a role for quorum sensing in modulating 
expression of blocks of virulence genes in a reciprocal fashion in vivo” (p. 3130).  
Diagnostic and Treatment Considerations. 
 In many ways, Vibrio cholerae is an elusive bacterium that can elude ready detection that 
confounds diagnosis. In this regard, Henrickson, Wong, Allen, Ford and Epstein (2001) report that some 
gram-negative organisms such as V. cholerae are capable of adapting to low-nutrient environments 
through reductive division; in other words, although there is no change in total biomass, more organisms 
develop but they develop at a significantly reduced metabolic rate. When there are unfavorable 
environmental conditions, such as cold or reduced nutrients, Vibrio cholerae bacteria can shrink to 1/300th 
of its original size and enter a dormant state; remaining in the dormant state for extended periods of time, 
increasing in size when environmental conditions once again become favorable. Moreover, V. cholerae 
can become nonculturable on routine culture plates, but remain viable, and could regrow under 
appropriate conditions (Henrickson et al.). 
 As noted above, cholera has a rapid onset and most frequently occurs in epidemics that are spread 
through contaminated water. According to Long, “Oral rehydration is an effective treatment, but left 
untreated, cholera causes severe diarrhea that has a high mortality rate, particularly in young children” (p. 
39). Even some simple precautionary methods can reduce the incidence of infection by Vibrio cholera, 
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though. For instance, Holzman (2007) emphasizes that if people in the least stable situations--for 
example, in war-torn developing countries—are provided with sufficient warning, they could filter 
drinking water using low-tech devices, cutting 
the infection rate by 50%. Researchers have successfully monitored and predicted cholera epidemics in 
Bangladesh through the use of satellites, as reported in the 15 February 2000 issue of Proceedings of the 
National Academy of Sciences (Holzman). In this regard, Dremeaux (2003) reports that, “Ingesting a high 
dose of the waterborne bacteria Vibrio cholerae O1 produces cholera, an infection that causes severe 
dehydration brought on by acute diarrhea and vomiting. Left untreated, cholera can kill a person in 24 
hours. Filtering water with a folded piece of old cloth before drinking it cuts the rate of cholera 
contraction by half, according to a three-year study in 65 Bangladeshi villages published in January 2003 
in the U.S. journal Proceedings of the National Academy of Sciences” (p. 9). According to Gibbs (2005), 
“Up to 90 per cent of cases of cholera will have only mild diarrhea. The remainder may exhibit severe 
watery diarrhea leading to dehydration. Since neither the bacteria nor its toxins can pass through the gut 
wall and into the blood, cholera does not increase the sufferer's temperature. In severe cases, a simple 
antibiotic such as Tetracycline will decrease the diarrhea. Rehydration is imperative. “Oral rehydration 
salts are usually sufficient, but severe cases will need intravenous fluids” (p. 101). 
Discussion. 
 As noted above, simply filtering contaminated water with a folded piece of old cloth before 
drinking it reduces the rate of cholera contraction by fully 50 percent. According to Dremeaux (2003), 
“The finding has the potential to save thousands of lives annually. Fabric from saris, the flowing, colorful 
garments South Asian women often wear, was cheap and readily available to the 133,000 people who 
participated in the study, and comparable fabrics could function as filters for populations at risk for 
cholera around the world” (p. 9). The sari cloth does not trap V. cholerae per se, but rather the copepods, 
a type of zooplankton onto whose mouths, surfaces, and egg cases the vibrios attach (Dremeaux). While a 
majority of the vibrios did remain 
free in the filtered water, their numbers were frequently diminished sufficiently to fall short of an 
infective dose, estimated at [104] to [106] V. cholerae; in fact, the dilution lowered the rate of cholera 
infection by almost half (48%). According to Dremeaux, “For those who did contract cholera via filtered 
water, the severity of the disease appears to have lessened, the report says. Electron microscopy had 
revealed that sari cloth, when folded four to eight times, would create a filter of approximately 20 mm 
pore size, removing all copepods--and the cholera-causing bacteria attached to them--from the water. The 
old saris used in the experiment were expected to be more effective than new ones, their laundered fabric 
resulting in a smaller pore size” (p. 9). Although clean potable water would be preferable of course, and 
boiled water would be an acceptable alternative, there remains a paucity of fuel for many villagers to use 
for this purpose. In this regard, Dremeaux reports, “Rivers and ponds are a common source of drinking 
water for the villages in rural Matlab, Bangladesh. Boiling water, which kills all waterborne 
microorganisms, is often impossible for the villagers, who are hard-pressed to find dry wood for fuel or 
the money to buy it. High concentrations of arsenic in the groundwater make well sources a poor 
alternative (Dremeaux, p. 9). Although nylon mesh filter was nearly as effective as the sari cloth in 
reducing cholera, that material is more costly and harder to find in rural Bangladesh than material from 
saris (Dremeaux). In sum, Colwell (2006) emphasizes that, “The interaction of humans, cholera bacteria, 
the zooplankton host of the bacterium (the copepod), and the environment in the case of cholera can be 
employed to make reasonable predictions about this climate-driven disease. The issues are truly 
international and represent those that comprise a global scientific enterprise and encompass many other 
infectious diseases” (p. 754). 
Conclusion 
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 The research showed that the disease caused by Vibrio cholerae has plagued mankind for 
thousands of years, but the pathogen that was responsible for causing cholera was only discovered a 
century and a half ago. Over the past two centuries, cholera has caused seven pandemics and has been 
responsible for tens of thousands of deaths. The research also showed that even during periods when it is 
dormant, Vibrio cholerae, continues to thrive in brackish waters in both harmless and disease-causing 
forms. Researchers have discovered that it is possible to predict with some accuracy future outbreaks of 
cholera epidemics using satellite observations of sea surface temperature, sea surface height, and 
chlorophyll in the water. Finally, the research also showed that bacteria such as Vibrio cholerae are 
capable of communicating with other members of their species in order to coordinate their behavior in 
response to cell density in a process known as quorum sensing that relies on the production and sensing of 
one or more secreted signal molecules. A growing body of scientific studies has identified a complex 
quorum sensing network in the Vibrio cholerae that may help researchers identify superior diagnostic and 
treatment protocols in the future, but in the meantime, there have been some commonsense approaches to 
treating water contaminated by Vibrio cholerae that reduce its incidence by almost half.  
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Atherosclerosis	and	Antioxidants	
Yehoshua	Lewis	
Abstract:	
Cellular	lipid	oxidation	is	a	known	cause	for	the	cascade	leading	to	the	formation	of	lipid	laden	
foam	 cells,	 which	 can	 cause	 of	 atherosclerosis.	While	 statins	 and	 antioxidants	 have	 recently	
come	 under	 question	 in	 the	 amelioration	 of	 atherosclerosis,	 Flavonoids	 have	 recently	 been	
touted	as	a	powerful	antioxidant	and	suppresser	of	atherosclerosis.	This	paper	will	attempt	to	
show	 why	 statins	 and	 vitamin	 E	 have	 come	 under	 scrutiny,	 and	 how	 the	 desired	 effects	 of	
Flavonoids	can	be	attributed	to	the	role	 it	plays	 in	 increased	paraoxonase-1	activity	(a	known	
anti	 inflammatory	associated	with	HDL),	decreased	C-	Reactive	protein	activity,	and	 increased	
nitric	oxide	(NO)	in	endothelial	cells	among	other	factors.		
Introduction:	
Coronary	artery	disease	(CAD)	is	the	leading	cause	of	death	in	the	United	States	every	year.	According	to	
the	 Center	 for	 Disease	 Control	 and	 the	 National	 Center	 for	 Health	 Statistics,	 data	 for	 the	 year	 2004	
indicate	that	heart	disease	killed	652,486	people	(U.S.	DEPARTMENT	OF	HEALTH	AND	HUMAN	SERVICES,	
2008).	This	is	nearly	100,000	more	than	the	second	leading	cause	of	death	in	the	United	States,	cancer.	
Atherosclerotic	plaque	build-up	 in	the	arteries	 is	the	cause	of	CAD,	and	has	been	the	primary	focus	of	
scientists	 in	 search	 of	 a	 cure	 for	 CAD.	Needless	 to	 say,	much	 research	 has	 been	 done	 on	 finding	 the	
causes	of	heart	disease	and	developing	drugs	that	inhibit	its	development.	Other	then	pharmacological	
products,	there	is	a	very	large	body	of	research	into	more	natural	remedies	for	atherosclerosis,	including	
antioxidants	 such	 as	 vitamin	 E	 that	 have	 been	 touted	 as	 providing	 protection	 against	 lipid	 oxidation.	
Recently,	 however,	 there	 is	 a	 growing	body	of	 evidence	 that	 statins	 and	antioxidant	 supplementation	
may	not	be	beneficial	as	thought.	In	contrast,	Flavonoids,	by	operating	under	mechanisms	different	then	
antioxidants	and	statins,	offers	new	hope	in	the	treatment	of	atherosclerosis.			
Coronary	Artery	Disease:	
While	there	are	many	factors	that	contribute	to	CAD,	there	are	a	number	of	factors	specifically	related	
to	atherosclerosis	that	play	a	key	role	in	its	development.	Atherosclerosis	is	a	progressive	disease	of	the	
arteries	and	is	the	result	of	plaque	buildup	in	the	arteries	driven	by	the	
uptake	of	cholesterol	in	artery	walls	(Medline	Plus,	2007).		Lipids	are	not	
water	 soluble,	and	must	 rely	on	 lipoproteins,	produced	 in	 the	 liver	and	
small	 intestines,	 in	 order	 to	be	 transported	 in	 the	blood.	By	 combining	
lipids	with	lipoproteins,	the	lipids	are	able	to	be	transported	either	to	the	
liver	 for	 elimination,	 or	 from	 the	 liver	 for	 the	 production	 of	 steroid	
hormones,	 bile	 salts,	 and	 for	 cell	 membrane	 repair.	 The	 two	 major	
lipoproteins	 involved	 in	 these	 functions	 are	 low-density	 lipoproteins	
(LDL),	 and	 high-density	 lipoprotein	 (HDL);	 with	 LDL	 being	 responsible	
Figure	1.	Dissected	aorta	with	
atherosclerotic	lesions	(Ewing,	
1972)	
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lipid	 transport	 from	 the	 liver,	 and	 HDL	 being	 responsible	 for	 transport	 of	 lipids	 to	 the	 liver	 for	
elimination	(Tortora	&	Derrickson,	2006).		
Plaque	formation	begins	with	the	aggregation	of	excess	LDL	 in	 the	 inner	 layer	of	arterial	walls	
where	 the	 lipoproteins	 are	 subject	 to	 oxidation.	 In	 response,	 substances	 released	 by	 endothelial	 and	
smooth	muscle	cells	attract	macrophages	that	ingest	the	oxidized	LDL	forming	plaque.	So	much	so,	that	
the	 macrophages	 take	 on	 a	 foamy	 appearance	 under	 the	 microscope	 (foam	 cells).	 	 Additionally,	
lymphocytes	 (T	 cells)	 follow	 the	 macrophages	 into	 the	 arterial	 wall	 and	 increase	 the	 streaks	 in	 the	
arterial	walls.	Subsequently,	the	macrophages	cause	the	migration	of	the	middle	 layer	of	the	artery	to	
the	 surface	 of	 the	 plaque	 thus	 separating	 it	 from	 the	 bloodstream,	 but	 also	 narrowing	 the	 arterial	
lumen.	In	the	event	that	the	cap	over	the	plaque	bursts,	the	T	cells	stimulate	the	foam	cells	to	produce	
tissue	 factor	 (TF),	 which	 ultimately	 leads	 to	 blood	 clot	 formation	 and	 possible	 obstruction	 of	 the	
coronary	 artery,	 resulting	 in	 myocardial	 infarction	 (MI).	 Other	 factors	 currently	 being	 considered	 by	
researchers	include	C-reactive	proteins,	which	bind	to	damaged	cells	and	assist	in	phagocytosis,	clotting	
factors,	 and	 the	 amino	 acid	 homocysteine	 that	 promotes	 platelet	 aggregation	 (Tortora	&	 Derrickson,	
2006).		
Statins:	
In	 order	 to	 treat	 atherosclerosis,	
scientists	 have	 focused	 their	 attention	 on	
reducing	 the	 amount	 of	 cholesterol	
available	 in	 the	 bloodstream	 for	 oxidation	
with	the	use	of	statin	drugs.	
In	 the	 1960’s	 (Endo,	 1992)	 scientists	
discovered	 that	 when	 cholesterol	 is	
completely	 eliminated	 from	 the	 diet,	 the	
liver	 takes	 over	 and	 produces	 up	 to	 82%	
percent	 of	 the	 required	 cholesterol.	
However,	when	cholesterol	 is	added	to	the	
diet	 the	 synthesis	 of	 cholesterol	 is	 almost	
completely	 suppressed.	 They	 discovered	
that	 the	 production	 or	 suppression	 of	
cholesterol	 was	 in	 response	 to	modulation	
by	 HMG-CoA	 reductase	 which	 modulates	
the	 inhibition	 of	 the	 Mevalonate	 pathway	
of	cholesterol	synthesis	 (Figure	2).	Through	
modulating	 this	 enzyme	 they	were	 able	 to	
alter	 the	 production	 of	 cholesterol.	 Thus	
was	 born	 the	 first	 statin	 drugs.	 However,	 there	
are	medical	 researchers	 who	 challenge	 the	 claim	 that	 statin	 drugs	 actually	 lower	 the	 risk	 factors	 for	
myocardial	 infarction	 (MI).	 In	 a	 scathing	 review	 of	 studies	 purporting	 to	 show	 that	 by	 lowering	
Figure	2.	Mevalonate	pathway	of	cholesterol	synthesis	
(Chemistry	Daily,	2007)		
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cholesterol	with	 statin	 drugs	mortality	 rates	 are	 decreased,	 Kauffman	 (Kauffman,	 2007)	 cites	 a	 study	
carried	out	in	New	York	City	of	a	group	of	2,277	people	with	the	median	age	of	76	who	were	studied	for	
a	period	of	ten	years.	What	he	found	was	that	“The	chance	of	dying	was	twice	as	great	in	subjects	with	
the	 lowest	 quartile	 of	 total	 cholesterol	 (TC)	 or	 LDL-C	 levels,	 compared	 with	 those	 in	 the	 highest	
quartile”.	 Kauffman	 goes	 on	 to	 cite	 another	 study	which	 shows	 that	 for	men	 aged	 35-57	 “all	 cause”	
mortality	 rates	 increased	 for	 those	 with	 a	 TC	 of	 <170	 mg/dL	 and	 the	 risk	 increased	 further	 as	 TC	
decreased	 to	 <140	 mg/dL	 to	 the	 same	 levels	 seen	 for	 subjects	 with	 extremely	 high	 cholesterol	
>300mg/dL.	 Kaufmann	 flatly	 states	 “Serum	 TC	 level	 is	 not	 even	 predictive	 of	 cardiovascular	 disease	
(CVD)	 in	men	over	 the	age	of	47”.	Kauffman	 is	not	alone	 in	 challenging	 the	use	of	 statins;	 the	British	
Medical	 Journal	 (Ravnskov	 et	 al.,	 2006)	 also	 challenges	 its	 widespread	 use,	 safety	 and	 efficacy.	 This	
raises	serious	questions	about	how	the	medical	community	is	facing	the	challenge	of	CAD.	
Oxidation:	
While	 statins	 focus	 on	 reducing	 TC	 as	 a	 remedy	 to	 the	 formation	 of	 atherosclerosis,	 there	 is	
another	very	important	juncture	in	the	formation	of	atherosclerosis	that	has	been	the	focus	of	research,	
namely	oxidative	stress	caused	by	free	radicals	and	reactive	oxygen	species	(ROS).	ROS	and	free	radicals	
are	 injurious	 to	 lipids,	DNA,	and	proteins	 if	 left	unchecked	by	 the	bodies’	native	defense	mechanisms	
(Davis,	1995).	What	are	ROS	and	free	radicals	and	why	are	they	so	important?		
Examples	 of	 ROS	 include	 hydrogen	 peroxide	 (H2O2),	 hypochlorous	 acid	 (HClO).	 Free	 radicals	
include	superoxide	anion	(·O2−)	and	hydroxyl	radical	(·OH)	(Davis,	1995).	One	source	of	the	free	radical	
superoxide	 anion	 (·O2−)	 is	 that	 produced	 by	 the	 NADH/NADPH	 oxidase	 in	 macrophages	 during	 the	
uptake	of	LDL	(Runge,	1999).	The	superoxide	is	formed	during	the	electron	transport	chain	(ETS)	when	
the	 reduction	 of	 coenzyme	Q	 in	 complex	 III	 forms	 the	 unstable	 Q·−	 radical	 which	 can	 leak	 electrons	
directly	 to	 oxygen	 instead	 of	 cascading	 down	 the	 rest	 of	 the	 ETS	 thus	 forming	 superoxide	 radicals	
(Holbrook,	2000).		
Considering	 that	1%	 -	 15%	of	O2	 respired	by	mammals	undergoes	 the	 superoxide	anion	 (·O2−)	
state	(McGraw-Hill's	Access	Science),	there	is	also	ample	opportunity	to	form	undesired	side	reactions.		
An	example	of	a	side	reaction	causing	oxidative	stress	results	when	superoxide	reacts	with	nitric	oxide	
(NO)	to	form	peroxynitrite	(·O2−	+	·NO	→	ONO2−).	Peroxynitrite	then	reacts	as	a	strong	oxidizing	agent	
with	lipids,	DNA,	and	proteins.	Superoxide	and	NO	individually	can	both	be	efficiently	removed	from	the	
body.	Superoxide	reacts	with	hydrogen	in	the	presence	superoxide	dismutase	(SOD)	to	form	oxygen	and	
hydrogen	peroxide	(2·O2−	+	2H+	 	 	→	O2	+	H2O2),	which	can	then	be	converted	by	catalase	to	water	and	
oxygen.	 NO	 is	 rapidly	 removed	 by	 its	 diffusion	 through	 tissues	 into	 red	 blood	 cells.	 However,	 when	
compared	with	SOD,	the	kinetics	and	thermodynamics	during	a	reaction	of	NO	and	superoxide	favor	the	
formation	 of	 peroxynitrite	 -	 resulting	 in	 the	 inevitable	 formation	 of	 a	 highly	 reactive	 oxidizing	 agent.	
Peroxynitrite	acts	as	a	potent	oxidizing	agent	towards	LDL	which	then	becomes	the	target	for	scavenger	
cells	 and	 the	 formation	 of	 foam	 cells.	 	 Various	 studies	 have	 also	 shown	 that	 LDL	 can	 be	 oxidized	 by	
peroxynitrite	even	in	the	presence	of	endogenous	lipophilic	antioxidants	(Pacher	et	al.,	2007).		
Another	 source	 of	 oxidation	 is	 the	 Hydroxyl	 radicals	 (•OH)	 that	 are	 produced	 in	 the	 iron	
catalyzed	Haber-Weiss	reaction.	The	Haber-Weiss	reaction	(Koppenol,	2001)	was	first	discovered	in	the	
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early	 1930’s	 by	 Fritz	 Haber	 and	 Josef	 Weiss	 and	 proceeds	 as	 follows:	 Recalling	 that	 1%-15%	 of	 O2	
respired	 by	 mammals	 undergoes	 the	 superoxide	 anion	 (·O2−)	 state,	 we	 can	 propose	 the	 following	
reactions:			
Fe3+	+	•O2−	→	Fe2+	+	O2,	
Followed	by	the	Fenton	reaction:	
Fe2+	+	H2O2	→	Fe3+	+	OH−	+	•OH,	
For	a	net	reaction	of:	
•O2-	+	H2O2	→	•OH	+	HO-	+	O2.	
Hydroxyl	radicals	are	short	lived	in	vivo,	(Approx	10-9	s)	and	are	highly	reactive	(Yan	et	al.,	2005).	
They	also	cannot	be	enzymatically	removed	because	of	 its	short	half	 life	and	tends	to	react	extremely	
quickly	with	whatever	is	in	its	vicinity	including:	carbohydrates,	nucleic	acids,	lipids,	and	amino	acids.		
The	limitations	of	this	process	are	inherent	in	that	it	requires	Iron	III	in	order	to	proceed,	and	the	
blood	 plasma	 protein	 Transferrin	 is	 very	 effective	 at	 scavenging	 free	 iron,	 making	 it	 unavailable	 for	
reduction.	However,	if	there	is	a	buildup	of	iron	either	due	to	dietary	Iron	overload	or	any	other	multiple	
of	diseases,	it	can	outstrip	the	ability	of	Transferrin	to	perform	properly	and	results	in	the	production	of	
free	radicals	(Fouad,	2008).		
Antioxidants:	
As	the	oxidation	of	lipids	form	a	key	step	in	the	formation	of	atherosclerosis,	it	should	also	lead	
to	 the	 conclusion	 that	 “antioxidants”	 offer	 protection	 against	 lipid	 oxidation.	 However,	 the	 more	
research	 that	 is	 being	 done,	 the	more	 it	 becomes	 clear	 that	 exogenous	 sources	 of	 antioxidants	 have	
questionable	 effects	 in	 vivo.	 The	 field	 of	 antioxidants	 is	 very	 broad	 and	 can	 be	 the	 subject	 of	 many	
papers,	but	just	to	scratch	the	surface;	antioxidants	can	be	broken	down	into	metabolite	and	enzymatic	
categories	as	well	as	lipid	soluble	and	water	soluble.	The	difference	between	them	is	their	mechanism	as	
well	as	site	of	action.	For	example:	 lipid	soluble	antioxidants	act	 in	cell	membranes,	and	water	soluble	
antioxidants	 act	 in	 the	 blood	 plasma	 and	 cytoplasm.	 Lipid	 soluble	 antioxidants	 include	 vitamin	 E	 and	
coenzyme	Q	(Q10).	Water	soluble	antioxidants	include	ascorbic	acid	(vitamin	C),	glutathione,	lipoic	acid,	
uric	 acid,	 and	 polyphenols	 (Flavonoids,	 tannins).	 Enzymatic	 antioxidants	 include	 the	 previously	
mentioned	SOD,	catalase,	as	well	as	glutathione	among	others	(Sies,	1997).		
Vitamin	E	 is	a	potent	antioxidant	and	some	research	has	shown	that	 it	can	regulate	HMG-CoA	
reductase	(Pal	et	al.,	2003;	Parker,	1993).		Vitamin	E	is	the	name	for	a	group	of	four	tocopherols	and	four	
tocotrienols,	of	which	the	most	 interesting	to	scientists	 is	 the	α-tocopherol	variety	because	of	 its	high	
bioavailability.	Vitamin	E	is	the	main	lipid-soluble	antioxidant	in	the	body	and	it	works	in	cell	membranes	
where	it	prevents	the	propagation	of	free	radical	reactions	(Herrera	&	Barbas,	2001).		
Because	vitamin	E	is	lipid	soluble,	when	absorbed	vitamin	E	is	packaged	in	Chylomicrons	(large	
lipoprotein	 particles)	 that	 are	 produced	 in	 the	 absorptive	 cells	 in	 the	 small	 intestine.	 They	 are	 then	
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secreted	via	exocytosis	into	lacteals	of	the	lymphatic	system	and	delivered	into	the	circulatory	system	at	
the	juncture	of	the	thoracic	duct	and	the	left	subclavian	where	they	are	transported	to	the	liver.	At	the	
liver,	 lipoprotein	 lipase	 (LPL)	 induces	 the	unloading	of	some	of	 the	chylomicrons	 into	the	extrahepatic	
tissue	 and	 the	 remainder	 chylomicrons	 transports	 the	 tocopherols	 into	 the	 liver.	 Here,	 “α-tocopherol	
transfer	protein"	incorporates	α-tocopherol	into	very	low	density	lipoprotein	(VLDL)	the	excess	of	which	
is	excreted	into	the	bile	duct.	The	α-tocopherol	binded	VLDL	is	then	transported	into	circulation	where	it	
is	converted	to	LDL	again	by	the	action	of	LPL.	The	α-tocopherol	is	then	taken	up	by	the	endothelial	cell	
membrane	by	the	uptake	of	LDL	via	cell	receptors	(Herrera	&	Barbas,	2001).		
Once	in	the	cell	membrane,	α-tocopherol	can	act	as	a	terminator	to	lipoprotein	oxidation	chain	
reaction	as	follows:		
Where	“I”	is	the	initiator	and	“LH”	is	the	fatty	 acid	
and	L•	is	formed	from	the	fatty	acid	
I	+	LH	→	L•	+	IH			[1]	
Propagation	continues	as	follows:			
L•	+	O2	→	LOO•	[2]	
LOO•	+	LH	→	LOOH	+	L•	[3]	
(See	Figure	3)	
Termination	occurs	when	tocopherol	“TO”	
breaks	the	chain	reaction:	
LOO•	+	TOH	→	LOOH	+	TO•	[4]	
The	 tocopheroxyl	 radical	 then	 reacts	 with	
another	 peroxyl	 radical	 to	 form	 tocopheryl	
quinine	 (Q10)	 and	 thereby	 arresting	 the	 chain	
reaction	(Wolf,	2005).		
As	 with	 almost	 every	 system	 in	 the	 body,	 vitamin	 E	 does	 not	 function	 in	 isolation	 but	 is	 part	 of	 an	
antioxidant	 network	 in	 which	 vitamin	 E	 can	 be	 synthesized	 from	 vitamin	 C	 and	 thiol	 redox	 cycles	
involving	 glutathione	 and	 lipoic	 acid.	 (See	 attachment).	 Vitamin	 C	 has	 pro-oxidant	 properties	 as	 well	
because	of	 its	ability	 to	 reduce	metal	 ions	via	 the	Fenton	 reaction	which	can	be	a	 source	of	oxidative	
stress.	However,	this	is	thought	to	be	of	minor	significance	as	compared	with	its	antioxidant	properties	
(FREI,	1999).				
On	the	other	front,	research	has	shown	that	vitamin	E,	specifically	tocotrienols,	can	modulate	HMG-CoA	
reductase	similar	way	to	that	done	by	statins	as	discussed	previously.	(Parker	et	al.,	1993)	
Figure	3.	The	free	radical	mechanism	of	lipid	
peroxidation	
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A	number	of	 studies	showed	this	effect	 in	mammals.	 In	one	study	hyperlipidemic	pigs	given	a	
diet	 rich	 in	 tocotrienols	 showed	 a	 marked	 decrease	 in	 plasma	 concentrations	 of	 cholesterol,	
apolipoprotein	B	(required	in	the	formation	of	LDL),	thromboxane	B2	and	platelet	factor	4(both	required	
for	blood	coagulation),	indicating	a	protective	effect	on	endothelium	and	platelet	aggregation	(Qureshi	
et	al.,	1991).	There	have	been	some	conflicting	results	 in	similar	trials	 in	humans;	however,	those	may	
be	attributed	 to	plasma	 levels	of	 tocotrienols	and	not	 to	 the	efficacy	of	 the	 compound	 (Packer	et	al.,	
2001).	It	would	thus	seem	that	by	ingesting	vitamin	E	one	would	be	able	to	take	concrete	measures	in	
arresting	the	propagation	of	atherosclerosis.		
However,	 a	 recent	 Meta	 analysis	 by	 The	 Cochrane	 Collaboration	 -	 of	 studies	 proving	 the	
remedial	effects	of	vitamin	E	as	well	as	other	antioxidants	-	has	not	supported	those	results.	Not	only	did	
the	ingestion	of	exogenous	antioxidants	not	prove	to	be	beneficial	but	has	also	shown	to	be	detrimental.	
The	 study	 included	 232,550	 participants	 who	 were	 “randomised	 to	 antioxidant	 supplements	 (beta-
carotene,	vitamin	A,	vitamin	C,	vitamin	E,	and	selenium)	versus	placebo	or	no	intervention”.	“A	total	of	
17,880	of	 136,023	participants	 (13.1%)	 randomised	 to	 antioxidant	 supplements	 and	 10,136	of	 96,527	
participants	(10.5%)	randomised	to	placebo	or	no	intervention	died.	In	the	analyses	of	the	trials	with	low	
risk	of	bias,	beta-carotene,	vitamin	A,	and	vitamin	E	significantly	 increased	mortality.”	The	study	 flatly	
states	that	there	is	no	evidence	to	support	antioxidant	supplementation.	This	study	brings	into	question	
the	widespread	use	of	antioxidants	as	a	remedial	and/or	prophylactic	compound	for	oxidative	diseases	
(Bjelakovic	et	al.,	2008).		
Flavonoids:	
Increased	 consumption	 of	 fruits	 and	 vegetables	 is	 associated	with	 reduced	 incidences	 of	 CAD	
and	other	disease.	 The	 cause	of	 this	has	been	attributed	 in	part,	 to	antioxidant	 Flavonoids	present	 in	
these	foods.	The	hypothesis	in	this	case	is	that	because	after	the	consumption	of	Flavonoids	there	is	a	
marked	 increase	 in	 the	 antioxidant	 properties	 of	 blood	 plasma	 and	 it	 can	 play	 a	 direct	 role	 in	 the	
prevention	of	 lipid	oxidation	 (Lotitoa	&	Frei,	2006).	A	clear	example	of	 this	 can	be	seen	 in	 the	French	
paradox,	where	despite	the	French	consuming	 large	amounts	of	red	meat	that	are	rich	 in	unsaturated	
fats	 they	still	develop	 lower	 instances	of	death	from	CAD	then	Americans.	This	has	been	attributed	to	
their	consumption	of	red	wine	which	is	rich	in	Flavonoids	(Ferrières,	2004).		
Michael	Aviram	of	the	Technion	faculty	of	medicine	has	done	extensive	research	in	the	field	of	
pomegranate	polyphenols	(Flavonoids),	and	has	made	a	very	important	contribution	to	the	field.	Among	
the	 points	 studied	 three	will	 be	 focused	 on:	 	 Antioxidant	 properties	 of	 blood	 plasma,	 paraoxonase-1	
(PON-1)1	levels,	and	aortic	stenosis	-	all	after	the	ingestion	of	PJ.	In	one	study	(Aviram,	et	al.,	2000),	both	
healthy	 human	 males	 and	 atherosclerotic	 E-deficient	 (E0)	 mouse	 subjects	 were	 fed	 PJ	 for	 variable	
periods	 of	 time.	 The	 objective	 of	 the	 study	 was	 to	 determine	 what	 effect	 PJ	 consumption	 had	 on	
lipoprotein	oxidation,	aggregation	and	retention;	macrophage	atherogenicity;	platelet	aggregation;	and	
atherosclerosis.	The	results	of	the	study	were	striking.	In	humans,	PJ	consumption	resulted	in	a	decrease	
in	 LDL	 susceptibility	 to	 aggregation	 (-11%	 ex	 vivo)	 and	 retention,	 also	 observed	 was	 serum	 PON-1	
increased	activity	by	20%	and	that	it	also	had	a	protective	effect	against	LDL	oxidation.	Human	plasma	in	
																																								 																				
1 Paraoxonase1	(PON1)	is	an	anti-inflammatory	enzyme	located	on	HDL.		
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one	 case	 showed	a	decrease	 in	 lipid	plasma	peroxidation	of	 ≤33%.	 In	 E0	mice,	 a	 90%	decrease	 in	 LDL	
oxidation	was	observed	as	well	as	a	20%	decrease	in	the	uptake	of	LDL	by	peritoneal	macrophages.	Also	
observed	 was	 a	 44%	 decrease	 in	 atherosclerotic	 lesions	 and	 foam	 cells	 as	 compared	 with	 water	 fed	
mice.	Aviram	et	 al.,	 attributes	 the	protective	 antioxidant	 effect	of	 PJ	 to	 increased	 cellular	 glutathione	
content,	 and	 states	 that	 the	 reduction	 of	 atherosclerotic	 lesions	 is	 directly	 related	 to	 the	 antioxidant	
properties	 of	 PJ.	 Another	 study	 by	 Aviram	 of	 the	 long	 term	 effects	 of	 PJ	 consumption	 -	 in	 human	
subjects	with	carotid	artery	stenosis	(CAS)	-	on	carotid	lesions	and	changes	in	oxidative	stress	and	blood	
pressure	had	 remarkable	 results.	After	 1	 year	 control	 subjects	 showed	a	9%	 increase	 in	 intima-media	
thickness	(IMT)	as	opposed	to	the	PJ	group	that	showed	a	30%	decrease	in	IMT.	PON-1	activity	increased	
by	83%,	serum	LDL	basal	oxidative	state	was	reduced	by	90%,	copper	ion	induced	oxidation	was	reduced	
by	59%	and	total	antioxidant	status	(TAS)	 increased	by	130%.	Again,	Aviram	attributes	these	results	to	
the	antioxidant	characteristics	of	PJ	polyphenols	(Aviram,	et	al.,	2004).		
Jane	Higdon,	 Ph.D.	 of	 The	 Linus	 Pauling	 Institute	 at	Oregon	 State	University	 takes	 a	 different	
tack	 and	 claims	 that	 because	 the	 bioavailability	 of	 Flavonoids	 is	 very	 low,	 its	 antioxidant	 properties	
cannot	 be	 attributed	 to	 the	 antioxidant	 properties	 proved	 in	 vitro.	 For	 example,	 the	bioavailability	 of	
Flavonoids	in	vivo	is	100-1000	times	lower	than	the	bioavailability	of	vitamin	C	or	glutathione	and	thus	
has	a	 very	 small	 antioxidant	effect.	However,	 it	 is	 available	 in	 concentrations	 that	effect	 cell	 signaling	
proteins.	 “Numerous	 studies	 in	 cell	 culture	 suggest	 that	 flavonoids	 may	 affect	 chronic	 disease	 by	
selectively	 inhibiting	kinases”	 including	 those	 related	 to	growth	 factors.	Higdon	hypothesizes	 that	 it	 is	
this	property	 that	protects	against	CAD	by	decreasing	 inflammation,	decreasing	vascular	cell	adhesion	
molecule	 expression,	 increasing	 endothelial	 nitric	 oxide	 synthase	 (eNOS)	 activity,	 and	 decreasing	
platelet	aggregation	(Higdon,	2005).	Another	study	(Lotito	&	Frei,	2006),	attributes	the	protective	effect	
of	 Flavonoids	 not	 directly	 to	 its	 antioxidant	 activity,	 but	 rather	 to	 the	 consequence	 of	 increased	 uric	
acid.2	What	 is	clear	from	all	these	studies	 is	that	 it	 is	not	the	antioxidant	properties	of	Flavonoids	that	
directly	 protect	 against	 CAD	 but	 rather	 to	 a	 whole	 host	 of	 activities	 including:	 increased	 native	
antioxidants	 such	as	glutathione,	uric	acid,	modified	cell	 signaling	pathways,	 increased	PON-1	activity,	
and	increased	NO	levels.			
Possible	Risks	of	Antioxidants	vs.	Flavonoids:	
So	then	what	really	does	account	for	the	differences	 in	Flavonoids	and	for	example	vitamin	E?	
What	may	be	at	play	is	as	follows:		
Vitamin	E	as	well	as	having	antioxidant	properties	is	a	pro-oxidant	as	well	(Bowry	et	al.,	1992).	
For	example:	instead	of	the	termination	reaction	by	tocopherol	to	the	oxidative	chain	reaction	of	lipids	
as	a	final	step:		
LOO•	+	TOH	→	LOOH	+	TO•	[4]	
We	instead	form	
																																								 																				
2 Recent	studies	have	implicated	hyperuricemia	as	being	a	true	risk	factor	in	development	of	cardiovascular	
disease	(Jing	Fang	&	Michael	H.	Alderman,	2000).	However,	nearly	half	of	the	bodies’	antioxidant	activity	is	from	
uric	acid	and	in	moderation	may	play	a	positive	role.					
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TO•	+	LH	→	TOH	+L•	[5]	
This	will	then	feed	into	the	chain	reaction	
L•	+	O2	→	LOO•	[2]	
LOO•	+	LH	→	LOOH	+	L•	[3]	
One	study	(Bowry,	Ingold,	&	Stocker,	1992)	has	found	that	in	aqueous	solution,	strikes	between	
the	stable	TO•	and	other	radicals	were	 found	to	 take	upward	of	17	minutes,	a	 time	 long	enough	that	
even	 the	 most	 stable	 radical	 will	 find	 “`something	 to	 do’”	 i.e.	 propagate	 the	 chain	 reaction.	 The	
termination	of	this	reaction	must	then	rely	on	two	endogenous	antioxidants	vitamin	C,	as	demonstrated	
by	 the	 thiol	 redox	 cycles	 (Appendix	 1),	 and	 ubiquinol	 (Q10H2,	 a	 reduced	 form	 of	 Q10)	 in	 the	 electron	
transport	chain.	What	can	be	inferred	from	this	is	that	by	ingesting	vitamin	E	the	body	sets	off	a	cascade	
of	endogenous	antioxidants,	 in	order	 to	minimize	 the	damage	being	 incurred	by	vitamin	E.	While	 the	
body	does	have	the	mechanisms	of	scavenging	TO•	how	can	making	more	of	them	by	ingesting	vitamin	
E	be	advantageous?	Essentially	 there	 is	a	delicate	balance	of	electron	radicals	 that	are	passed	down	a	
cascade	 until	 they	 can	 be	 neutralized	 to	 a	 non	 reactive	 end	 product,	 and	 by	 adding	 more	 electron	
radicals	in	the	form	of	α-tocopherol	it	may	have	the	effect	of	being	counterproductive.	
C	-	reactive	protein	and	PON-1	
By	contrast,	Flavonoids	are	effective	not	by	acting	as	antioxidants	but	through	modulating	the	
inflammatory	response	of	oxidized	cells.			
The	relationship	between	C	-	reactive	protein	(CRP)	and	Flavonoids	illustrates	this	point.	CRP	is	
found	to	be	elevated	during	 inflammatory	response	by	the	body,	specifically,	macrophages	and	T	cells	
release	 Interleukin-6	 (IL-6)	 as	 a	 pro	 inflammatory	 to	 stimulate	 a	 response	 to	 tissue	 damage.	 CRP	
production	is	then	part	of	the	acute-phase	response	to	most	forms	of	inflammation,	infection,	and	tissue	
damage.	 CRP	 levels	 by	 themselves	 cannot	 be	used	 as	marker	 for	 atherosclerosis,	 but	 they	have	been	
positively	correlated	with	CAD	(Pepys	&	Hirschfield,	2003).	Flavonoids	have	an	inverse	relationship	with	
CRP.	 One	 study	 using	 demographic	 data	 (Chun	 et	 al.,	 2008)	 found	 that	 the	 greater	 consumption	 of	
Flavonoid	rich	foods,	the	lower	the	concentrations	of	serum	CRP	thus	clearly	indicating	that	Flavonoids	
affect	 inflammatory	response.	 	Another	study	has	also	found	an	inverse	relationship	between	levels	of	
CRP	 and	 levels	 of	 PON-1	 expression.	 They	 found	 that	 “Higher	 levels	 of	 CRP	 seem	 to	 be	 generally	
associated	 with	 low	 levels	 of	 PON1	 activity”	 (Macknessa	 et	 al.,	 2006).	 Which	 should	 lead	 to	 the	
conclusion	that	the	atherosclerotic	protection	associated	with	Flavonoids	 is	not	related	to	an	 inherent	
antioxidant	activity	but	rather	to	other	factors	as	mentioned.				
Another	study	also	found	that	polyphenols	(i.e.	Flavonoids)	acutely	enhanced	nitric	oxide	bioactivity.	NO	
is	 necessary	 to	 maintain	 vasodilatation	 -	 the	 lack	 of	 which	 is	 implicated	 in	 increased	 risk	 of	
cardiovascular	disease	(Anter	et	al.,	2004).		
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Conclusions:	
In	 comparing	 the	 protective	 effects	 on	 atherosclerosis	 associated	with	 statins,	 vitamin	 E,	 and	
Flavonoids,	there	are	many	questions	as	to	the	ability	of	statins	and	vitamin	E	to	afford	real	protection	
against	 atherosclerosis.	 The	data	 in	many	 cases	 implicates	 these	 very	 compounds	 increased	mortality	
rates.	 By	 contrast,	 Flavonoids	 have	 shown	 themselves	 able	 to	 boost	 the	 bodies’	 native	 antioxidants	
including	uric	acid	and	glutathione,	while	at	the	same	time	reducing	the	inflammatory	response	to	the	
uptake	of	oxidized	lipids.	It	could	be	that	mother	really	knew	best	all	along	“an	apple	a	day	–	really	does	
–	keep	the	doctor	away”.	 (Apple	peals	have	been	found	to	consist	of	40%	flavonols	by	weight	 (Łata	&	
Tomala,	2007	)).		
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Excitoxicity	in	Retinal	Ischemia	and	Treatment	Using	Non-Competitive	Receptor	Antagonists	
Jacob	Rube	
Ischemia	 is	 defined	 as	 an	 inadequacy	 of	 blood	 flow	 to	 tissue.	 	 Ischemia	 can	 deprive	 tissue	 of	
oxygen	and	metabolic	substrates	and	it	can	also	prevent	the	removal	of	waste	products.		If	the	ischemia	
is	maintained	over	enough	time	the	tissue	will	lose	its	homeostasis	and	eventually	die	causing	an	infarct.			
Retinal	ischemia	occurs	when	the	blood	supply	to	the	retina	does	not	meet	the	metabolic	needs	that	are	
required	to	sustain	the	retina.		This	can	lead	to	retinal	damage	and	severe	vision	loss.	Ischemia	is	caused	
by	occluded	blood	vessels.	
The	 retinal	 blood	 supply	 originates	 in	 the	 ophthalmic	 artery	 and	 branches	 into	 the	 different	
sections	 of	 the	 retina.	 	 The	 external	 retina,	 which	 contains	 the	 cell	 bodies	 of	 the	 photoreceptors,	 is	
provided	with	nutrients	by	the	choroid	blood	vessels.		The	inner	layer	and	ganglion	layer,	which	contains	
the	ganglion	bipolar	and	amacrine	cell	bodies,	 is	nourished	by	the	central	 retinal	artery	 (CRA)	 (Brown,	
1991).	
Complete	 retinal	 ischemia	 occurs	 when	 the	 opthalamic	 artery	 is	 occluded.	 	 Major	 causes	 of	
retinal	 ischemia	 are	 central	 retinal	 artery	 occlusion	 (CRAO),	 branch	 retinal	 artery	 occlusion	 (BRAO),	
central	 retinal	 vein	 occlusion	 (CRVO),	 and	 branch	 retinal	 vein	 occlusion	 (BRVO).	 	 CRAO	 is	 caused	 by	
either	a	thrombosis	of	the	CRA	or	an	embolisation	of	an	artherosclerotic	internal	carotid	artery	(Brown,	
1991).		Ischemia	caused	by	the	CRAO	leads	to	an	infarction	and	loss	of	function	of	all	the	inner	layers	of	
the	retina	while	the	outer	layers	of	the	retina	including	a	portion	of	the	inner	nuclear	layer	remain	intact	
(Kincaid	et	al,	1998).			
The	CRA	branches	off	 into	several	different	branches	in	order	to	perfuse	the	inner	layer	of	the	
retina.	 	BRAO	occurs	when	one	or	some	of	these	vessels	are	occluded.	 	BRAO	has	the	same	pathology	
and	 risk	 factors	 of	 CRAO	 but	 affects	more	 of	 a	 specific	 area	 of	 the	 inner	 retina	 depending	 on	which	
branch	is	occluded	(Brown,	1991).	
Venous	occlusive	diseases	are	more	common	clinically	than	arterial	occlusions.		The	risk	factors	
for	 CRVO	 are	 similar	 to	 those	 of	 CRAO	 but	 also	 include	 an	 elevated	 intraocular	 pressure	 (IOP)	 or	 an	
underlying	hematological	disease (Mitchell et al., 1996). 
Ionotropic	Receptors 
Ionotropic	receptors	are	a	group	of	transmembrane	 ion	channels	that	are	opened	or	closed	 in	
response	to	the	binding	of	a	chemical	messenger.	NMDA	(N-methyl-D-aspartic	acid),	AMPA	(α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate),	 and	 kainite	 receptors	 are	 ionotropic	 receptors	 in	 neurons	
that	are	activated	by	glutamate	which	is	a	main	neuron	neurotransmitter	(Digledine	et	al	1999).		NMDA	
receptors	are	 responsible	 for	 regulating	 the	 influx	of	calcium	and	other	 ions	 in	 the	cell.	 	Normally	 the	
channel	 is	 blocked	 by	Mg2+	 ions	 (Eby	 and	 Eby,	 2006).	 	 Under	 normal	 circumstances	 a	 nearby	 AMPA	
receptor	 is	 activated	 during	 resting	 polarization	 by	 glutamate,	 which	 starts	 depolarization.	 	 This	
depolarization	spreads	to	the	NMDA	receptor	and	it	releases	the	Mg2+	ions.			Once	the	NMDA	receptor	is	
open	glutamate	will	activate	the	receptor,	which	causes	an	influx	of	Ca2+	and	Na+.		Ca2+	is	used	by	the	cell	
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to	activate	metabolic	pathways	and	reactions	in	the	cell.			
Kainate	 receptors	 are	 not	 as	 well	 understood	 as	 other	 receptors	 but	 its	 conductance	 is	 very	
similar	to	that	of	AMPA	receptors.	
Metabotropic	Glutamate	Receptors	
Metabotropic	receptors	differ	from	ionotropic	receptors,	like	NMDA	and	AMPA,	in	that	instead	
of	 activating	 an	 integral	 ion	 channel	 they	 activate	 secondary	 messengers	 usually	 G-proteins,	 which	
activate	 ion	 channels	 on	 the	 plasma	 membrane.	 	 To	 date	 eight	 distinct	 subtypes	 of	 metabotropic	
glutamate	receptors	(mGluRs)	have	been	identified	and	separated	into	three	groups	based	on	function	
and	 sequence	 homology	 (Thoreson	 and	Witkovsky,	 1999).	 	 Group	 1	mGluRs	 (mGlu1	 and	mGlu5)	 are	
usually	 located	postsynaptically	and	enhance	the	cell’s	excitability	by	mobilizing	 intracellular	Ca2+	and	
activating	protein	kinase	C,	which	leads	to	several	signal	transduction	pathways.	
Group	 II	 (mGlu2	 and	 mGlu3)	 and	 Group	 III	 (mGlu4	 and	 mGlu6-8)	 are	 typically	 found	
presynaptically.		The	transduction	process	of	these	receptors	involve	a	negative	coupling	with	adenylate	
cyclase	and	 their	activation	causes	a	 reduction	 in	glutamate	 release	which	 lowers	 synaptic	excitability	
(Nicoletti	et	al,	1996).		
Ischemic	Cascade	
On	the	cellular	level	death	from	ischemic	attack	is	brought	about	by	many	factors.		The	start	of	
the	 cascade	 comes	 from	 the	 lack	 of	 oxygen	 and	 glucose	 supply.	 	 This	 leads	 to	 decreased	 rates	 of	
glycolysis	and	oxidative	phosphorylation,	which	causes	levels	of	ATP	to	fall	(Lipton,	1999).		
The	main	 impact	 of	 the	decrease	of	ATP	 in	 the	neuron	 is	 the	 inhibition	of	 the	Na⁺/K⁺-ATPase	
transporter,	which	is	a	transporting	enzyme	on	the	cell	membrane.	The	main	function	of	this	enzyme	is	
to	restore	the	resting	potential	of	the	neuron	after	it	has	been	hyperpolarized	from	the	release	of	excess	
potassium.	 	When	 the	 neuron	 becomes	 hyperpolarized	 the	Na⁺/K⁺-ATPase	 actively	 transports	 sodium	
ions	out	of	 the	cell	and	potassium	 ions	 inside	the	cell	 to	restore	the	neuron	to	 its	 resting	potential	so	
that	 it	 can	 depolarize	 and	 make	 an	 action	 potential.	 	 Once	 this	 enzyme	 is	 inhibited	 the	 voltage	
dependent	Mg2+	on	the	NMDA	(N-methyl-D-aspartic	acid)	receptors	becomes	loose	which	allows	for	an	
excess	uptake	of	calcium	by	the	cell	(Zeevalk	and	Nicklas,	1992).		Ionotropic	AMPA	(α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate)/kainite	 type	glutamate	 receptors	also	become	more	activated	which	
leads	to	an	influx	of	 ions	and	osmotically	obligated	water	which	can	lead	to	cell	 lysis.	The	inhibition	of	
the	Na⁺/K⁺-ATPase	is	the	cause	of	the	hyper	activation	of	these	receptors.	
These	 receptors	 are	 activated	 by	 glutamate,	which	 is	 an	 extracellular	 neurotransmitter	 in	 the	
brain.		During	ischemia,	through	some	proposed	mechanisms,	which	will	be	elaborated	later,	there	is	an	
increase	 in	 extracellular	 glutamate	 levels,	 which	 in	 turn	 activate	 the	 now	 active	 receptors	 during	
reperfusion,	which	leads	to	cell	death	as	will	be	explained	later	on	in	this	paper.		This	rise	in	glutamate	
levels	has	been	documented	in	several	studies	(Neal	et	al,	1994;	Shimada	et	al,	1993).			
The	early	mechanism	proposed	for	the	increase	in	extracellular	glutamate	levels	was	that	after	
the	 opening	 of	 the	 Ca2+	 channels	 there	 would	 be	 an	 increase	 in	 exocytotic	 neurotransmitter	 release	
through	normal	metabolic	pathways.		This	is	because	an	increase	in	Ca2+	in	a	cell	will	cause	an	increase	in	
cell	metabolism.	However,	due	to	the	depletion	of	ATP	in	the	cell,	this	mechanism	cannot	really	account	
the	 very	 high	 levels	 of	 glutamate	 because	 of	 the	 lack	 of	 energy	 available	 for	 this	 process	 to	 occur	
(Nishazawa,	2001).	
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The	 main	 candidate	 for	 an	 alternative	 mechanism	 is	 the	 reverse	 transport	 of	 glutamate	
transporter	 proteins.	 	 The	 transport	 of	 glutamate	 into	 the	 cell	 in	 order	 to	 prevent	 excessive	
depolarization	is	not	driven	by	ATP	but	rather	by	the	Na+	gradient	inside	the	cell	and	the	concentration	
of	K+	and	pH-changing	anions	out	of	the	cell	 (Barbour	et	al	1998).	 	When	 ischemia	occurs	and	Na⁺/K⁺-
ATPase	 begins	 to	 reduce	 in	 activity,	 the	 Na+	 gradient	 is	 decreased	 and	 the	 K+	 accumulates	 in	 the	
extracellular	 space,	 which	may	 reverse	 glutamate	 uptake	 (Attwell	 et	 al,	 1993).	 	 This	mechanism	was	
proposed	when	it	was	noticed	that	there	was	an	increase	in	extracellular	glutamate	in	anoxic	conditions	
(David	et	al,	1988).		Other	studies	have	shown	that	glutamate	levels	are	increased	when	there	is	either	
an	increase	in	extracellular	K+	on	intracellular	Na+	(Barbour	et	al,	1991).			
Normally	glutamate	 is	 taken	up	by	glia	and	converted	by	glutamine	synthetase	 into	glutamine	
and	 returned	 back	 into	 the	 neural	 soma	 (Thoreson	 and	Witkovsky,	 1999).	 	 Ischemia	 lowers	 the	 ATP	
levels	 in	 glia	 and	 causes	 a	 decrease	 in	 the	 conversion	 of	 glutamate.	 	 This	 causes	 an	 increase	 in	 the	
glutamate/glutamine	ratio,	which	may	also	lead	to	extracellular	glutamate	(Oliver	et	al,	1990).	
Once	the	cell	constantly	becomes	depolarized	excess	calcium	enters	the	cell	and	sets	off	many	
cascades	 that	 lead	 to	 cell	 death.	 Among	 the	most	 critical	 are	 free	 radical	 production	 and	 nitric	 oxide	
(NO)	synthesis,	activation	of	phospholipase	A2,	DNA	cleavage,	activation	of	proteases,	and	subsequent	
damage	 to	 cytoskeleton.	 	 	 One	 of	 the	 main	 influences	 of	 the	 high	 calcium	 level	 is	 the	 formation	 of	
superoxide	radicals	(Bonne	et	al,	1998).		Calcium	activates	a	dependent	protease	calpain,	which	converts	
xanthine	dehydrogenase	to	xanthine	oxidase.		Upon	reperfusion,	this	enzyme	converts	hypoxanthine	to	
uric	acid,	which	results	 in	the	release	of	superoxide	radicals	 (Chan,	1996).	One	of	the	major	ways	that	
superoxide	damages	the	cell	is	that	it	attacks	unsaturated	fatty	acids	which	lead	to	lipid	perioxidation	of	
membranes	(Doly	et	al,	1984).	 	This	will	result	 in	 loss	of	membrane	fluidity,	cell	swelling,	oedema,	and	
feed	forward	production	of	more	oxygen-derived	radicals.	 	There	are	many	other	pathways	that	cause	
cell	damage	that	stem	from	the	increase	in	calcium	ions,	which	can	lead	to	the	activation	of	procaspases	
which	leads	to	apoptosis.	
The	following	figure	illustrates	the	different	steps	in	retinal	ischemia.	
73	
	
	
Fig.	1.	Summary	of	hypothesised	key	events	in	the	process	of	ischemic	retinal	neurodegeneration.	An	interruption	
in	the	supply	of	blood	to	the	retina	 leads	to	tissue	ischemia	which	causes	rapid	failure	of	energy	production	and	
subsequent	events	as	outlined	in	the	figure.	Key	steps	include	the	failure	of	the	Na+/K+–ATPase	pump,	membrane	
depolarisation,	cytoplasmic	accumulation	of	sodium	and	calcium	ions	and	the	formation	of	destructive	free	radical	
species.	The	summed	cellular	 response	of	 these	processes,	 if	 left	unchecked,	 is	cell	death.	This	can	occur	by	the	
classical	and	rapid	necrotic	process	or	by	longer-duration	apoptosis	(Osborne	et	al.,	2004).		
Retina	Damage	in	Ischemia	
Glutamate	 is	 the	 major	 excitatory	 retinal	 neurotransmitter	 and	 is	 released	 in	 vivo,	 by	
photoreceptors,	bipolar	cells,	and	ganglion	cells.	The	photoreceptors	have	only	shown	susceptibility	to	
be	damaged	after	the	rest	of	the	retina	has	shut	down	and	studies	have	shown	that	 ischemia	has	 less	
effect	 on	 the	 outer	 layer	 of	 the	 retina	 than	 the	 inner	 layer	 of	 the	 retina	 (Peachey	 et	 al,	 1993).	 	 	 The	
reason	 that	 photoreceptors	 are	 less	 sensitive	 remains	 unknown.	 	 One	 possibility	 is	 that	 their	
mitochondria	have	a	high-density	inner	segment	and	is	maintained	on	a	smaller	pO2.		In	addition	there	is	
more	 neuroglobin	 in	 photoreceptors	 (Schmidt	 et	 al,	 2003)	 which	 helps	maintain	 oxygen	 levels	 inside	
cells	 in	 the	 cerebral	 and	 peripheral	 nervous	 system.	 Neuroglobin	 has	 a	 high	 affinity	 for	 oxygen	 and	
provides	extra	oxygen	for	cells	under	ischemic	attack	or	in	hypoxic	conditions.	
Ganglion	cells	are	highly	susceptible	to	ischemic	attack	and	all	known	retinal	ischemic	paradigms	
have	been	described	as	a	 loss	of	ganglion	cells	(Akiyama	et	al,	2002;	Goto	et	al.,	2002).	 	Ganglion	cells	
express	both	the	NMDA	receptor	and	kainite	type	receptor	(Fletcher	et	al.,	2000),	which	are	activated	by	
the	excessive	glutamate	levels,	which	lead	to	chronic	depolarization.		Amacrine	cells	also	contain	these	
receptors	 and	 are	 susceptible	 to	 ischemic	 attack	 through	 the	 same	mechanism.	 	 Both	 amacrine	 and	
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ganglion	 cells	 have	 many	metabotropic	 glutamate	 receptors	 which	 also	 may	 be	 the	 reason	 for	 their	
susceptibility	to	ischemic	attack	(Osborne	et	al.,	1991).	
	What	sets	ischemic	attack	on	the	retina	different	from	the	brain,	is	the	fact	that	the	retina	has	a	
much	 longer	 tolerance	 time.	 	A	 few	minutes	of	 cerebral	 ischemia	 in	 the	human	 results	 in	widespread	
injury,	but	it	has	been	demonstrated	that	a	primate	retina	can	suffer	up	to	100	minutes	of	CRAO	without	
permanent	injury	(Hayreh	and	Weingeist,	1980).		This	can	be	explained	by	the	fact	that	retina	contains	
about	100	times	more	neuroglobin	and	other	energy	reserves	that	can	be	used	up	during	the	hypoxic	
conditions	of	ischemia	(Schmidt	et	al.,	2003).			
Alternatively	 there	 is	a	“no	flow”	phenomenon	that	may	explain	this	difference	 (Fischer	et	al.,	
1977).	This	phenomenon	 is	 involved	 in	where	 the	 rigid	cranium	compresses	 the	microvasculature	 in	a	
swollen	brain,	which	causes	an	ongoing	ischemic	attack	even	though	macroscopic	blood	flow	is	restored.		
In	retina	ischemia	oedematous	retina	does	not	compress	the	microvasculature	since	there	is	a	vitreous	
cavity	to	expand	into.		This	large	amount	of	time	before	irreversible	retina	destruction	has	allowed	for	
many	studies	to	be	done	on	how	to	reverse	ischemia	or	minimize	ischemic	damage.	
Treatment	Using	NMDA	Antagonists	
It	has	been	shown	in	vivo	that	with	the	addition	of	NMDA	antagonist	one	can	protect	a	neuron	
from	ischemic	attack	(Lombardi	et	al.,	1994).				Competitive	antagonists	although	shown	to	be	effective,	
will	only	 likely	be	used	 in	experimental	studies.	 	These	receptor	antagonists	may	not	be	useful	 in	man	
due	to	long	lasting	actions,	which	can	affect	neural	processes.		However,	major	interest	has	arisen	in	the	
use	of	non-competitive	NMDA	antagonists.		This	is	because	these	compounds	have	shown	the	ability	to	
cross	blood	retinal	barrier	and	it	is	believed	that	such	drugs	will	block	the	toxic	actions	NMDA	receptors	
in	 ischemia	 and	 yet	 sustain	NMDA	 receptor	 functions	 in	 the	brain	 to	maintain	 cognitive	 and	memory	
processes.		
This	evidence	supports	the	idea	that	using	a	NMDA	antagonist	one	can	slow	down	or	even	stop	
ischemic	attack.	 	One	particular	 antagonist	 that	has	been	 showing	great	 results	 is	dextromethorphan.			
Dextromethorphan	is	an	antiussive	drug	and	is	used	in	over	the	counter	cough	and	cold	medicines	and	it	
has	been	shown	to	have	uses	in	pain	relief	(Bem	and	Peck,	1992).							
Evidence	 on	 retina	 health	 after	 ischemic	 attacks	 were	 obtained	 through	 Electroretinography	
(ERG),	which	 is	 a	 test	 in	which	electrodes	are	attached	 to	 the	eye	and	 it	measures	 the	activity	of	 the	
retina	by	measuring	the	electrical	activity	of	the	retina	 in	response	to	 light.	The	ERG	will	contain	an	a-
wave	(initial	negative	deflection)	followed	by	a	b-wave	(positive	deflection).		
In	studies	done	using	dextromethorphan	while	 invoking	a	retinal	 ischemic	attack,	results	show	
that	retinas	that	were	treated	with	dextromethorphan	were	able	to	maintain	function	better	after	the	
restoration	 of	 blood	 flow	 than	 retina	 that	 were	 not	 treated	 with	 dextromethorphan.	 	 In	 30	 and	 60	
minute	 strokes,	 rats	 that	 were	 treated	 with	 dextromethorphan	 had	 a	 better	 recovery	 time	 and	 less	
retinal	 damage	 than	 the	 mice	 not	 treated	 with	 the	 drug	 (Cao	 et	 al.,	 1994).	 	 However,	 caution	 is	
necessary	when	studying	this	drug	because	it	may	be	that	dextromethorphan	increases	cerebral	blood	
flow	 and/or	 decrease	 cerebral	 metabolic	 requirements	 instead	 of	 blocking	 the	 ischemic	 stroke	
pathology	(Osborne	et	al.,	2004).	 	Also	 it	could	be	that	dextromethorphan	was	only	protecting	the	rat	
retinas	from	the	increased	pressure	brought	on	by	the	induced	stroke	in	the	rat	and	therefore	may	not	
be	potent	for	clinical	use	(George	et	al.,	1988).	
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	Dizocilpine	 (MK-801),	 another	 NMDA	 antagonist	 has	 shown	 better	 results	 in	 stopping	 retinal	
ischemia	 (Lam	 et	 al.,	 1997).	 	 However,	 it’s	 neurotoxic	 side	 affects	 causes	 reduced	 brain	 function	 and	
make	 it	 almost	 impossible	 for	 clinical	 use.	 	 Also,	 the	 lowing	 of	 ischemic	 affects	may	 be	 due	 to	 other	
metabolic	 side	 affects	 of	 MK-801	 in	 that	 it	 lowers	 CNS	 temperature,	 which	 lowers	 the	 oxygen	
consumption	during	ischemia	(Chi	et	al.,	1991).		
Other	NMDA	antagonists	have	been	used	in	studies	for	retinal	diseases.		They	include	eliprodil,	
which	 blocks	 at	 the	 polyamine	 site	 of	 the	 NMDA	 receptor	 (Biton	 et	 al.,	 1994),	 fliurpitine,	 and	
memantine.			Even	though	it	has	been	well	noted	that	NMDA	receptor	antagonists	block	excitoxicity,	the	
therapeutic	use	should	be	questioned	because	of	the	negative	affects	that	they	can	have	on	the	patient.		
It	has	been	suggested	that	memantine	may	be	better	tolerated	than	other	NMDA	antagonists	because	
of	it	low	affinity	for	the	NMDA	channel	(Parsons	et	al.,	1993).	
Conclusion	
In	 conclusion,	 ischemia	 in	 the	 retina,	 if	 left	 untreated,	 is	 almost	 certain	 to	 cause	 permanent	
damage	to	the	retina	and	eventually	to	severe	vision	 loss.	 	 Ischemia	unleashes	a	cascade	starting	with	
the	lack	of	oxygen,	which	causes	the	Na+/K+	ATPase	to	lose	function,	which	leads	to	hyper-activation	of	
glutamate	receptors.		The	lack	of	oxygen	also	leads	to	an	increase	in		 extracellular	 glutamate,	 which	
can	cause	two	forms	of	death.		Glutamate	can	lead	to	an	influx	of	ions,	which	will	be	followed	by	water	
under	osmosis	 and	 cause	 cell	 lysis.	 	Also,	 glutamate	allows	an	 increase	 in	 the	uptake	of	 calcium	 ions,	
which	activates	mechanisms	to	form	radicals	that	can	activate	apoptotic	mechanisms	in	the	cell.		
One	 proposed	 way	 of	 treating	 retinal	 ischemia	 is	 to	 administer	 non-competitive	 NMDA	
antagonists,	 which	 should	 block	 the	 entrance	 of	 calcium	 into	 the	 cell.	 	 The	 interest	 in	 using	 these	
chemicals	has	been	big	because	they	can	cross	the	blood	retinal	barrier	and	are	believed	to	not	severely	
impair	cognitive	processes.		Also,	they	can	be	administered	after	the	ischemic	attack	has	already	begun.		
However,	clinically	there	have	been	no	real	breakthroughs	because	of	concerns	that	in	vivo	experiments	
only	exhibit	positive	results	because	of	other	mechanisms	involved	and	the	concern	of	damaging	normal	
receptor	function.		 	 	 	 	 	 	 	
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The	Nerve	Cells	of	the	Retina	
Penina	Winkler	
Abstract	
	 The	 visual	 pathway	 in	 the	 retina	 consists	 of	 a	 chain	 of	 different	 nerve	 cells.	 Light	 first	 travels	
through	all	the	layers	until	 it	reaches	the	photoreceptor	layer,	the	rod	and	cone	layer.	Rods	and	cones	
use	photopigments,	which	 contain	opsin	 and	a	 chromophore,	 to	help	 them	convert	 light	 into	energy.	
This	 energy	 is	 then	 passed	 on	 to	 the	 horizontal	 and	 bipolar	 cells.	 Horizontal	 cells	 prevent	 the	
hyperpolarization	 of	 peripheral	 rods	 and	 cones	 if	 needed,	 and	 they	 receive	 color-coded	 signals	 from	
cones	that	they	then	continue	along	the	optic	pathway.	Bipolar	cells	can	be	divided	into	rod	bipolar	cells	
and	cone	bipolar	cells.	Cone	bipolar	cells	can	be	further	subdivided	into	midget	cone	bipolar	cells,	which	
only	contact	one	cone	cell	and	one	ganglion,	and	diffuse	cone	bipolar	cells,	which	can	contact	several	
cone	 and	 ganglion	 cells.	 Bipolar	 cells	 can	 either	 hyperpolarize	 or	 depolarize	with	 light,	 and	 they	 pass	
their	 signal	 on	 to	 amacrine	 cells	 or	 ganglion	 cells.	 Amacrine	 cells	 provide	 inhibition	 to	 the	 visual	
pathway,	either	through	feedback	 inhibition	on	the	bipolar	cells	or	 feedforward	 inhibition	on	ganglion	
cells.	 A1	 amacrine	 cells	 provide	 long-range	 inhibition	 of	 ganglion	 cells.	 Indoleamine-accumulating	
amacrine	cells	provide	a	reciprocal	 response	to	bipolar	cells,	preventing	them	from	hyperpolarizing	so	
that	 their	 signal	does	not	 continue.	AII	 amacrine	 cells	 receive	 input	 from	bipolar	 cells	 and	output	 the	
signal	to	different	bipolar	cells	to	be	transmitted	to	ganglion	cells.	Ganglion	cells,	the	last	nerve	cells	in	
the	 visual	 pathway,	 only	 receive	 input	when	 light	 hits	 the	part	 of	 the	 receptive	 zone	 that	produces	 a	
discharge	when	 stimulated	 by	 a	 light	 source.	 Ganglion	 cells	 are	 specialized	 to	 detect	movement	 in	 a	
specific	direction.	This	prevents	the	brain	from	receiving	unnecessary	information.	EphrinA	and	EphrinB	
are	 two	molecules	 that	 form	gradients	 that	 lead	 the	 ganglion	 cells	 to	 their	 specific	 destination	 in	 the	
brain.	Magnocellular	(MC)	ganglion	cells	and	intrinsically	photosentive	retinal	ganglion	cells	(ipRGCs)	are	
specific	types	of	ganglion	cells,	with	MC	cells	dominating	during	fixational	eye	movements,	and	ipRGCs	
working	as	circadian	photoreceptors	like	rods	and	cones,	contributing	to	light-stimulated	effects	on	the	
body.	 Müller	 cells	 are	 not	 part	 of	 the	 visual	 pathway,	 but	 they	 provide	 support	 for	 the	 retina	 and	
regulation	 of	 nutrients	 and	 molecules,	 as	 well	 as	 perform	
many	other	functions	in	the	retina.	
	
	
(Kolb	H.	et.	al.	1996)	
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Introduction	
	 The	eye	is	a	complex	sensory	organ	which	receives	visual	images	and	carries	them	to	the	brain.		
When	a	light	stimulus	is	initiated,	the	light	coming	into	the	eye	touches	the	three	tunics,	or	layers,	of	the	
eye;	 the	 outer	 tunic,	 the	middle	 tunic,	 and	 the	 inner	 tunic.	 The	 first	 tunic	 is	 the	 outer	 tunic	 (colored	
white	in	diagram	above),	which	consists	of	the	sclera	and	the	cornea.	This	layer	provides	protection	to	
the	inner	structures	of	the	eye,	and	maintains	the	shape	and	consistency	of	the	eyeball.	The	sclera	is	the	
part	 of	 the	 outer	 tunic	 that	 covers	 the	 back	 of	 the	 eye,	while	 the	 transparent	 cornea,	 a	 clear	 dome,	
covers	the	front	of	the	eye.	 (Szaflarski,	D.M.	1999)	The	aqueous	humor	 is	a	thin,	watery	fluid	that	fills	
the	space	between	the	cornea	and	the	iris	of	the	middle	tunic.	The	middle	tunic	is	also	called	the	uvea	
(colored	blue	 in	diagram	above),	which	reduces	 the	reflection	of	 light	and	contains	blood	vessels.	The	
back	of	the	uvea,	located	under	the	sclera,	is	called	the	choroid.	The	ciliary	bodies	of	the	uvea	cause	the	
iris	to	constrict	or	dilate	to	control	the	amount	of	light	entering	the	pupil,	the	hole	through	which	light	
enters	 the	 lens.	 After	 light	moves	 through	 the	 lens,	 it	 enters	 the	 vitreous	 humor	 and	 then	 the	 inner	
tunic.	The	inner	tunic	is	the	retina	(colored	red	in	diagram	above),	the	most	important	part	of	the	eye	in	
terms	 of	 sight.	 The	 retina	 is	 the	 part	 of	 the	 eye	 that	 receives	 light	 impulses	 and	 converts	 them	 into	
energy	 that	 can	 be	 passed	 on	 to	 the	 brain.	 (Montgomery,	 T.,	 1998)	 Therefore,	 to	 understand	 how	 a	
human	being	is	able	to	see,	one	must	look	into	the	inner	workings	of	the	retina,	the	most	vital	part	of	
the	visual	process.	The	purpose	of	this	paper	is	to	describe	the	functions	of	the	different	types	of	cells	
found	in	the	retina,	and	how	each	contributes	to	sight.	
The	retina	has	ten	layers;	the	pigmented	epithelium,	the	inner	and	outer	segments	of	rods	and	
cones,	the	outer	limiting	membrane,	the	outer	nuclear	layer,	the	outer	plexiform	layer,	the	inner	nuclear	
layer,	 the	 inner	 plexiform	 layer,	 the	 ganglion	 cell	 layer,	 the	 nerve	 fiber	 layer,	 and	 inner	 limiting	
membrane.	 By	 following	 the	 nerve	 cells	 through	 these	 layers,	 one	 can	 see	 the	 pathway	 that	 the	
converted	energy	of	light	impulses	takes	to	reach	the	optic	nerve,	which	leads	to	the	brain.	
The	pigmented	epithelium	is	located	on	the	external	retinal	wall,	providing	vitamin	A,	or	retinal	
to	the	photoreceptors	that	it	contacts.	The	layer	of	the	rods	and	cones	is	where	the	conversion	of	light	
to	energy	takes	place.	The	junctions	between	the	rods	and	cones	and	the	Müller	cells	make	up	the	outer	
limiting	 membrane,	 which	 forms	 a	 blood	 retina	 barrier,	 isolating	 the	 inner	 layers	 of	 the	 retina	 from	
harmful	substances	 in	blood.	The	outer	nuclear	 layer	contains	the	nuclei	of	rods	and	cones.	The	outer	
plexiform	layer	is	the	layer	in	which	the	axons	of	the	cones	and	rods	synapse	with	the	dendrites	of	the	
bipolar	and	 the	neurites	of	horizontal	 cells.	The	 inner	nuclear	 layer	contains	 the	nuclei	of	 the	bipolar,	
horizontal,	and	amacrine	cells.	 In	the	inner	plexiform	layer,	the	axons	of	bipolar	cells	synapse	with	the	
neurites	of	amacrine	cells	and	the	dendrites	of	ganglion	cells.	In	this	layer,	the	neurites	of	amacrine	cells	
also	synapse	with	ganglion	cell	dendrites.	The	ganglion	cell	layer	contains	the	nuclei	of	the	ganglion	cells,	
which	then	converge	 in	the	nerve	fiber	 layer.	The	 inner	 limiting	membrane	is	made	up	of	Müller	cells,	
which	 form	 a	 barrier	 between	 the	 retinal	 nerve	 cells	 and	 the	 potentially	 harmful	 substances	 in	 the	
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vitreous	humor.	(Caceci	T.,	2001)	Each	type	of	cell	 in	the	pathway	has	 its	own	functions	which	help	to	
increase	the	accuracy	and	speed	of	vision.		
(Kolb	H.	et.	al.	1996)	
	 (Gurney	P.W.V.	1999)	
Rods	and	Cones	
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When	 light	 hits	 the	 retina,	 it	 first	 goes	 through	 all	 the	 layers	 of	 the	 retina	 before	 the	 cells	 begin	 to	
respond.	This	is	because	the	photoreceptor	cells,	the	rods	and	cones,	are	located	on	the	outer	region	of	
the	retina,	furthest	from	the	lens.	
																														 	(Juelich	F.,	2004)	
Both	rods	and	cones	are	made	up	of	two	segments,	the	outer	segment	and	the	inner	segment.	
The	outer	segment	exhibits	flat,	membranous	disks	containing	a	photo	pigment.	The	disks	are	infoldings	
of	 the	 plasma	 membrane	 that	 become	 narrower	 as	 they	 move	 away	 from	 the	 modified	 cilium,	 the	
connecting	 region	 between	 the	 inner	 and	 outer	 segments.	 These	 disks	 are	 produced	 in	 the	 inner	
segment	and	are	transported	by	kinesins	and	cytoplasmic	dyneins	along	microtubules	toward	the	outer	
segment	across	the	bridge	of	modified	cilium.	The	disks	are	continuously	being	renewed;	the	used	disks	
are	 phagocytosed	 by	 cells	 of	 pigmented	 epithelium.	 The	 inner	 segment	 is	 abundant	 in	mitochondria;	
mitochondria	 are	 involved	 in	 the	 synthesis	 of	 adenosine	 triphosphate,	 the	 Golgi	 apparatus,	 and	
endoplasmic	reticulum.	(Caceci	T.,	2001)	
	 Rods	 contain	 the	pigment	 rhodopsin,	which	 functions	during	night	vision,	while	 cones	 contain	
iodopsin,	which	helps	to	see	more	accurate	detail	and	color.	There	are	three	types	of	cone	cells,	which	
respond	to	different	regions	of	the	spectrum,	discriminating	the	colors	blue,	green,	and	red.	There	are	
other	differences	between	the	two	cells.	In	the	cone	cell	the	outer	segment	is	conical,	while	in	the	rod	
cell	it	is	cylindrical.	The	cone	cell	axon	ends	in	a	cone	pedicle,	a	large,	conical,	flat	end,	which	is	thicker	
than	 the	 rod	 spherule,	 small	 round	 enlargements	 of	 the	 axon.	 Both	 rod	 and	 cone	 synapse	 with	 the	
cytoplasmic	processes	of	bipolar	and	horizontal	cells.	(Kolb	H.	et.	al.	1996)		
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Rods	and	cones	are	transducers;	they	convert	light	into	electrical	or	neural	energy.	In	order	for	
this	 to	occur,	 the	rods	and	cones	need	photopigments.	The	protein	opsin	and	a	chromophore,	retinal,	
constitute	the	photopigments	of	the	rods	and	cones.	The	chromophore	is	needed	so	that	color	will	be	
absorbed;	without	the	chromophore,	the	photoreceptor	would	just	absorb	UV	light.	The	photopigments	
are	needed	to	provide	the	energy	required	to	cause	an	electrical	change	in	the	membrane	of	the	rod	or	
cone	that	will	be	propagated	from	the	point	of	absorption	of	the	light	to	the	rod	spherule.	The	electrical	
change	occurs	when	the	photoreceptor	 is	bleached,	the	process	 in	which	the	photopigment	absorbs	a	
photon	and	changes	chemically	 into	 its	constituents,	which	are	 less	 sensitive	 to	 light.	 In	darkness,	 the	
rod	and	cone	cells	are	depolarized,	and	they	continuously	release	the	neurotransmitter	glutamate	to	the	
bipolar	 cell;	 this	 inhibition	 of	 the	 bipolar	 cell	 is	 known	 as	 the	 “dark	 current.”	 As	 light	 hits	 the	
photopigment,	 retinal	 is	 activated.	 This	 causes	 the	 opsin	 to	 activate	 transducin,	 which	 activates	
phosphodiesterase.	 Phosphodiesterase	 breaks	 cyclic	 guanosine	monophosphate	 down	 into	 guanosine	
monophosphate.	The	cell	membrane	becomes	hyperpolarized,	and	glutamate	 is	no	 longer	 released	 to	
the	bipolar	cell.	This	causes	the	bipolar	and	horizontal	cells	 to	hyperpolarize	as	well,	and	the	message	
continues	along	the	chain.	(Stockman	A.	et.	al.	2007)	
	
	 (Stockman	A.	et.	al.	2007)	
	
	
	
Horizontal	Cells	
	 Horizontal	cells	are	one	of	the	intermediaries	between	photoreceptors	and	ganglion	cells.	Their	
nuclei	are	found	in	the	inner	nuclear	layer,	and	their	neurites,	their	cytoplasmic	processes	(they	do	not	
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have	axons	or	dendrites),	attach	to	the	rod	spherules,	cone	pedicles,	the	dendrites	of	bipolar	cells,	and	
the	 neurites	 of	 other	 horizontal	 cells	 in	 the	 outer	 plexiform	 layer.	 One	 horizontal	 cell	 synapses	 with	
more	than	one	type	of	cell	at	the	same	time,	because	each	neurite	can	have	many	branches.	Because	
the	horizontal	cell	has	many	branches	and	can	reach	many	cells	horizontally	across	the	outer	plexiform	
layer,	 it	allows	one	part	of	the	retina	to	 influence	the	other	part’s	activity.	Horizontal	processes	are	 in	
close	proximity	 to	retinal	capillaries,	and	there	may	be	neurovascular	coupling	between	the	processes	
and	 the	 capillaries.	 Such	 intimate	 contact	 with	 the	 capillaries	 was	 previously	 thought	 to	 be	 a	
characteristic	 of	Müller	 glial	 cells	 and	 astrocytes;	 some	 species	 of	 horizontal	 cells	 have	 glial	 proteins	
(glial	fibrillary	acidic	protein	or	vimentin),	and	both	horizontal	cells	and	glial	cells	develop	from	the	same	
precursors	during	retinal	development.	(Mojumder	D.K.	2009)	
	 The	membrane	of	the	horizontal	cell	contains	ionotropic	glutamate	receptors	which	need	direct	
activation	by	glutamate.	The	 receptors	are	 ionotropic	because	 the	 receptor	and	 the	 ion	channel	 form	
one	 complex,	 so	 they	 directly	 gate	 ion	 channels;	 they	 open	 ion	 channels	 when	 receiving	 glutamate.	
Glutamate	 release	 from	 rods	 and	 cones	 causes	 glutamate	 to	 be	 received	 by	 the	 glutamate	 receptor,	
which	 then	 causes	 the	 cell	 to	 be	 depolarized;	 a	 decrease	 in	 glutamate,	 a	 response	 to	 light,	 causes	
hyperpolarization	 of	 the	 cell.	 The	 horizontal	 cells	 provide	 feedback	 control	 of	 photoreceptor	 synaptic	
output.	They	perform	negative	feedback	to	photoreceptor	synaptic	terminals	at	the	first	synapse	of	the	
visual	 pathway.	 The	 cell	 exerts	 a	 restraining	 influence	on	 the	 junction	by	 stopping	 the	 response	 from	
continuing	to	the	bipolar	cells.	It	is	widely	believed	that	these	restraining	influences	only	occur	on	cones,	
not	rods.	The	role	of	horizontal	cells	on	the	rod	pathway	is	unclear.	(Bloomfield	S.A.	et	al	2001)	
	 The	three	different	types	of	cones	transmit	their	effects	to	bipolar	and	horizontal	cells.	In	many	
experiments	 conducted	 on	 horizontal	 cells,	 the	 cells	 showed	 two	 types	 of	 potentials	when	 recorded,	
color	 and	 luminosity.	 The	 color	 types	 of	 cell	 give	 an	 opponent	 type	 of	 response;	 the	 colors	 blue	 and	
yellow	have	opposing	effects	in	some	cells,	while	red	and	green	have	opposing	effects	in	other	cells.	The	
blue-yellow	 cell	 has	 connections	 with	 blue	 and	 red	 and	 green	 cones,	 while	 the	 red-green	 cell	 has	
connections	with	only	red	and	green	cones.	The	transmission	of	different	wavelengths	to	different	types	
of	 horizontal	 cells	 leads	 to	 a	 detailed	 color-coded	 message	 that	 is	 passed	 on	 to	 the	 optic	 nerve.	
(Burkhart	D.A.	et.	al.,	1978)	
	
Bipolar	Cells	
Bipolar	cells,	like	horizontal	cells,	are	intermediaries	between	photoreceptors	and	ganglion	cells.	
Their	nuclei	are	found	in	the	inner	nuclear	layer,	their	dendrites	contact	photoreceptor	cell	terminals	in	
the	outer	plexiform	layer,	and	their	axons	stretch	into	the	inner	plexiform	layer	to	contact	ganglion	cells.	
Bipolar	cells	can	be	subdivided	based	on	the	photoreceptor	cells	they	synapse	with.	Therefore,	there	are	
rod	bipolar	cells,	which	synapse	with	rod	spherules	only,	and	there	are	cone	bipolar	cells,	which	synapse	
with	cone	pedicles	only.	The	cone	bipolar	cells	can	be	further	divided	into	the	midget	cone	bipolar	cell	
and	the	diffuse	cone	bipolar	cell.	The	midget	bipolar	cell	synapses	with	a	single	cone	cell,	and	has	only	
one	axon	which	contacts	a	single	ganglion	cell,	which	is	continuous	with	the	optic	nerve.	In	reality,	a	true	
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one	to	one	connection	in	the	retina	does	not	exist,	because	although	one	midget	bipolar	cell	can	contact	
one	 cone	 pedicle,	 a	 diffuse	 bipolar	 cell	 can	 attach	 to	 the	 same	 cone	 as	 well.	 Also,	 horizontal	 and	
amacrine	 cells	 contact	 midget	 bipolar	 cell,	 ganglion	 cells,	 and	 cones	 laterally.	 Because	 of	 the	
interconnections	between	the	nerve	cells,	no	optic	nerve	fiber	actually	carries	messages	from	one	cone,	
but	because	of	the	midget	bipolar	cell	pathway,	an	increased	level	of	acuity	is	reached	when	a	less	dilute	
message	reaches	the	optic	nerve.	It	is	this	pathway	that	causes	cone	vision	to	be	more	accurate	than	rod	
vision.	The	diffuse	cone	bipolar	cell	contacts	up	to	seven	cone	cells	at	one	time	and	synapses	with	many	
ganglion	at	a	time.	The	diffuse	cone	bipolar	cell	has	wider	input	and	output	pathways	than	the	midget	
bipolar	cell.	 (Kolb	H.	et.	al.	1996)	Cone	bipolar	cells	can	also	be	divided	 into	 invaginating	cone	bipolar	
cells,	whose	dendrites	penetrate	the	synaptic	 invaginations	of	the	cone	pedicles,	and	flat	cone	bipolar	
cells,	whose	dendrites	remain	superficial	and	establish	basal	contacts.	(Bloomfield	S.A.	et	al	2001)	
	 One	rod	bipolar	cell	can	synapse	with	up	to	fifty	rods.	This	causes	the	same	effect	 if	 there	are	
one	 hundred	 quanta	 falling	 on	 a	 single	 rod	 or	 one	 quanta	 falling	 on	 one	 hundred	 rods.	 There	 is	 no	
difference,	because	ultimately	the	same	signal	will	reach	the	bipolar	cell.	Also,	if	a	high	density	of	rods	
converges	 on	 a	 single	 bipolar	 cell,	 and	 a	 high	 density	 of	 bipolar	 cells	 converges	 on	 one	 ganglion	 cell,	
there	 are	 many	 signals	 falling	 on	 one	 ganglion	 cell.	 During	 night	 vision,	 the	 power	 of	 bipolar	 and	
ganglion	 cells	 to	 collect	 impulses	 increases;	 the	 impulses	 were	 previously	 inhibited	 by	 higher	
illumination	 of	 the	 retina.	 This	 causes	 an	 increase	 in	 the	 amount	 of	 signals	 on	 the	 ganglion	 cell;	 it	 is	
because	of	this	large	amount	of	converging	that	during	night	vision,	visual	acuity	is	decreased.	With	so	
many	impulses	entering	the	ganglion	cell,	the	cell	can	not	interpret	all	the	impulses	to	the	degree	where	
vision	would	be	as	accurate	as	it	is	during	normal	vision.	(Kolb	H.	et.	al.	1996)	
When	 there	 is	 a	 decrease	 in	 glutamate	 levels	 as	 a	 response	 to	 light,	 the	 photoreceptor	 cells	
depolarize,	which	causes	the	bipolar	cell	to	depolarize	or	hyperpolarize	depending	on	whether	the	cell	is	
an	ON-bipolar	cell	or	an	OFF-bipolar	cell.	With	decreased	glutamate,	an	ON-bipolar	cell	depolarizes	and	
an	 OFF-bipolar	 cell	 hyperpolarizes.	 In	 the	 rod	 vision	 pathway,	 rod	 bipolar	 cells	 contact	 two	 types	 of	
amacrine	 cells,	 which	 serve	 as	 interneurons	 in	 the	 transmission	 of	 light	 signals	 in	 night	 vision.	 These	
amacrine	cells,	AII	amacrine	cells,	then	transmit	the	signal	to	cone	bipolar	cells,	the	final	conduit	to	the	
ganglion	cell	during	rod	vision.	Cone	bipolar	cells	are	used	during	rod	vision,	revealing	that	the	rod	and	
cone	circuits	are	intertwined.	(Bloomfield	S.A.	et	al	2001)	
	
Amacrine	Cells	
	 Amacrine	cells	 are	 interneurons	with	nuclei	 in	 the	 inner	nuclear	 layer.	They	have	one	neuritic	
process	which	branches	and	connects	to	the	axons	of	the	bipolar	cells	and	the	dendrites	of	the	ganglion	
cells	 in	 the	 inner	plexiform	 layer.	 Like	horizontal	 cells,	 amacrine	 cells	 connect	 to	bipolar	 and	ganglion	
cells	 horizontally,	 so	 that	 one	 area	 of	 the	 retina	 can	 impact	 another	 area.	 All	 amacrine	 cells	 display	
dendritic	 and	 somatic	 impulse	 activity.	 This	 impulse	 activity	 is	 important,	 as	 it	 performs	 feedforward	
inhibition	on	ganglion	cells	and	feedback	 inhibition	on	bipolar	cells	via	action	potentials.	The	amacrine	
cell	exerts	a	restraining	influence	on	certain	junctions	of	the	retina,	reducing	the	spread	of	messages.	In	
86	
	
relation	 to	 the	 ganglion	 dendritic	 tree,	 bipolar	 cells	make	 up	 the	 center	 of	 the	 receptive	 field,	 while	
amacrine	cells	make	up	the	periphery.	 	When	the	amacrine	cells	exert	an	inhibitory	action,	the	bipolar	
cells	in	the	central	zone	of	the	field	are	prevented	from	responding	to	the	receptors,	and	the	message	is	
not	sent	to	the	ganglion	cell.	(Kolb	H.	2003)	The	inhibition	caused	by	the	amacrine	cell	has	two	distinct	
modes,	 local	and	global.	 If	 the	action	potential	 can	not	be	propagated	down	 the	cell	 to	 the	dendrites	
then	they	provide	local	 inhibition.	If,	however,	the	action	potential	 invades	the	entire	dendritic	tree,	 it	
provides	global	 inhibition.	Amacrine	cells	can	be	divided	into	different	types	based	on	the	size	of	their	
dendritic	 spread,	 dendritic	 sublamination	 patterns,	 neurotransmitter	 subtypes,	 and	 variations	 in	 the	
morphological	features.	(Royer	A.S.	et	al	2007)	There	are	three	specific	types	of	amacrine	cells	discussed	
in	this	paper;	A1	amacrine	cells,	indoleamine-accumulating	cells	(IAC),	and	AII	amacrine	cells.		
	 	The	A1	amacrine	cell	is	a	spiking,	axon-bearing	interneuron	in	the	retina,	with	thick,	spiny,	and	
highly	 branched	 dendrites	 in	 the	 inner	 plexiform	 layer.	 A1	 cells	 receive	 inputs	 to	 their	 dendrites	 that	
cause	depolarization,	which	initiates	an	action	potential.	The	action	potential	then	propagates	down	the	
axon	and	crosses	the	retina.	The	A1	cells	have	extensive	branching,	 indicating	that	they	serve	a	global	
function	in	vision	processing.	A1	cells	are	mediators	of	long-range	inhibition	of	ganglion	cells	in	response	
to	 global	 image	 motion.	 Their	 spiking	 output	 structures	 may	 be	 a	 key	 element	 in	 long	 range	 lateral	
inhibition	of	the	retina.	The	A1	cells	have	center-surround	receptive	fields	which	combine	 inputs	 from	
ON	bipolar	cells	and	OFF	surrounds	and	OFF	bipolar	cells	and	ON	surrounds.	Because	amacrine	cells	are	
stimulated	 by	 both	 ON-center	 and	OFF-surround,	 and	OFF-center	 and	ON-surround,	 the	 inhibition	 of	
amacrine	 cells	 is	 postsynaptic	 to	 all	 bipolar	 cells,	 regardless	 of	 their	 responses	 to	 stimulation.	 A1	
amacrine	cells	provide	inhibitory	feedback	on	all	bipolar	cells.	(Davenport	C.M	et	al	2007)	
	 	IAC	amacrine	 cells,	 also	 known	as	A17	amacrine	 cells,	 account	 for	half	 of	 the	 rod	bipolar	 cell	
output.	 IAC	cells	 receive	 input	 from	rod	bipolar	cells	and	multiple	 types	of	amacrine	cells	 in	 the	 inner	
plexiform	layer.	The	sole	postsynaptic	target	of	 IAC	cells	 is	rod	bipolar	cells;	 IAC	cells	return	reciprocal	
synapse	back	onto	rod	bipolar	cells.	This	arrangement	causes	an	interconnecting	of	rod	bipolar	cells	 in	
the	 inner	plexiform	 layer.	 IAC	amacrine	cells	 contain	GABA,	and	 there	are	GABA	receptors	present	on	
the	axons	of	the	rod	bipolar	cells;	this	indicates	that	the	IAC	cell	has	an	inhibitory	feedback	function	in	
the	reciprocal	synapse.	(Bloomfield	S.A.	et	al	2001)	
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(Kolb	H.	et.	al.	1996)	
	 AII	amacrine	cells	function	during	rod	and	cone	vision.	In	scotopic	vision,	night	or	dim-lit	vision,	
AII	cells	are	major	carriers	of	rod	signals	to	ganglion	cells.	They	receive	input	from	rod	bipolar	cells,	but	
do	not	return	the	signal	back	to	rod	bipolar	cells.	Instead,	the	cells	form	homogenous	gap	junctions	with	
other	AII	 cells	near	 the	site	of	 the	synapse	of	 the	 rod	bipolar	cell.	The	AII	 cells	 then	synapse	with	 the	
axon	terminals	of	cone	bipolar	cells.	AII	cells	also	receive	 input	from	cone	bipolar	cells,	 indicating	that	
the	cells	are	also	part	of	the	photopic,	normal	light	vision.	AII	amacrine	cells	are	in	dense	population	in	
most	of	the	retina	because	they	are	a	key	element	in	the	visual	process.	(Bloomfield	S.A.	et	al	2001)	
	
	
Ganglion	Cells	
Ganglion	cells	are	the	last	retinal	cells	in	the	visual	pathway;	their	axons	form	part	of	the	optic	
nerve.	The	nuclei	of	the	ganglion	cells	are	in	the	ganglion	cell	layer,	and	their	dendrites	extend	into	the	
inner	 plexiform	 layer	 and	 synapse	 with	 bipolar	 cells.	 There	 are	 two	 types	 of	 ganglion	 cells;	 midget	
ganglion	cells,	which	synapse	with	only	one	bipolar	cell,	and	diffuse	ganglion	cells,	which	synapse	with	
several	bipolar	cells.	The	midget	ganglion	cells	receive	impulses	from	midget	cone	bipolar	cells,	so	they	
are	part	of	 the	 cone	visual	pathway	only.	 (Kolb	H.	et.	 al.	 1996)	The	ganglion	cell	 receives	 information	
from	all	stages	 in	the	visual	pathway.	The	ganglion	cell	can	convey	signals	that	drive	the	circadian	and	
pupillomotor	 systems	 by	 combining	 the	 rod	 and	 cone	 photoresponses,	 as	 well	 as	 its	 own	
photoresponses.	(Dacey	D.	M.	et	al	2005)	
The	ganglion	cell	response	 is	not	switched	on	and	off	as	the	 light	source	 is	switched	on	or	off.	
When	the	light	source	is	emitting	light	to	the	central	zone	of	the	receptive	field,	a	discharge	is	produced.	
The	periphery	zone	of	the	receptive	field	has	the	opposing	response,	and	will	only	produce	discharge	if	
there	 is	no	 light.	 The	 center	and	 the	periphery	usually	have	opposite	 responses	 in	 terms	of	 color;	 for	
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example,	an	off-response	to	green	in	the	surrounding	area	and	an	on-response	to	red	 in	the	center	of	
the	 field.	 A	 simultaneous	 stimulation	 of	 red	 in	 the	 center	 and	 green	 in	 the	 periphery	would	 elicit	 no	
response,	because	the	on-response	of	the	center	is	cancelled	out	by	the	off-response	of	the	periphery.	
This	opponent	organization	 serves	 to	enable	 the	 retina	 to	emphasize	different	 colors;	 the	 involuntary	
movements	of	the	eye	in	normal	vision	keeps	shifting	the	boundaries	of	the	center	and	the	periphery,	
causing	different	colors	to	be	seen.	Another	effect	of	this	inhibitory	organization	is	to	prevent	unneeded	
information	from	reaching	the	brain.	There	are	about	one	million	optic	nerve	fibers,	and	if	all	of	them	
were	 discharging	 information	 at	 once,	 the	 brain	 would	 have	 too	 many	 messages	 to	 decode.	 This	
mechanism	 helps	 to	 cut	 down	 the	 amount	 of	 information	 the	 brain	 needs	 to	 process.	 (Encyclopædia	
Britannica	 2009)	 Another	 method	 that	 some	 ganglion	 cells	 use	 to	 decrease	 the	 amount	 of	 action	
potentials	it	sends	to	the	optic	nerve	is	to	respond	to	light	moving	only	in	a	specific	direction.	When	an	
object	moves	in	the	ganglion’s	preferred	direction	an	excitatory	impulse	occurs.	When	the	object	moves	
in	the	opposite	direction,	however,	both	excitatory	and	inhibitory	impulses	occur,	effectively	canceling	
each	other	out.	(Barinaga	M.	2000)	
	 Each	ganglion	cell	carries	a	chemical	tag	that	corresponds	to	chemicals	in	the	tectum,	the	dorsal	
part	 of	 the	 midbrain;	 these	 chemicals	 convey	 positional	 information	 to	 the	 cell.	 The	 ganglion	 cell	
interprets	 this	 information	and	 responds	by	connecting	 to	a	 specific	point	 in	 the	brain.	There	are	 two	
gradients	 in	 the	ganglion	 cell	 pathway	 to	help	 the	axons	of	 the	ganglion	 cells	hit	 their	 target	position	
exactly.	The	gradient	made	up	of	molecules	 in	the	tectum	called	EphrinA	specifies	where	the	ganglion	
axons	 will	 end	 up	 in	 terms	 of	 the	 anterior-posterior	 axis.	 The	 gradient	made	 up	 of	 molecules	 called	
EphrinB	 specifies	where	 along	 the	medial-lateral	 axis	 the	 axon	will	 end	 up.	 If	 an	 axon	 is	moving	 in	 a	
direction	that	is	either	medial	or	lateral	to	its	destination,	it	projects	branches	towards	the	destination.	
The	 EphrinB	 regulates	 this	 branching.	 The	Wnt3	 protein	 counteracts	 the	 pull	 of	 EphrinB	 towards	 the	
most	 medial	 tectum,	 so	 the	 lateral	 tectum	 is	 not	 empty.	 The	 gradient	 of	 Wnt3	 is	 along	 the	 same	
direction	as	EphrinB’s	gradient,	but	 is	a	repellent	gradient.	Ryk,	the	receptor	for	Wnt3	on	the	ganglion	
on	 cell,	 is	 expressed	 in	 ganglion	 cells	 in	 the	 same	 direction	 as	 EphrinB,	 proving	 that	 it	 is	Wnt3	 that	
provides	the	repellent	gradient.	(Liqun	Luo	2006)	
	 A	specific	type	of	ganglion	cell,	the	magnocellular	(MC)	ganglion	cell,	was	experimented	on	and	
found	to	be	responsible	for	the	visual	illusions	that	are	seen	during	fixational	eye	movements.	When	one	
stares	at	a	stimulus,	such	a	star	or	an	optical	illusion,	for	a	period	of	time,	there	is	an	apparent	splitting	
of	the	lines,	as	well	as	a	fading	of	 lines	or	whole	wedges	of	the	stimulus.	These	characteristics	are	not	
found	 in	parvocellular	 (PC)	 ganglion	 cells,	 the	other	 type	of	 ganglion	 cell.	 This	 indicates	 that	MC	 cells	
dominate	during	fixational	eye	movements,	as	their	properties	are	such	that	this	would	happen.	In	the	
diagram	below,	it	is	shown	that	in	fixational	eye	movements,	such	as	staring	at	the	star	shaped	stimulus	
(A),	MC	cells	exhibit	more	line	fading	and	splitting	than	PC	cells.	(Hennig	M.H.	et	al	2007)	
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	(Hennig	M.H.	et	al,	2007)	
	 Intrinsically	photosensitive	retinal	ganglion	cells	(ipRGCs),	or	melanopsin-positive	ganglion	cells,	
are	ganglion	cells	that	function	as	a	circadian	photoreceptor.	Mice	with	severe	degeneration	of	rods	and	
cones,	 or	 with	 no	 rods	 and	 cones	 at	 all,	 still	 follow	 circadian	 rhythms	 based	 on	 light.	 Light	 affects	 a	
circadian	 phase	 by	 activating	 the	 retinohypothalamic	 tract,	 which	 connects	 ipRGCs	 to	 the	
superchiasmatic	nucleus,	a	part	of	 the	hypothalamus.	The	 ipRGCs	are	 the	only	ganglion	cells	 found	 to	
contain	melanopsin,	an	opsin	which	 is	photosensitive,	 indicating	that	this	 is	the	part	of	the	 ipRGC	that	
makes	it	a	photoreceptor.	IpRGCs	are	different	than	the	classical	photoreceptors	in	that	they	depolarize	
when	stimulated	by	 light,	while	rods	and	cones	hyperpolarize.	 IpRGCs	are	also	 less	sensitive	and	more	
sluggish	 than	 the	 classic	 photoreceptors.	 The	 melanopsin-positive	 ganglion	 cells	 contribute	 to	 light-
stimulated	effects	on	sleep,	heart	rate,	cortisol	levels,	alertness	and	other	effects	of	the	circadian	cycle.	
The	pupillary	 light	reflex,	where	 light	causes	the	size	of	the	pupil	to	decrease	and	darkness	causes	the	
pupil	 to	dilate,	 is	controlled	by	 ipRGCs	as	well.	The	cells	also	perform	the	normal	 function	of	ganglion	
cells,	receiving	synaptic	input	from	bipolar	and	amacrine	cells.	(Berson	D.	M.	2003)	
	
Müller	Cells	
	 Müller	 cells,	 a	 specific	 type	 of	 glial	 cell,	 fill	 the	 spaces	 between	 the	 photoreceptors,	
bipolar	cells,	ganglion	cells,	and	other	cells	in	the	visual	pathway.	Müller	cells	are	not	part	of	the	visual	
pathway;	they	do	not	synapse	with	any	cells,	and	they	do	not	receive	or	send	signals.	Their	function	is	
mainly	to	support	and	regulate	the	retina.	The	nuclei	of	Müller	cells	are	found	in	the	inner	nuclear	layer,	
and	 their	 cytoplasmic	 processes	 extend	 to	 the	 outer	 and	 the	 inner	 limiting	 membranes.	 The	 inner	
limiting	membrane,	which	separates	the	retina	from	the	vitreous	body,	is	made	up	of	the	basal	lamina	of	
Müller	 cells.	 The	 outer	 limiting	membrane	 is	 located	 at	 the	 contact	 site	 where	 zonula	 adherens	 and	
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microvilli	 extending	 from	 Müller	 cells	 connect	 the	 photoreceptors	 with	 the	 glial	 Müller	 cells.	
(Kierszenbaum	A.L.	2007)	
(Dyer,	M.A.	et.	al.,	2001)	
Before	 reaching	 the	photoreceptors,	 light	 has	 to	 go	 through	each	 layer	of	 the	 retina.	At	 each	
layer,	 the	 light	 is	 refracted	 by	 the	 cells	 in	 that	 layer,	 ultimately	 causing	 less	 light	 to	 fall	 on	 the	
photoreceptors.	The	Müller	cells	have	a	higher	refractive	 index	than	the	other	cells,	which	means	that	
light	can	be	channeled	through	the	cells	with	little	loss,	so	most	of	the	light	hitting	the	retina	is	received	
by	the	photoreceptors.	This	high	refractive	 index	 is	caused	by	the	tight	bundles	of	polymer	fibers	that	
extend	along	their	lengths.	(Castelvecchi,	D.	2007)	
Müller	cells	have	many	different	functions	 in	the	retina.	They	regulate	extracellular	space,	and	
ion	 and	 water	 levels.	 They	 maintain	 the	 blood-retinal	 barrier,	 and	 retinal	 blood	 flow.	 They	 provide	
trophic	 substances	 to	 the	 nerve	 cells,	 and	 they	 remove	 neural	 waste,	 such	 as	 carbon	 dioxide	 and	
ammonia.	 (Kolb	 H.	 et	 al	 1996)	 They	 also	modulate	 neuronal	 excitability	 and	 transmission	 by	 sending	
gliotransmitters	to	the	neurons.	They	also	supply	the	end	product	of	anaerobic	metabolism,	they	break	
down	glycogen,	so	that	the	nerve	cells	 in	the	retina	can	perform	aerobic	metabolism.	Müller	cells	and	
astrocytes,	 another	 type	 of	 glial	 cell	 found	 in	 the	 retina,	 remove	 glutamate,	 an	 excitatory	
neurotransmitter,	 and	 gamma-Aminobutyric	 acid	 (GABA),	 an	 inhibitory	 neurotransmitter	 from	 the	
extracellular	 sites	 in	 the	 retina.	Müller	 cells	 take	up	glutamate	by	utilizing	glutamate	 transporters	 like	
GLAST,	 glutamate-aspartate	 transporter,	 and	 convert	 it	 into	 glutamine	 with	 the	 enzyme	 glutamine	
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synthetase.	 If	 the	 glutamate	 transporter	 is	 malfunctioning,	 the	 extracellular	 glutamate	 levels	 rise	 to	
excitotoxic	 levels,	 causing	 damage	 to	 the	 retina.	 Müller	 cells	 uptake	 GABA	 using	 GABA	 transporters	
(GATs),	and	convert	it	to	glutamate	using	GABA	transaminase.	(Bringmann	A.	et.	al.	2009)	
	 	(Kolb	H.	et.	al.	1996)	
The	 fovea	centralis	 is	 a	unique	portion	of	 the	 retina	where	an	abundance	of	 light	 is	 absorbed	
and	as	such	contains	no	rods;	only	cones.	These	Müller	cells	provide	the	primary	structural	support	for	
the	 fovea	 centralis,	 binding	 the	photoreceptor	 cells	 together.	 The	 cells	 are	 also	 a	 reservoir	 for	 retinal	
xanthophyll,	 yellow	 accessory	 pigment,	 which	 is	 partly	 responsible	 for	 the	 low	 density	 of	 the	 cell	
cytoplasm	in	the	fovea.	Müller	cells	in	the	fovea	centralis	also	have	a	primary	role	in	age	related	macular	
hole	formation,	providing	an	anatomical	substrate	for	schisis	to	occur.	X-linked	juvenile	retinoschisis,	the	
abnormal	splitting	of	the	retina’s	neurosensory	 layers,	 is	 thought	to	be	caused	by	degeneration	of	the	
inner	portion	of	the	Müller	cells	in	the	fovea	centralis.	(Gass	J.D.M.	1999)	
In	 addition	 to	Müller	 cells	 and	 astrocytes,	 there	 are	 also	 other	 glial	 cells	 found	 in	 the	 retina.	
Microglial	cells	are	blood-derived	immune	cells	which	reside	in	the	retina.	They	play	important	roles	in	
host	defense	against	 invading	microorganisms	and	 the	 initiation	of	 inflammatory	processes	and	 tissue	
repair.	They	are	present	in	all	layers	of	the	retina.	(Bringmann	A.	et.	al.	2009)	
	
Conclusion	
	 At	first	glance,	the	reason	for	the	retina’s	interbranching	visual	pathway	is	hard	to	understand.	
But,	 after	 putting	 together	 the	 functions	 of	 each	 type	 of	 retinal	 nerve	 cell,	 one	 sees	 that	 each	 cell	 is	
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essential.	 The	 complexity	 of	 the	 pathway	 serves	 to	 clarify	 the	messages	 coming	 into	 the	 eye,	 and	 to	
prevent	 unnecessary	 information	 from	being	 transmitted	 to	 the	 brain.	 Understanding	 how	 the	 retina	
functions	 is	 important	 for	 doctors	 and	 scientists	 who	 are	 diagnosing	 and	 treating	 patients	 who	 have	
nerve	damage	 in	 the	retina.	Knowing	the	 function	of	each	area	and	cell	 type	 in	 the	retina	can	help	to	
diagnose	 what	 area	 is	 damaged	when	 seeing	 certain	 symptoms	 present,	 and	 treatment	 can	 then	 be	
administered.	 We	 know	 that	 Müller	 cells	 in	 the	 fovea	 centralis	 have	 roles	 in	 X-linked	 juvenile	
retinoschisis	 and	 age	 related	macular	 hole	 formation.	 Further	 research	 is	 being	 done	 by	 foundations	
such	as	the	Retina	Research	Foundation	in	Houston,	Texas,	in	order	to	further	understand	the	function	
of	each	nerve	cell	in	the	eye	and	how	each	cell	can	lead	to	ocular	disease.	
	 The	intricacy	of	the	eye,	and	especially	the	retina,	which	is	such	a	small	part	of	our	body,	is	awe-
inspiring.	 It	 is	 amazing	 to	 learn	 the	 workings	 of	 vision,	 something	 that	 is	 done	 almost	 every	 waking	
second,	and	to	actually	understand	what	is	happening	each	moment	in	one’s	eye.		
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